object
evalu
commerci
kit
detect
salmonella
spp
faecal
specimen
base
realtim
pcr
realart
tm
salmonella
rg
pcr
kit
method
total
faecal
specimen
obtain
consecut
individu
patient
thessalia
central
greec
includ
studi
genom
dna
extract
perform
use
commerci
avail
isol
kit
commerci
kit
describ
accord
instruct
manufactur
realtim
pcr
result
obtain
realtim
pcr
assay
compar
bacteri
cultur
result
determin
sensit
specif
result
accord
result
obtain
realtim
pcr
fiftythre
faecal
specimen
posit
salmonella
spp
salmonella
detect
bacteri
cultur
except
two
posit
specimen
repetit
two
neg
cultur
enrich
detect
pathogen
micro
organ
mean
time
detect
salmonella
realtim
pcr
approxim
hour
detect
tradit
cultur
method
requir
day
conclus
high
sensit
specif
realtim
pcr
assay
emphas
need
applic
routin
clinic
laboratori
rapid
accur
detect
salmonella
faecal
specimen
object
prospect
assess
perform
pcrelisa
assay
bio
advanc
franc
diagnosi
onychomycosi
due
dermatophyt
patientsmethod
threeunivers
hospit
lab
special
medic
mycolog
particip
studi
lab
nail
sampl
ns
collect
patient
pt
suspect
onychomycosi
n
healthi
control
n
lab
b
train
mycologist
take
care
collect
sampl
close
possibl
lesion
collect
ns
lab
c
ns
collect
physician
refer
lab
ns
process
classic
mycolog
techniqu
ie
direct
examin
de
cultur
cult
test
blindli
result
mycolog
pt
addit
distal
sampl
ds
obtain
clip
nail
plate
collect
dystroph
nail
test
sampl
improp
mycolog
process
ns
follow
dna
extract
amplif
pcr
hybrid
label
dermatophytespecif
probe
immobil
micropl
well
recoat
captur
probe
result
express
od
valu
consid
posit
od
neg
od
borderlin
grey
zone
od
result
use
pcrrflp
method
examin
polymorph
gap
gene
studi
determin
gap
genotyp
alui
pcrrflp
six
staphylococc
speci
therefor
abl
increas
list
speci
pcrrflp
result
consist
result
partial
sequenc
rrna
soda
rpob
biochem
test
agre
method
test
conclus
result
suggest
pcrrflp
assay
provid
rapid
accur
reliabl
specieslevel
identif
staphylococci
use
seri
control
strain
experi
assay
easi
standardis
interpret
object
determin
clonal
featur
catheterrel
bloodstream
infect
crbsi
coagulaseneg
staphylococcu
cn
evalu
applic
molecular
tool
crbsi
diagnosi
method
studi
cn
crbsi
episod
patient
cn
cultur
peripher
blood
cathet
tip
cultur
differ
cn
morphotyp
coloni
differ
morpholog
pick
cultur
biotyp
antibiotyp
genotyp
pfge
type
obtain
result
morpholog
differ
correl
differ
pfge
type
case
among
correl
differ
antibiogram
biotyp
speci
level
simultan
presenc
one
cn
clone
polyclon
found
cathet
bloodstream
infect
cn
crbsi
suspect
case
confirm
molecular
method
true
cn
crbsi
episod
diagnos
singl
coloni
randomli
select
blood
cathet
tip
cultur
molecularli
confirm
crbsi
two
differ
cn
clone
track
cathet
tip
blood
cultur
caus
polyclon
crbi
half
true
crbsi
episod
cn
clone
involv
crbsi
accompani
cn
clone
cn
crbsi
clone
minor
found
blood
cultur
less
isol
involv
epidemiolog
studi
reveal
clone
group
mayor
cluster
isol
cluster
homolog
greater
presenc
clone
hospit
servic
particular
month
conclus
molecular
tool
allow
reveal
microbiolog
complex
crbsi
cn
precis
analysi
diagnost
cn
crbsi
requir
consid
find
consequ
redefin
microbiolog
procedur
tool
effici
manag
entiti
screen
conventi
cultur
take
day
would
possibl
women
object
numer
pcrbase
assay
develop
identif
brucella
improv
diagnost
capabl
purpos
simpl
identif
brucella
adequ
howev
pcr
primer
reliabl
tool
rapid
identif
brucella
speci
differenti
close
relat
organ
fundament
question
aris
epidemiolog
investig
outbreak
whether
outbreak
strain
genet
relat
propos
strain
highli
discrimin
genet
marker
character
bacteri
strain
help
clarifi
genet
relationship
among
strain
brucella
amo
abortusmelitensisovissui
pcr
assay
previous
develop
identifi
differenti
specif
brucella
speci
materi
method
twenti
strain
b
melitensi
isol
human
anim
use
tradit
techniqu
four
field
trip
rural
area
two
region
kazakhstan
total
peopl
examin
b
melitensi
biovar
isol
case
individu
presum
infect
brucella
sp
two
b
melitensi
biovar
isol
sheep
milk
twenti
isol
identifi
test
convent
biochem
test
pcrbase
brucella
amo
pcr
result
twenti
isol
identifi
test
convent
biochem
test
pcrbase
brucella
amo
pcr
includ
isol
identifi
b
melitensi
biovar
b
melitensi
biovar
b
melitensi
biovar
result
classic
type
b
melitensi
cultur
isol
human
anim
confirm
genet
level
pcr
high
specif
pcrbase
assay
demonstr
test
biovar
twenti
strain
b
melitensi
brucella
amo
pcr
correctli
identifi
isol
b
melitensi
howev
due
amo
biolog
type
genet
featur
strain
b
melitensi
found
two
b
melitensi
biovar
isol
peopl
serolog
posit
acut
brucellosi
sat
conclus
pcrbase
test
amospcr
could
use
complementari
test
identifi
genu
brucella
differenti
specif
brucella
speci
howev
explain
genet
distinct
fingerprint
requir
direct
detect
salmonella
spp
faecal
specimen
realtim
pcr
assay
result
see
tabl
pt
cultur
proven
onychomycosi
due
dermatophyt
sensit
lab
b
c
respect
mean
includ
grey
zone
specif
consid
healthi
subject
true
neg
control
pt
suspect
onychomycosi
neg
cultur
dermatophyt
posit
pt
posit
de
pt
neg
de
base
result
mycolog
proven
onychomycosi
healthi
control
result
consid
true
posit
low
perform
mycolog
sampl
relat
nonprop
condit
sampl
ds
mycolog
result
properli
collect
sampl
nail
use
refer
sampl
posit
case
proven
dermatophyt
onychomycosi
conclus
provid
diagnosi
onychomycosi
due
dermatophyt
without
speci
identif
within
hour
sampl
sensit
properli
collect
sampl
ds
close
mycolog
techniqu
perform
properli
collect
sampl
valid
pcrrflp
analysi
gap
gene
use
tool
specieslevel
identif
staphylococc
isol
grzeszczuk
sabat
bartoszewicz
przondomordarska
w
hryniewicz
warsaw
wroclaw
pl
object
increas
number
infect
due
coagul
neg
staphylococcu
con
document
therefor
rapid
accur
identif
con
speci
may
provid
import
diagnost
inform
would
allow
select
appropri
cours
treatment
time
effect
manner
gap
gene
encod
dehydrogenas
propos
target
polymeras
chain
reactionrestrict
fragment
length
polymorph
pcrrflp
analysi
identif
staphylococcu
speci
goal
studi
evalu
reliabl
pcrrflp
system
identif
staphylococci
speci
level
method
collect
mostli
clinic
well
laboratori
strain
compris
staphylococc
speci
select
isol
identifi
speci
level
partial
sequenc
analysi
rrna
soda
rpob
gene
pcrbase
amplif
gap
gene
follow
rflp
analysi
restrict
enzym
alui
biochem
test
base
id
staph
biomerieux
presenc
clump
factor
coagulas
effect
treatment
toxoplasmaspecif
igg
antibodi
igg
avid
matur
v
meroni
f
genco
g
ferrari
l
bollani
l
piccoli
c
bodini
p
lanzarini
pavia
milan
object
aim
studi
evalu
influenc
treatment
spiramycin
increas
igg
titr
igg
avid
index
pregnant
women
seroconvers
recent
toxoplasma
gondii
infect
twofold
greater
igg
antibodi
increas
igm
posit
low
avid
index
begin
therapi
deliveri
comparison
adult
patient
recent
acquir
pharmacolog
treat
toxoplasmosi
method
eighteen
pregnant
women
seroconvers
toxoplasmosi
andor
low
igg
avid
index
follow
begin
therapi
spiramycin
deliveri
fifteen
pregnant
women
also
test
month
deliveri
interrupt
therapi
igg
antibodi
respons
igg
avid
index
also
evalu
control
group
adult
patient
seroconvers
recent
infect
serum
sampl
test
commerci
avail
kit
vida
toxo
igg
ii
vida
toxo
igg
avid
toxoisaga
biomerieux
marci
letoil
franc
liaison
toxo
igg
ii
liaison
toxo
igg
avid
ii
diasorin
saluggia
itali
result
matur
toxoplasmaspecif
igg
antibodi
igg
avid
delay
therapi
administr
pregnant
women
compar
time
curv
obtain
untreat
patient
observ
faster
matur
igg
igg
avid
index
latter
one
addit
antibodi
rebound
observ
treat
pregnant
popul
igg
avid
matur
deliveri
interrupt
therapi
conclus
previous
describ
therapi
spiramycin
may
modifi
igg
antibodi
respons
igg
avid
matur
pregnant
women
reason
delay
serolog
respons
may
reduct
parasit
load
earli
treat
infect
due
effect
spiramycin
trophozoit
stage
antibodi
rebound
observ
deliveri
therapi
interrupt
may
thu
also
explain
object
group
b
streptococc
infect
lead
caus
neonat
mortal
prevent
sever
diseas
especi
earli
onset
diseas
either
riskbas
screeningbas
approach
use
identifi
candid
intrapartum
antibiot
latter
case
women
screen
carriag
group
b
streptococci
week
gestat
cultur
intrapartum
chemoprophylaxi
offer
carrier
howev
cultur
strategi
may
accur
predict
genit
tract
colon
time
labour
potenti
treatment
well
treatment
issu
debat
studi
look
new
rapid
polymeras
chain
reaction
pcr
assay
alternativescreen
tool
method
evalu
fast
polymeras
chain
reaction
test
cepheid
rapid
identif
b
streptococci
colon
women
ad
admiss
deliveri
rapid
pcr
techniqu
sampl
genitalan
swab
analys
use
fluoresc
hybrid
probe
fluoresc
detect
result
avail
less
hour
result
two
month
period
analys
swab
vaginalan
women
deliveri
presenc
b
streptococci
cultur
pcr
parallel
result
method
congruent
b
streptococci
detect
case
bstreptococci
penicillin
suscept
conclus
one
potenti
advantag
use
test
screen
could
use
time
admiss
labour
therefor
offer
better
sensit
specif
predict
colon
women
time
labour
furthermor
mother
receiv
prenat
care
could
screen
pcr
techniqu
time
admiss
hospit
rapid
process
make
possibl
admist
chemoprophylaxi
promptli
women
deliveri
mrsaspecif
gene
sequenc
within
sccmec
orfx
sccmec
mobil
genet
element
harbour
meca
gene
evalu
assay
detect
mrsa
nasal
rectal
swab
obtain
hospitalis
patient
compar
chromogen
mrsa
select
medium
method
copan
swab
liquid
stuart
media
use
collect
nasal
rectal
specimen
idimrsa
assay
nasal
swab
process
describ
warren
et
al
j
clin
microbiol
rectal
swab
vortex
ml
sampl
buffer
ml
ad
lysi
tube
brief
vortex
tube
tube
heat
minut
subsequ
ml
cool
sampl
buffer
ad
pcr
master
mix
mrsaselect
marn
la
coquett
franc
plate
either
inocul
directli
nasal
swab
ml
sampl
buffer
prepar
rectal
swab
result
total
pair
nasal
rectal
swab
test
result
cultur
idi
mrsa
assay
shown
cultur
posit
pcrneg
result
could
consid
true
posit
mrsa
isol
subsequ
nasal
rectal
specimen
posit
predic
valu
increas
result
regard
true
posit
thirtyon
rectal
nasal
specimen
could
evalu
repeat
inhibit
amplif
reaction
conclus
idimrsa
assay
rapid
sensit
mrsa
detect
method
nasal
rectal
specimen
assay
advantag
realtim
pcr
convent
pcr
method
perform
directli
patient
specimen
allow
day
result
disadvantag
idimrsa
includ
high
initi
invest
equip
high
cost
test
also
observ
higher
rate
inhibit
previous
report
evalu
septifast
new
commerci
avail
broadrang
realtim
pcr
assay
detect
bacteria
fungi
blood
g
lisbi
h
westh
hvidovr
dk
introduct
blood
cultur
bc
gold
standard
detect
bacteraemia
fungaemia
sever
limit
fals
posit
result
due
contamin
fals
neg
result
due
eg
antibiot
treatment
time
sampl
well
known
problem
nucleic
acid
target
amplif
pcr
could
potenti
supplement
tradit
bc
object
compar
new
commerci
avail
broadrang
realtim
pcr
assay
septifast
bc
detect
bacteria
fungi
blood
patient
suspect
sepsi
sir
septifast
detect
total
pathogen
speci
method
bc
sampl
ml
obtain
use
steril
techniqu
immedi
ml
blood
sampl
obtain
pcr
depart
clinic
microbiolog
hvidovr
hospit
bc
bactalert
biomerioux
perform
accord
standard
oper
procedur
pcr
septifast
roch
diagnost
perform
accord
manufactur
descript
use
magna
lyser
lightcycl
roch
diagnost
result
total
episod
combin
bc
sampl
pcr
sampl
collect
patient
episod
neg
bc
pcr
episod
posit
one
assay
episod
bc
posit
yield
bc
isol
posit
rate
non
contamin
bc
two
isol
includ
pcr
panel
three
isol
consid
contamin
remain
seven
isol
avail
direct
comparison
pcr
detect
five
episod
pcr
posit
posit
rate
non
contamin
pcr
detect
total
microorgan
two
detect
microorgan
consid
contamin
six
also
detect
bc
detect
bc
pcr
bcisol
six
confirm
cultur
micororgan
clinic
relev
anatom
site
five
could
confirm
cultur
combin
test
posit
rate
noncontamin
six
episod
posit
pcr
bc
pcr
would
reveal
speci
identif
approx
hour
perform
daili
basi
bc
averag
delay
day
gram
stain
day
speci
identif
conclus
studi
show
septifast
pcr
valuabl
addon
convent
bc
detect
bacteria
fungi
blood
multipl
aetiolog
urethr
cervic
sexual
transmit
diseas
clinic
caus
chlamydia
trachomati
neisseria
gonorrhoea
mycoplasma
genitalium
trichomona
vaginali
advanc
diagnost
test
chlamydia
trachomati
eickhoff
cramer
grew
hamburg
de
object
genom
oblig
intracellular
bacterium
c
trachomati
consist
circular
chromosom
mb
conserv
cryptic
plasmid
approxim
kb
size
present
multipl
copi
organ
plasmid
great
practic
import
favour
target
nucleic
acid
amplif
technolog
naat
howev
isol
c
trachomati
describ
contain
plasmid
evalu
perform
artu
tm
c
trachomati
plu
rg
pcr
kit
qiagen
diagnost
gmbh
germani
combin
highli
sensit
detect
chlamydi
dna
swab
urin
sperm
sampl
high
specif
use
combin
ompaand
cryptic
plasmidbas
pcr
method
artu
tm
c
trachomati
plu
rg
pcr
kit
constitut
readi
use
system
detect
c
trachomati
dna
realtim
polymeras
chain
reaction
pcr
use
rotorgen
tm
instrument
corbett
research
australia
c
trachomati
plu
rg
master
contain
reagent
enzym
specif
amplif
direct
detect
bp
region
c
trachomati
genom
bp
region
chlamydi
cryptic
plasmid
addit
contain
second
amplif
system
intern
control
identifi
possibl
pcr
inhibit
control
isol
procedur
swab
sperm
specimen
purifi
use
dna
mini
kit
urin
specimen
use
viral
rna
mini
kit
qiagen
germani
evalu
assay
perform
retrospect
swab
sampl
urethr
cervic
vagin
swab
retrospect
urin
sampl
male
femal
well
prospect
sperm
sampl
result
diagnost
sensit
specif
sperm
sampl
shown
swab
urin
sampl
artu
tm
c
trachomati
plu
rg
pcr
kit
show
diagnost
sensit
specif
conclus
result
show
new
realtim
pcr
assay
provid
sensit
specif
way
detect
c
trachomati
variou
sampl
materi
artu
tm
c
trachomati
plu
rg
pcr
kit
laboratori
physician
longer
need
implement
confirmationpcr
necessari
commerci
test
system
use
base
cryptic
plasmid
lcr
method
detect
chlamydia
trachomati
patient
chronic
nonbacteri
prostat
n
draskov
belgrad
cs
object
chronic
prostat
frequent
men
age
almost
prostat
case
consist
chronic
nonbacteri
prostat
cnbp
unclear
aetiolog
recent
year
role
chlamydia
trachomati
ct
etiopathogenesi
cnbp
came
focu
genit
chlamydia
infect
widespread
frequent
asymptomat
chronic
therefor
form
prostat
consid
complic
genit
ct
infect
aim
studi
determin
whether
ct
infect
could
correl
cnbp
form
method
sampl
patient
cnbp
group
prostatodynia
control
group
analys
sampl
perform
accord
standard
starney
mear
method
urethr
swab
urin
flash
urin
flash
ep
express
prostat
secret
prostat
massag
kind
sampl
enabl
segment
local
infect
sampl
analys
bacteria
ct
determin
done
nucleic
acid
amplif
perform
ligas
chain
reaction
lcr
direct
microscopi
gramstain
prostat
experi
perform
infect
criterion
find
white
blood
cell
wbc
per
highpow
field
hpf
result
cnbp
group
ct
urethr
swab
sampl
ct
found
ep
sampl
sampl
control
group
prostatodynia
ct
found
one
ep
sampl
sampl
ct
present
conclus
cnbp
group
ct
determin
sampl
lcr
control
group
differ
statist
signific
cnbp
patient
ct
posit
ep
sampl
posit
ct
correl
form
cnbp
valid
assess
sampl
must
done
accord
stamey
mear
method
improv
exist
magnet
particl
base
naat
sampl
prepar
system
c
trachomati
urin
significantli
reduc
process
time
maintain
sensit
auriac
engen
uh
refseth
oslo
object
chlamydia
trachomati
lead
caus
sexual
transmit
diseas
worldwid
still
rise
obtain
control
pandem
health
author
promot
use
noninvas
sampl
collect
urin
increas
test
among
target
popul
howev
avail
technolog
repres
challeng
respect
cost
control
logist
diagnost
laboratori
major
bottleneck
associ
naat
base
analysi
c
trachomati
diagnost
use
urin
specimen
cumbersom
manual
procedur
obtain
dna
suffici
high
qualiti
autom
sampl
prepar
necess
reduc
handson
time
cross
contamin
method
base
magnet
particl
sampl
prepar
bug
n
bead
tm
genpoint
norway
previous
shown
well
suit
isol
c
trachomati
urin
autom
system
current
use
custom
tecan
miniprep
instrument
use
hour
process
sampl
howev
laboratori
may
requir
even
higher
throughput
could
achiev
tri
reduc
sampl
prepar
time
clinic
microbiolog
infect
volum
supplement
method
studi
simplifi
magnet
particl
base
protocol
complet
entir
sampl
process
hour
tecan
miniprep
robot
platform
compar
origin
bug
n
bead
procedur
total
urin
sampl
previous
determin
posit
c
trachomati
use
origin
bug
n
bead
tm
method
analys
use
new
prepar
protocol
combin
bdprobetec
detect
system
c
trachomati
amplif
control
ac
bdprobetec
kit
includ
new
method
reveal
potenti
inhibit
result
sampl
posit
new
sampl
prepar
protocol
indic
sensit
reduc
comparison
origin
bug
n
bead
tm
procedur
moreov
inhibit
encount
urin
sampl
demonstr
ac
mota
valu
cutoff
valu
defin
bdprobetec
detect
kit
conclus
new
faster
dna
prepar
method
allow
signific
increas
throughput
compar
origin
bug
n
bead
solut
final
consequ
reduct
process
time
new
method
allow
laboratori
access
full
naat
autom
introduct
smaller
cheaper
robot
system
compar
studi
three
differ
pcr
assay
detect
mycoplasma
genitalium
genit
specimen
men
women
object
aim
studi
compar
convent
rrna
pcr
realtim
rrna
pcr
real
time
mgpa
pcr
detect
method
mycoplasma
genitalium
infect
also
want
determin
preval
genitalium
patient
men
women
visit
sti
clinic
rural
area
west
sweden
method
first
void
urin
fvu
andor
urethr
swab
collect
men
women
fvu
andor
cervic
swab
andor
urethr
swab
collect
two
hundr
fifteen
specimen
use
pcr
compar
studi
consecut
specimen
consecut
specimen
patient
symptom
urethr
specimen
patient
posit
genitalium
real
time
mgpa
pcr
preval
studi
trueposit
sampl
defin
specimen
posit
two
pcr
assay
result
preval
genitalium
infect
men
women
respect
pcr
compar
studi
genitalium
dna
detect
convent
rrna
pcr
real
time
rrna
pcr
real
time
mgpa
pcr
trueposit
specimen
genitalium
dna
detect
addit
specimen
real
time
mgpa
pcr
four
specimen
women
anoth
trueposit
sampl
addit
specimen
also
women
anoth
trueposit
sampl
detect
convent
rrna
pcr
conclus
real
time
mgpa
pcr
indic
slightli
higher
sensit
compar
convent
rrna
pcr
increas
sensit
compar
real
time
rrna
pcr
detect
genitalium
dna
preval
men
women
attend
sti
clinic
concord
swedish
studi
new
realtim
quantit
taqman
pcr
detect
chlamydia
trachomati
dna
urin
urogenit
swab
k
jaton
j
bill
c
g
greub
lausann
ch
object
chlamydia
trachomati
infect
frequent
bacteri
sexual
transmit
diseas
urogenit
infect
often
asymptomat
remain
untreat
may
lead
sever
late
complic
women
includ
infertil
extrauterin
pregnanc
screen
chlamydia
trachomati
infect
may
perform
urin
urogenit
swab
use
molecular
detect
techniqu
howev
commerci
avail
method
remain
expens
associ
larg
laboratori
workload
reduc
cost
increas
throughput
develop
c
trachomati
specif
realtim
quantit
taqman
pcr
qpcr
materi
method
qpcr
may
use
abi
prism
sequenc
system
appli
biosystem
develop
system
coupl
liquid
handl
unit
tecanr
allow
automat
pipet
use
well
micro
plate
dna
extract
magnapur
roch
qpcr
perform
use
dna
pcr
mixtur
primer
probe
select
highli
conserv
sequenc
cryptic
plasmid
new
qpcr
compar
commerci
coba
amplicorr
cpcr
total
specimen
taken
patient
urogenit
swab
urin
sampl
result
qpcr
exhibit
analyt
sensit
cpcr
analyt
specif
qpcr
excel
signal
detect
presenc
bacteri
dna
other
chlamydia
speci
bacteri
speci
potenti
present
urogenit
sampl
inhibit
pcr
reaction
observ
qpcr
wherea
sampl
inhibit
cpcr
comparison
remain
specimen
show
overal
agreement
cpcr
qpcr
consid
cpcr
gold
standard
specif
sensit
discrep
result
reinvestig
second
run
cpcr
qpcr
one
found
strongli
posit
method
found
neg
second
run
coba
posit
qpcr
addit
replic
done
suggest
low
amount
dna
sampl
conclus
qpcr
specif
method
exhibit
similar
sensit
cpcr
detect
c
trachomati
given
high
throughput
potenti
low
cost
qpcr
reagent
per
sampl
may
contribut
futur
largescreen
program
first
void
urin
use
transport
medium
cervic
swab
specimen
detect
mycoplasma
genitalium
polymeras
chain
reaction
june
three
type
sampl
collect
patient
fvu
cervic
swab
transport
medium
cervic
swab
transport
fvu
sampl
analys
genitalium
dna
real
time
mgpa
pcr
smartcyclerii
cepheid
sunnyval
usa
result
genitalium
dna
detect
sampl
cervic
swab
transport
patient
fvu
wherea
genitalium
dna
detect
fvu
sampl
cervic
swab
transport
medium
compar
two
differ
dna
extract
method
manual
extract
use
chelex
slurri
biorad
richmond
usa
autom
biorobot
extract
qiagen
hilden
germani
genitalium
dna
detect
addit
sampl
total
use
extract
compar
genitalium
posit
sampl
detect
use
chelex
extract
inhibit
detect
chelex
extract
sampl
wherea
inhibit
detect
use
extract
small
subset
sampl
abl
detect
genitalium
dna
week
storag
room
temperatur
conclus
studi
show
cervic
swab
transport
patient
fvu
genitalium
dna
detect
real
time
pcr
result
indic
medium
exclud
genitalium
analysi
procedur
lead
reduct
sampl
number
two
one
per
patient
reduc
cost
analysi
object
valid
integr
autom
magneticparticl
sampl
purif
system
routin
workflow
commerci
diagnost
laboratori
increas
standard
nucleic
acid
purif
use
midtolow
throughput
robot
workstat
method
nucleic
acid
purifi
use
workstat
use
protocol
dna
bacteria
card
viru
card
protocol
infecti
diseas
applic
packag
biorobot
bacteri
dna
extract
use
biorobot
workstat
togeth
dna
tissu
kit
biorobot
workstat
use
purifi
bacteri
dna
combin
magattract
dna
mini
kit
protocol
infecti
diseas
applic
packag
cd
viral
dna
andor
rna
purifi
use
viru
mini
kit
magattract
viru
mini
kit
pathogen
nucleic
acid
extract
rang
clinic
specimen
type
includ
plasma
respiratori
sampl
swab
whole
blood
artu
tm
assay
rang
inhous
design
downstream
assay
use
compar
extract
effici
result
autom
extract
follow
detect
bacteri
dna
group
b
streptococci
aureu
b
pertussi
show
high
sensit
specif
significantli
reduc
mean
timetoresult
workflow
effici
compar
manual
extract
method
cytomegaloviru
cmv
dna
nucleic
acid
perform
well
show
larg
dynam
rang
allow
accur
quantif
use
inhous
design
commerci
avail
artu
tm
assay
human
papilloma
viru
hpv
dna
hepat
c
viru
rna
perform
well
commerci
assay
conclus
biorobot
provid
standard
easytous
protocol
nucleic
acid
purif
wide
rang
clinic
sampl
type
biorobot
provid
process
capac
samplesrun
enabl
routin
applic
mid
high
throughput
clinic
laboratori
lowthroughput
biorobot
samplesrun
ensur
prioriti
sampl
handl
safe
quickli
without
decreas
laboratori
effici
perform
purifi
nucleic
acid
artu
tm
assay
excel
illustr
combin
efficaci
biorobot
sampl
prepar
artu
assay
use
diagnost
analys
object
develop
multiplex
realtim
pcr
method
detect
seven
common
candida
speciescaus
septicemia
c
albican
c
dubliniensi
c
glabrata
c
guilliermondii
c
krusei
c
parapsilosi
c
tropicali
evalu
dna
extract
method
detect
limit
pcr
direct
detect
candida
infect
human
venou
blood
method
multiplex
four
channel
realtim
pcr
assay
develop
target
gene
code
rna
subunit
ribonucleas
p
sequenc
seven
candida
speci
determin
multiplex
pcr
contain
four
primer
four
taqman
probe
label
fluorophor
differ
wavelength
three
probe
enabl
specif
detect
c
albican
c
glabrata
c
krusei
fourth
allow
gener
detect
remain
speci
candida
dna
extract
ml
human
blood
use
lyticas
qiaamp
tissu
kit
result
multiplex
pcr
abl
detect
genom
copi
detect
limit
test
repeatedli
four
speci
c
albican
c
glabrata
c
krusei
c
guillermondi
signific
differ
detect
limit
seen
multiplex
format
compar
singl
speci
pcr
ie
two
primer
one
probe
candida
dna
extract
spike
human
blood
detect
limit
cell
per
ml
reach
multiplex
system
inbuilt
specif
control
one
channel
posit
specif
speci
achiev
run
perform
sequenc
data
seven
candida
speci
show
surprisingli
larg
sequenc
variat
broadrang
primer
c
glabrata
produc
five
time
longer
amplicon
compar
speci
nucleotid
sequenc
similar
c
krusei
c
albican
low
gener
primer
satisfactori
realtim
pcr
could
design
speci
c
glabrata
c
krusei
result
multiplex
fourprim
system
conclus
sensit
specif
multiplex
realtim
pcr
develop
detect
seven
candida
speci
identif
c
albican
c
glabrata
c
krusei
use
detect
candida
spp
blood
sampl
applic
malditof
mass
spectrometri
qualiti
control
nctc
strain
assess
nation
intern
laboratori
centr
infect
current
suppli
preserv
strain
freezedri
cultur
preserv
provis
cultur
lenticul
format
rather
freezedri
cultur
howev
prefer
sinc
facilit
easier
process
cultur
increas
distribut
rate
provid
cost
effect
format
facilit
postag
worldwid
assess
effect
chang
format
therebi
ensur
qualiti
nctc
strain
remain
unchang
malditof
mass
spectrometri
use
direct
comparison
respect
nctc
preserv
strain
method
ten
nctc
type
refer
strain
repres
genera
speci
simultan
reviv
freezedri
equival
lenticul
disc
preserv
intact
microbi
cell
equival
sampl
inocul
onto
maldi
target
plate
cocrystallis
batch
maldi
matrix
laser
interrog
surfac
associ
molecul
pair
type
refer
strain
provid
compar
malditof
mass
spectral
profil
use
assess
differ
associ
preserv
format
result
mathemat
interrog
mass
spectral
profil
demonstr
neglig
differ
organ
recov
two
preserv
method
surfac
associ
molecul
intact
microbi
cell
therefor
remain
unalt
preserv
lenticul
conclus
applic
malditof
mass
spectrometri
qualiti
control
nctc
strain
suggest
lenticul
product
result
alter
morphotyp
ensur
qualiti
nctc
strain
maintain
object
present
one
main
medic
problem
hospit
increas
number
nosocomi
hospitalacquir
infect
epidemiolog
data
show
limit
number
microorgan
respons
major
bloodstream
infect
twentyf
speci
account
nosocomi
pathogen
rapid
diagnosi
sepsi
correct
identif
caus
pathogen
follow
immedi
appropri
antimicrobi
therapi
key
success
manag
bacteraemia
fungaemia
septic
patient
limit
method
septifast
test
develop
detect
differenti
pathogen
microbi
dna
human
whole
blood
specimen
prepar
base
semi
autom
procedur
use
magna
lyser
follow
manual
spin
column
base
nucleic
acid
prepar
amplif
detect
autom
use
lightcycl
instrument
result
compar
classic
method
blood
cultur
follow
gram
stain
speci
identif
base
cultur
method
septifast
test
offer
improv
sensit
much
better
time
result
case
result
avail
hour
instead
two
three
day
case
posit
pcr
result
therapi
adjust
two
day
earlier
might
lead
signific
save
hospit
well
improv
outcom
patient
case
neg
pcr
result
blood
cultur
remain
basi
medic
decis
conclus
septifast
test
first
ivd
assay
use
pcr
rapid
detect
identif
bacteri
fungal
pathogen
involv
nosocomi
infect
directli
whole
blood
present
nonclin
perform
data
well
select
data
sever
extern
clinic
studi
illustr
abil
power
assay
comparison
realtim
convent
pcr
assay
diagnosi
cat
scratch
diseas
patient
lymph
node
enlarg
object
realtim
polymeras
chain
reaction
pcr
novel
rapid
method
detect
identif
fastidi
grow
bacteria
like
bartonella
aim
studi
develop
realtim
pcr
base
method
abl
differenti
main
bartonella
speci
involv
human
endocard
cat
scratch
diseas
csd
ii
compar
realtim
pcr
convent
pcr
diagnosi
csd
method
realtim
pcr
assay
use
doubl
hybrid
probe
format
light
cycler
develop
identif
differenti
bartonella
speci
base
amplif
real
time
pcr
fragment
glta
gene
follow
tm
determin
convent
pcr
target
fragment
htra
gene
b
hensela
evalu
sampl
lymph
node
biopsi
cytopunctur
tenyear
period
patient
divid
three
group
accord
number
posit
diagnost
criteria
csd
patient
definit
csd
two
classic
criteria
possibl
csd
anoth
diagnosi
retain
use
control
group
result
convent
pcr
detect
b
hensela
wherea
realtim
pcr
method
could
detect
differenti
b
hensela
b
quintana
b
koehlera
b
vinsonii
b
alsatica
b
berkhoffii
specif
assay
sensit
convent
realtim
pcr
assay
sampl
patient
definit
csd
realtim
pcr
coupl
autom
dna
extract
magna
pure
robot
roch
less
suscept
inhibitor
manual
extract
magna
pure
conclus
light
cycler
pcr
assay
sensit
specif
less
time
consum
convent
pcr
therefor
realtim
pcr
analysi
could
use
csd
diagnosi
combin
epidemiolog
serolog
histolog
criteria
object
pneumocysti
jiroveci
remain
one
import
caus
pneumonia
immunocompromis
patient
detect
fungu
bronchoalveolar
lavag
bal
fluid
use
nest
pcr
great
sensit
specif
diagnost
pneumocysti
pneumonia
pcp
twostep
method
rather
time
consum
decid
replac
taqman
realtim
quantit
pcr
target
neighbour
region
gene
mtlsu
rrna
gene
method
total
number
bal
specimen
immunocompromis
patient
test
use
nest
pcr
assay
fortynin
specimen
p
jiroveci
posit
twentynin
p
jiroveci
posit
neg
specimen
retest
use
novel
realtim
pcr
assay
result
method
compar
detect
copi
number
correl
clinic
find
result
absolut
concord
posit
neg
result
obtain
method
realtim
pcr
assay
abl
detect
copi
plasmid
standard
per
tube
sensit
nest
pcr
copi
number
target
gene
posit
sampl
vari
copi
per
tube
median
copi
per
tube
posit
patient
retrospect
clinic
evalu
could
divid
group
patient
pcp
median
copi
number
rang
copi
per
tube
ii
patient
polymicrobi
pneumonia
p
jiroveci
anoth
pathogen
median
copi
number
rang
copi
per
tube
iii
patient
without
pcp
median
copi
number
rang
copi
per
tube
conclus
develop
rapid
sensit
realtim
pcr
assay
detect
p
jiroveci
use
assay
abl
obtain
result
hour
sampl
deliveri
contrari
hour
necessari
nest
pcr
moreov
assay
seem
discrimin
patient
pcp
p
jiroveci
carrier
certainli
sampl
must
test
determin
cutoff
valu
precis
work
support
ministri
health
czech
republ
grant
object
laboratori
diagnosi
whoop
cough
well
standard
differ
pcr
system
develop
detect
bordetella
pertussi
mainli
base
insert
sequenc
target
region
show
copi
number
per
cell
make
system
highli
sensit
howev
transpos
dna
element
capabl
horizont
transfer
across
speci
spontan
elimin
characterist
tend
compromis
specif
pcr
base
diagnost
system
goal
work
develop
evalu
highli
sensit
absolut
specif
reliabl
ivd
assay
base
realtim
pcr
technolog
detect
differenti
human
pathogen
bordetella
speci
b
pertussi
b
parapertussi
b
bronchiseptica
method
develop
isindepend
pcr
system
simultan
detect
b
pertussi
b
paraperussi
b
bronchiseptica
differenti
speci
melt
curv
analysi
use
lightcycl
instrument
roch
diagnost
combin
system
isdepend
pcr
system
intern
control
ic
pcr
test
type
strain
known
bordetella
speci
differ
clinic
isol
human
pathogen
bordetella
speci
differ
bacteri
viral
fungal
isol
valid
specif
analyt
clinic
sensit
assay
evalu
probit
analysi
test
clinic
specimen
differ
laboratori
result
abl
develop
one
tube
realtim
pcr
assay
detect
differenti
b
pertussi
b
parapertussi
b
bronchiseptica
intern
control
also
implement
system
test
dna
prepar
known
bordetella
speci
viral
bacteri
fungal
isol
either
close
relat
bordetella
caus
similar
symptom
observ
crossreact
analyt
sensit
assay
b
pertussi
determin
probit
analysi
copiesl
p
clinic
sensit
specif
demonstr
test
clinic
specimen
conclus
could
demonstr
new
realtim
pcr
assay
detect
differenti
human
pathogen
bordetella
speci
combin
high
sensit
insert
sequenc
base
pcr
system
reliabl
specif
independ
pcr
system
secur
intern
control
singl
reaction
object
evalu
nucleic
acid
amplif
procedur
detect
mycoplasma
pneumonia
chlamydia
pneumonia
respiratori
tract
specimen
method
use
rna
princip
target
amplif
perform
nasba
reagent
nuclisen
basic
kit
inhous
produc
primer
molecular
beacon
probe
intern
control
ic
rna
develop
monitor
procedur
individu
sampl
level
nucleic
acid
extract
respiratori
sampl
nuclisen
minimag
method
base
magnet
silica
use
method
evalu
sputa
bronchu
aspir
bronchoalveolar
lavag
throat
swab
sampl
patient
cap
result
respiratori
sampl
optim
ic
rna
input
level
establish
compromis
reliabl
detect
ic
rna
minim
effect
sensit
detect
pathogen
rna
ic
rna
spike
sampl
nucleic
acid
extract
follow
amplif
duplic
either
primerbeacon
combin
sensit
defin
hit
rate
found
copi
rna
per
extract
chlamydia
pneumonia
copi
mycoplasma
pneumonia
success
nucleic
acid
extract
reflect
effici
ic
rna
amplif
incident
invalid
result
obtain
could
resolv
second
amplif
analysi
nucleic
acid
extract
total
sampl
found
posit
mycoplasma
pneumonia
chlamydia
pneumonia
could
confirm
second
molecular
method
conclus
realtim
nasba
amplif
potenti
valuabl
tool
molecular
diagnosi
mycoplasma
pneumonia
chlamydia
pneumonia
multipl
amplif
analys
ic
rna
perform
singl
nucleic
acid
extract
evalu
need
confirm
clinic
valu
method
develop
realtim
pcr
use
sybr
green
melt
curv
analysi
identifi
bordetella
pertussi
bordetella
parapertussi
clinic
specimen
evalu
effect
current
practic
p
lehour
menard
j
sarlangu
c
laguent
ch
bebear
f
megraud
b
de
barbeyrac
bordeaux
fr
object
whoop
cough
affect
young
adult
teenag
thu
abl
contamin
infant
unvaccin
incomplet
vaccin
popul
evolv
readili
atyp
sever
form
difficult
diagnos
biolog
confirm
necessari
thu
molecular
techniqu
repres
invalu
tool
describ
realtim
pcr
assay
identif
b
pertussi
b
parapertussi
clinic
specimen
method
avail
sequenc
b
pertussi
align
identifi
conserv
region
primer
design
primer
detect
b
parapertussi
design
sequenc
univers
pcr
target
rdna
gene
also
develop
use
control
extract
absenc
pcr
inhibitor
pcr
primer
set
test
dna
extract
bordetella
speci
divers
bacteri
speci
commonli
found
human
sybr
realtim
pcr
amplif
melt
curv
tm
analysi
carri
abi
thermocycl
appli
biosystem
follow
melt
program
retrospect
studi
perform
posit
n
neg
n
nasopharyng
aspir
npa
test
prospect
npa
receiv
april
novemb
result
use
control
strain
dna
extract
b
pertussi
b
parapertussi
led
amplif
demonstr
specif
two
pcr
melt
curv
analysi
amplicon
b
pertussi
b
parapertussi
control
strain
exhibit
tm
approxim
respect
serial
dilut
extract
dna
bacteri
suspens
test
use
assay
regress
curv
linear
bacteri
genom
slope
close
maximum
effici
retrospect
analysi
posit
sampl
posit
b
pertussi
peak
appear
neg
sampl
prospect
assay
allow
detect
posit
clinic
sampl
b
pertussi
b
parapertussi
among
could
isol
cultur
conclus
develop
new
realtim
pcr
identif
b
pertussi
b
parapertussi
target
sequenc
method
use
sybr
green
chemistri
analysi
melt
point
rapid
sensit
specif
easili
implement
set
real
time
pcr
apparatu
avail
diagnosi
pertussi
realtim
lightcycl
pcr
alv
g
rocha
c
nogueira
coimbra
pt
object
pertussi
whoop
cough
wellknown
childhood
respiratori
diseas
caus
primarili
bordetella
pertussi
infect
although
immun
program
brought
diseas
control
decad
studi
conduct
recent
year
indic
reemerg
potenti
threat
even
among
vaccin
diseas
quit
preval
among
adult
adolesc
diseas
symptom
often
atyp
sourc
b
pertussi
major
reason
diseas
transmit
children
definit
diagnosi
pertussi
tradit
made
cultur
howev
insensit
slow
serolog
test
sensit
cultur
provid
late
retrospect
diagnosi
commerci
immunoassay
distinguish
b
pertussi
b
parapertussi
infect
aim
perform
rapid
highli
specif
sensit
detect
b
pertussi
b
parapertussi
essenti
provid
appropri
therapeut
intervent
control
transmiss
diseas
method
decemb
novemb
total
nasopharyng
aspir
npa
analys
b
pertussi
detect
also
analys
b
parapertussi
patient
age
day
month
femal
male
mean
month
npa
obtain
older
children
femal
median
age
year
npa
household
contactsnucl
acid
extract
npa
qiaamp
dna
mini
kit
accord
manufactur
instruct
extract
dna
directli
analys
lightcycl
pcr
without
storag
primer
probe
b
pertussi
b
parapertussi
respect
adopt
work
ster
k
et
al
j
clin
microbiol
result
npa
analys
children
adult
femal
male
posit
b
pertussi
b
parapertussi
sampl
test
neg
conclus
standard
lightcycl
protocol
use
complet
analysi
sampl
plu
neg
posit
control
within
total
assay
time
minut
achiev
high
specif
sensit
ad
specif
probe
sum
realtim
lightcycl
pcr
suitabl
diagnosi
b
pertussi
b
parapertussi
infect
routin
diagnost
laboratori
method
nasopharyng
swab
tracheal
secret
respiratori
materi
spike
variou
amount
b
pertussi
cell
commerci
avail
ionexchang
chromatographi
column
kit
one
compani
qiagen
compar
qiaamp
dna
mini
kit
valid
dna
extract
variou
materi
ii
qiaamp
min
elut
viru
vacuum
kit
iii
qiaamp
viru
biorobot
mdx
kit
iv
qiaamp
dsp
viru
kit
ce
mark
kit
valid
prepar
viral
rna
dna
cellfre
materi
blood
pcr
perform
two
realtim
pcr
base
hybrid
probe
format
lightcycl
roch
taqman
format
sd
appli
biosystem
pcr
amplifi
differ
part
insert
sequenc
bpertussi
result
four
kit
test
could
use
prepar
b
pertussi
dna
respiratori
materi
reproduc
kit
compar
procedur
show
linear
extract
broad
rang
bacteri
dna
organismspcr
object
ureaplasma
caus
respiratori
insuffici
newborn
detect
ureaplasma
infect
cultur
difficult
timeconsum
newborn
addit
problem
necess
antibiot
administr
diagnost
procedur
start
antibiot
inhibit
growth
ureaplasma
limit
reliabl
cultur
method
purpos
studi
estim
variou
diagnost
method
urea
plasma
infect
newborn
respiratori
disord
method
five
hundr
newborn
examin
specimen
cultiv
pplo
medium
accord
hayflick
ch
parallelli
examin
biomerieux
test
bm
polymeras
chain
reaction
pcr
assay
also
appli
test
specif
region
ureaplasma
speci
occur
man
ureaplasma
urealyticum
uu
ureaplasma
parvum
endotrach
aspir
collect
infant
place
transport
medium
bm
next
sub
cultur
liquid
solid
pplo
media
bm
medium
dna
isol
transportcultur
medium
bm
hour
incub
specimen
centrifug
g
dna
denatur
c
minut
two
pair
primer
specif
uu
use
dna
refer
strain
use
posit
control
pcr
product
separ
electrophoret
agaros
gel
visual
ethidium
bromid
uv
result
ureaplasma
detect
respiratori
tract
newborn
examin
ch
show
posit
result
case
bm
case
pcr
case
correl
result
ch
bm
ch
pcr
bm
pcr
respect
sensit
specif
pcr
comparison
ch
respect
bm
case
bacteria
made
imposs
recognis
result
ureaplasma
cultur
pcr
result
definit
case
posit
result
bm
test
could
confirm
method
case
posit
result
pcr
confirm
cultur
result
conclus
pcr
highli
sensit
specif
method
recommend
rapid
diagnost
respiratori
infect
newborn
suffer
respiratori
disord
allow
detect
ureaplasma
case
concomit
infect
identifi
speci
evalu
realtim
nucleic
acid
sequencebas
amplif
dipstickbas
detect
convent
nasba
pcr
rapid
detect
mycoplasma
pneumonia
respiratori
specimen
k
ohkusu
komatsu
n
ishiwada
hoshino
n
takeda
h
sakata
takeshima
ezaki
gifu
nara
chiba
hokkaido
shizuoka
jp
object
mycoplasma
pneumonia
import
etiolog
agent
respiratori
tract
infect
respons
communityacquir
pneumonia
adolesc
adult
pneumonia
sensit
blactam
antibiot
often
use
empir
treatment
lower
respiratori
tract
infect
lrti
therefor
rapid
accur
diagnost
method
like
improv
manag
patient
pneumonia
infect
studi
evalu
realtim
nasba
assay
pneumonia
rna
clinic
specimen
compar
realtim
pcr
addit
develop
nylon
membran
strip
method
rapid
visual
detect
nucleic
acid
hybrid
method
respiratori
specimen
paediatr
adult
patient
acut
lrti
five
hospit
japan
includ
studi
nucleic
acid
extract
use
magnet
extract
kit
realtim
nasba
assay
perform
use
basic
kit
easyq
analys
primer
molecular
beacon
probe
loen
et
al
j
clin
micobiol
refer
method
realtim
pcr
use
sybr
green
perform
icycl
iq
system
biorad
describ
morozumi
et
al
j
infect
chemoth
detect
nasba
amplifi
product
nylon
membran
strip
achiev
sandwich
nucleic
hybrid
two
targetspecif
oligonucleotid
probe
one
captur
detect
format
sandwich
complex
within
minut
membran
strip
result
visual
appar
aggreg
nucleic
acid
target
latex
conjug
probe
captur
zone
result
nasba
pcr
assay
specimen
test
posit
none
pcrneg
clinic
specimen
posit
realtim
nasba
analyt
sensit
strip
detect
copi
wild
type
vitrosynthes
rna
gener
minut
nasba
amplif
assay
posit
specimen
posit
visual
strip
detect
combin
nasba
conclus
sensit
specif
realtim
nasba
use
realtim
pcr
assay
standard
furthermor
combin
nasba
assay
strip
detect
could
facilit
use
nasba
resourcelimit
set
pointofcar
test
identif
legionella
speci
use
dna
sequenc
analysi
onlin
tool
nk
fri
b
afshar
w
bellami
underwood
rm
ratcliff
tg
harrison
london
uk
adelaid
au
object
fifti
speci
legionella
describ
identif
major
classic
phenotyp
method
increasingli
difficult
aim
studi
investig
feasibl
provid
dedic
databas
allow
onlin
identif
put
legionella
spp
follow
standard
pcr
amplif
sequenc
use
previous
publish
identif
scheme
legionella
legionella
mip
gene
sequenc
databas
creat
health
protect
agenc
centr
infect
http
wwwhpaorgukinfectionsdefaulthtm
also
reach
via
ewgli
websit
wwwewgliorg
method
dna
sequenc
enter
text
upload
sequenc
chromatogram
file
databas
provid
follow
function
align
sequenc
refer
align
top
five
databas
match
user
sequenc
ii
neighbourjoin
tree
align
includ
refer
speci
five
closest
match
databas
user
sequenc
iii
align
eight
sequenc
combin
align
similar
user
sequenc
result
abil
centr
correctli
identifi
legionella
speci
assess
follow
distribut
two
profici
panel
compris
code
isol
centr
correctli
identifi
isol
test
furthermor
train
need
highlight
address
result
improv
sequenc
qualiti
conclus
genotyp
identif
legionella
speci
essenti
refer
laboratori
standard
protocol
dedic
identif
librari
onlin
tool
provid
valuabl
resourc
help
achiev
goal
anticip
addit
gene
includ
code
rrna
rpob
rnpb
groel
ad
current
identif
system
aid
character
identif
known
potenti
novel
member
genu
object
creat
improv
realtim
pcr
mycoplasma
pneumonia
detect
method
use
primer
direct
adhes
gene
realtim
pcr
develop
fret
probe
simultan
detect
mycoplasma
pneumonia
inhibit
control
sensit
ascertain
use
sampl
previous
confirm
cultur
andor
serolog
specif
use
panel
respiratori
bacteria
mollicut
speci
sinc
introduct
routin
practic
clinic
sampl
screen
method
result
assay
use
panel
respiratori
sampl
patient
pneumonia
data
regard
respiratori
pathogen
avail
specif
excel
crossreact
mollicut
respiratori
bacteria
sensit
calcul
compar
serolog
ldl
assay
x
organ
ml
fold
lower
previous
describ
method
inhibit
detect
neat
sampl
extract
reduc
sampl
dilut
factor
sinc
introduct
total
clinic
sampl
test
posit
lung
biopsi
sputa
npa
discuss
highli
specif
rapid
method
realtim
pcr
mycoplasma
pneumonia
detect
describ
greater
sensit
previou
assay
detect
legionella
dna
clinic
sampl
use
realtim
pcr
l
franzin
cabodi
n
bonfrat
f
tortorelli
turin
object
cultur
gold
standard
diagnosi
legionella
infect
howev
sever
day
requir
obtain
posit
result
dna
techniqu
promis
rapid
detect
studi
real
time
rt
pcr
system
evalu
direct
detect
legionella
clinic
sampl
compar
cultur
method
cultur
rtpcr
perform
respiratori
sampl
sputum
bronchoalveolar
lavag
fluid
bronchial
aspir
lung
tissu
patient
pneumonia
legionella
infect
ld
confirm
patient
posit
least
one
test
urin
antigen
detect
elisa
serolog
fourfold
rise
antibodi
titr
indirect
immunofluoresc
andor
micro
agglutin
test
cultur
aliquot
untreat
heattreat
acidwash
sampl
plate
bcye
bmpa
mwi
plate
incub
day
blood
sampl
symptomat
old
patient
involv
ld
outbreak
also
examin
rtpcr
lpneumophila
lp
legionella
spp
lspp
perform
dna
extract
icycl
biorad
reagent
accord
modifi
protocol
result
cultur
respiratori
sampl
posit
patient
lp
serogroup
isol
subject
lp
one
lbozemanii
anoth
rtpcr
posit
total
sampl
sampl
ld
patient
posit
rtpcr
sampl
patient
without
ld
neg
discrep
observ
one
case
categori
patient
without
ld
three
patient
proven
ld
posit
rtpcr
l
spp
neg
lp
one
cultur
posit
lbozemanii
cultur
posit
respiratori
sampl
rtpcr
posit
except
one
isol
concord
respiratori
sampl
blood
cultur
sampl
neg
rtpcr
posit
outbreak
patient
laboratori
confirm
ld
patient
clinic
laboratori
confirm
ld
conclus
laboratori
diagnosi
ld
better
achiev
combin
urin
antigen
detect
serolog
cultur
result
studi
show
good
concord
criterion
base
tradit
method
rtpcr
new
sensit
techniqu
need
evalu
offer
advantag
rapid
diagnosi
rapid
diagnosi
mycobacterium
tuberculosi
triplex
realtim
pcr
assay
w
sougakoff
c
truffotpernot
g
millot
v
jarlier
pari
fr
object
sensit
rapid
techniqu
detect
identifi
mycobacterium
tuberculosi
directli
clinic
specimen
import
diagnosi
manag
patient
tuberculosi
studi
report
evalu
realtim
pcr
assay
target
element
specif
region
tool
rapidli
diagnos
differenti
tuberculosi
canetti
posit
neg
posit
mycobacteri
speci
includ
tuberculosi
complex
posit
neg
bovi
bovi
bcg
africanum
microti
capra
pinnipedii
method
perform
assay
assess
clinic
sampl
collect
patient
two
month
period
dna
prepar
amplif
carri
new
kit
develop
biorad
biorad
real
time
tb
assay
follow
manufactur
instruct
intern
control
ad
dna
extract
order
measur
effici
dna
recoveri
check
absenc
inhibitor
result
biorad
real
time
tb
assay
correctli
identifi
specimen
proven
cultur
contain
mtuberculosi
posit
posit
neg
seven
sampl
shown
cultur
contain
bovi
n
africanum
n
eight
sampl
remain
cultureneg
found
posit
either
amplif
n
amplif
n
n
final
sampl
neg
amplif
remain
neg
cultur
three
cultureposit
amplificationneg
sampl
yield
coloni
tuberculosi
cultur
conclus
assay
base
realtim
amplif
three
distinct
target
intern
control
found
robust
sensit
specif
characteris
complementari
pattern
identif
broad
amplif
specif
mtuberculosi
mcanetti
amplif
diagnost
laboratori
method
bacteria
multiresist
corynebacteria
c
jeikeium
c
urealyticum
well
known
contribut
mortal
immunocompromis
patient
haematolog
malign
report
api
coryn
franc
minimum
inhibitori
concentr
mic
profil
observ
c
resisten
method
period
year
march
septemb
isol
unknown
gram
posit
bacilli
recov
blood
sputum
oper
wound
pu
otorrhea
cv
line
specimen
base
rrna
sequenc
segment
organ
identifi
new
speci
corynebacterium
name
c
resisten
api
coryn
franc
examin
accord
design
method
microdilut
antimicrobi
suscept
studi
perform
use
tween
supplement
muellerhinton
broth
stimul
lipiphil
c
resisten
result
four
api
coryn
pattern
observ
strain
strain
strain
strain
alkalin
phosphatas
posit
strain
pyrrolidonyl
arylamidas
pyrazinamidas
vari
depend
strain
corynebacteria
defin
oxid
glucos
ribos
characterist
depend
inoculum
densiti
glucos
ribos
reaction
neg
api
coryn
mic
result
blactam
aminoglycosid
clindamycin
fluoroquinolon
tetracyclin
demonstr
resist
wherea
result
vancomycin
suscept
respect
vancomycin
mic
lgml
linezoloid
show
activ
lgml
conclus
c
resistenss
capabl
caus
seriou
infect
compar
c
jeikeium
import
assess
clinic
signific
isol
recov
clinic
specimen
furthermor
need
updat
api
coryn
date
base
reflect
c
resisten
linezoloid
vancomycin
given
consider
firstlin
drug
rapid
phenotyp
detect
pneumococci
betahaemolyt
streptococci
directli
blood
cultur
j
montgomeri
b
mayal
melbourn
au
object
lanc
field
group
b
c
g
major
betahaemolyt
streptococci
bh
caus
human
infect
life
threaten
toxic
shocklik
syndrom
bacteraemia
restrict
sole
group
streptococci
incid
recent
increas
aim
studi
determin
accuraci
pneumococc
antigen
test
pn
detect
pneumonia
spn
modifi
streptococc
group
msg
test
directli
blood
cultur
broth
bcb
day
detect
bacteraemia
becton
dickinson
usa
method
gramposit
cocci
resembl
streptococci
seen
gram
ml
bcb
centrifug
gel
tube
pneumococc
antigen
pn
test
done
supernat
use
pneumonia
kit
instruct
manufactur
remel
inc
usa
pn
neg
bcb
group
msg
test
use
streptococc
group
kit
oxoid
ltd
england
supernat
discard
bacteri
pellet
resuspend
extract
enzym
group
perform
instruct
manufactur
result
compar
standard
cultur
method
result
pn
perform
bottl
gram
stain
resembl
streptococci
total
sp
two
fals
neg
fals
posit
reaction
occur
sensit
sn
specif
sp
posit
predict
valu
ppv
neg
predict
valu
npv
msg
perform
pn
neg
bottl
patient
five
enterococci
autoagglutin
exclud
group
ad
f
g
nongroup
streptococci
three
fals
posit
twelv
group
method
group
problemat
six
neg
enterococci
four
neg
bovi
overal
sn
sp
ppv
npv
respect
bh
group
b
c
g
group
correctli
sn
sp
ppv
npv
conclus
direct
group
blood
cultur
gram
resembl
streptococci
pn
neg
unreli
enterococci
gave
accur
rapid
phenotyp
detect
group
b
c
g
signific
impact
laboratori
turnaround
time
may
impact
therapi
clinic
relev
result
especi
sever
invas
diseas
periop
monitor
endotoxin
chemic
marker
procalcitonin
blood
plasma
concentr
cardiosurg
patient
nv
beloborodova
da
popov
ay
olenin
archipova
ea
chernevskaya
moscow
ru
object
fatti
acid
fa
chain
length
constitu
lipopolysaccharid
gramneg
bacteria
thu
acid
use
chemic
marker
determin
endotoxin
aim
studi
periop
blood
plasma
level
fa
marker
system
inflamm
bacteri
originprocalcitonin
pct
cardio
surgic
patient
pt
method
blood
plasma
sampl
consecut
adult
pt
acquir
heart
diseas
mean
age
year
taken
day
surgeri
pct
concentr
measur
immunoluminometr
method
pct
lia
brahm
aktiengesellschaft
gmbh
germani
level
acid
detect
ga
chromatographymass
spectrometri
gcm
agil
technolog
usa
postop
pt
divid
two
group
less
ngml
group
n
ngml
group
b
n
pct
level
data
compar
mannwhitney
utest
wilcoxon
match
pair
test
pvalu
consid
statist
signific
data
express
median
percentil
result
none
patient
exhibit
sign
infect
surgeri
initi
pct
concentr
nt
exceed
normal
valu
ngml
level
significantli
higher
postop
compar
baselin
ngml
vs
ngml
p
postop
level
ngml
group
ng
ml
group
b
p
rate
system
inflammatori
respons
syndrom
sir
day
postop
also
significantli
higher
group
b
vs
group
p
conclus
gcm
method
may
suitabl
tool
detect
endotoxin
chemic
marker
blood
plasma
sampl
elev
level
associ
develop
sir
bacteri
origin
confirm
pcttest
blood
cultur
necessari
manag
women
complic
pyelonephr
chen
nitzan
w
saliba
b
chazan
r
colodn
r
raz
afula
haifa
il
object
data
previou
studi
suggest
blood
cultur
women
uncompl
acut
pyelonephr
apn
limit
valu
object
assess
role
blood
cultur
manag
complic
apn
women
examin
demograph
clinic
characterist
outcom
relat
bacteraem
statu
patient
method
data
medic
record
women
hospitalis
complic
apn
period
analys
retrospect
includ
demograph
clinic
laboratori
data
empir
antimicrobi
therapi
urin
blood
cultur
result
complic
clinic
outcom
result
women
complic
apn
urin
cultur
grew
pathogen
bacteraemia
great
major
patient
blood
cultur
steril
contain
phenotyp
profil
pathogen
isol
urin
patient
blood
cultur
grew
pathogen
differ
found
urin
initi
empir
antimicrobi
therapi
chang
patient
signific
differ
exist
bacteraemia
nonbacteraemia
patient
demograph
clinic
characterist
sever
diseas
outcom
take
ml
venou
blood
sampl
patient
admiss
ward
separ
serum
store
sampl
frozen
sampl
sever
haemoglobin
valu
gdl
haemolyt
exclud
pct
level
measur
use
semiquantit
immunochromatograph
rapid
test
pct
q
diagnostica
germani
sampl
examin
bring
room
temperatur
new
individu
test
use
determin
data
analys
student
test
oneway
analysi
varianc
use
ssp
softwar
version
result
patient
sepsi
posit
test
slightli
elev
pct
ngml
moder
elev
pct
ngml
markedli
elev
pct
ngml
sever
elev
pct
sepsi
sir
moder
elev
level
pct
conclus
survey
pct
show
sensit
specif
clearli
discrimin
sepsi
nonsepsi
sirspct
titr
rais
progress
toward
sepsi
syndrom
septic
shock
pct
titr
aid
diagnos
monitor
outcom
predict
septic
patient
consid
routin
use
test
initi
workup
sepsi
brain
natriuret
peptid
diagnost
prognost
marker
patient
bacteri
infect
sepsi
marker
congest
cardiac
failur
myocardi
infarct
critic
ill
patient
sepsi
septic
shock
left
ventricular
dysfunct
subsequ
high
serum
level
bnp
report
studi
suggest
potenti
prognost
valu
bnp
patient
sepsi
purpos
studi
determin
bnp
serum
level
increas
sepsi
b
bnp
predict
outcom
valuabl
prognost
marker
method
examin
retrospect
patient
febril
bacteri
infect
admit
depart
period
one
year
one
histori
establish
cardiac
failur
diagnosi
infect
base
clinic
laboratori
data
among
patient
sepsi
admiss
measur
bnp
blood
sampl
taken
first
two
day
hospit
outcom
determin
survivor
nonsurvivor
statist
test
appli
student
ttest
chisquar
test
result
male
femal
patient
patient
sepsi
mean
bnp
valu
sd
patient
without
sepsi
sd
signific
increas
bnp
level
patient
sepsi
p
among
patient
survivor
nonsurvivor
nonsurvivor
sever
sepsi
percentag
death
among
septic
patient
mean
bnp
survivor
sd
nonsurvivor
sd
differ
statist
signific
p
conclus
studi
bnp
measur
soon
admiss
increas
significantli
patient
sepsi
b
seem
valuabl
prognost
marker
patient
suffer
febril
bacteri
infect
sepsi
studi
particip
need
confirm
hypothesi
valu
automatis
blood
cultur
system
diagnosi
capd
periton
k
azap
f
timurkaynak
sezer
cagir
g
yapar
h
arslan
n
zdemir
ankara
tr
object
periton
common
clinic
problem
occur
patient
endstag
renal
diseas
treat
periton
dialysi
pd
therapi
guid
cultur
result
antimicrobi
sensit
aim
studi
evalu
valu
blood
cultur
system
diagnosi
capd
continu
ambulatori
periton
dialysi
periton
method
twentysix
sampl
periton
fluid
obtain
patient
suspicion
capd
periton
includ
leukocyt
count
gram
wright
stain
sampl
perform
sampl
inocul
onto
solid
agar
media
blood
cultur
broth
bactec
agar
plate
incub
hour
blood
cultur
bottl
incub
day
unless
posit
signal
obtain
result
leukocyt
count
sampl
cultur
sampl
grew
bacteria
sampl
leukocyt
count
sampl
grew
solid
agar
andor
blood
cultur
media
etiolog
agent
detect
blood
cultur
broth
agar
plate
sampl
hand
sampl
bacteria
grew
blood
cultur
broth
two
sampl
solid
agar
media
sampl
two
growth
solid
agar
media
interpret
contamin
result
signific
growth
detect
sampl
strike
find
result
obtain
blood
cultur
bottl
identifi
pathogen
methicillinsensit
coagulaseneg
staphylococci
sampl
alphahaemolyt
streptococci
sampl
corynebacterium
spp
sampl
escherichia
coli
sampl
enterococcu
faecali
sampl
conclus
infecti
complic
account
approxim
two
third
pd
cathet
loss
treatment
base
antimicrobi
suscept
result
mandat
proper
manag
sampl
obtain
capd
patient
use
blood
cultur
bottl
inocul
periton
fluid
bedsid
rather
submit
specimen
laboratori
later
process
advoc
benefici
impact
shorten
microbiolog
procedur
either
hospit
patient
overal
patient
bacteraemia
object
shorten
turnaround
time
microbiolog
procedur
use
autom
system
bacteri
identif
suscept
test
associ
improv
clinic
outcom
reduct
hospit
cost
accord
two
american
studi
investig
whether
benefici
effect
could
report
patient
hospit
netherland
conduct
singl
blind
random
control
trial
method
patient
hospit
isala
klinieken
zwoll
netherland
bacteri
infect
confirm
cultur
randomli
assign
control
intervent
rapid
group
customari
practic
clinic
microbiologist
oral
report
clinic
relev
inform
clinician
patient
patient
complet
cultur
result
report
paper
identif
suscept
test
overnight
method
use
control
group
rapid
group
vitek
system
marci
letoil
franc
use
three
consecut
studi
period
acceler
factor
ad
stepup
manner
laboratori
workflow
rapid
group
increas
oral
report
extend
work
day
ad
extra
hardcopi
report
deliveri
workflow
control
group
remain
ident
throughout
studi
analys
whether
turnaround
time
report
shorten
use
vitek
system
addit
factor
assess
effect
shorten
turnaround
time
term
mortal
morbid
cost
overal
patient
group
ii
subgroup
patient
bacteraemia
result
overal
patient
group
n
time
interv
oral
report
final
suscept
result
significantli
shorter
rapid
group
threestudi
period
time
report
paper
significantli
shorter
third
period
subgroup
patient
bacteraemia
n
similar
shorten
turnaround
time
found
neither
overal
patient
group
subgroup
signific
differ
clinic
impact
variabl
cost
reduct
found
conclus
although
turnaround
time
report
microbiolog
result
shorten
significantli
overal
patient
group
subgroup
bacteraem
patient
hospit
set
clinic
impact
cost
reduct
could
report
result
routin
use
bactalert
fan
anaerob
bottl
indic
b
van
meensel
j
verhaegen
j
fran
h
castryck
n
blanckaert
leuven
object
tradit
routin
blood
cultur
adult
patient
consist
pair
aerob
anaerob
blood
cultur
bottl
howev
expert
opinion
differ
routin
use
anaerob
blood
cultur
bottl
debat
substitut
anaerob
bottl
addit
aerob
bottl
way
optim
volum
ml
blood
per
cultur
detect
bacteraemia
would
collect
aim
studi
evalu
benefit
routin
use
combin
bactalert
fan
aerob
anaerob
bottl
tertiari
care
medic
centr
method
perform
retrospect
studi
blood
cultur
bottl
pair
unpair
obtain
adult
patient
admit
emerg
room
januari
august
statist
analysi
use
signtest
limit
isol
classifi
clinic
signific
perform
least
isol
per
categori
recov
result
total
signific
microbi
strain
isol
patient
analysi
isol
reveal
signific
differ
yield
fan
aerob
fan
anaerob
bottl
howev
significantli
pseudomona
aeruginosa
p
streptococcu
pneumonia
p
recov
aerob
bottl
significantli
strictli
anaerob
bacteria
p
enterobacteriacea
escherichia
coli
p
recov
anaerob
bottl
twentytwo
patient
posit
blood
cultur
strictli
anaerob
bacteria
recov
anaerob
bottl
mainli
elderli
patient
abdomin
patholog
neutropen
fever
decubitu
ulcer
tooth
abscess
two
patient
result
blood
cultur
led
chang
diagnosi
adjust
antibiot
therapi
conclus
data
suggest
routin
use
bact
alert
fan
anaerob
bottl
still
recommend
institut
rel
high
proport
strictli
anaerob
bacteraemia
facult
organ
appar
grew
preferenti
anaerob
bottl
furthermor
although
infrequ
knowledg
anaerob
bacteraemia
influenc
manag
patient
develop
clinic
rule
urinari
dipstick
rule
predict
urinari
tract
infect
primari
care
set
p
littl
turner
k
rumsbi
g
warner
moor
h
smith
c
hawk
mulle
southampton
hast
uk
background
suspect
uti
one
commonest
acut
infect
systemat
review
document
adequ
power
studi
primari
care
assess
independ
predictor
rigor
laboratori
diagnosi
robustli
estim
perform
urinari
dipstick
typic
primari
care
popul
aim
estim
independ
clinic
dipstick
predictor
infect
develop
clinic
decis
rule
method
women
present
suspect
uti
primari
care
laboratori
diagnosi
assess
use
european
urinalysi
guidelin
standard
independ
clinic
dipstick
predictor
diagnosi
estim
result
women
confirm
uti
nitrit
leukocyt
esteras
greater
blood
haemolyz
trace
greater
independ
predict
diagnosi
multivari
odd
ratio
respect
dipstick
rule
base
nitrit
leukocyt
blood
moder
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
predict
valu
improv
vari
cut
point
npv
threedipstick
result
neg
ppv
nitrat
either
blood
leukocyt
esteras
clinic
rule
base
urin
cloudi
offens
smell
report
moder
sever
dysuria
moder
sever
nocturia
less
sensit
specif
ppv
npv
npv
none
four
clinic
featur
ppv
featur
conclus
simpl
decis
rule
could
improv
target
investig
treatment
strategi
use
rule
need
take
account
limit
sensit
lower
expect
previou
research
quantit
sputum
cultur
versu
direct
sputum
cultur
akan
e
ozyilmaz
k
ahm
uysal
gulha
ankara
tr
object
gram
stain
prefer
diagnosi
lower
respiratori
tract
infect
ltri
microbiolog
practic
sputum
cultur
still
need
isol
pathogen
antibiot
suscept
test
studi
perform
evalu
quantit
sputum
cultur
qsc
compar
direct
sputum
cultur
dc
isol
common
bacteria
caus
ltri
method
sputum
obtain
adult
without
chronic
obstruct
lung
diseas
clinic
andor
radiolog
diagnos
lrti
includ
studi
sampl
contain
polymorphonuclear
leucocyt
pnl
epitheli
cell
per
lowpow
field
lpf
light
microscopi
reveal
least
one
microorgan
caus
agent
gram
stain
direct
inocul
cultur
plate
sputum
sampl
mix
sputasol
oxoid
ratio
serial
dilut
quantit
cultur
perform
blood
chocol
agar
plate
use
cultur
standard
microbiolog
method
use
bacteri
identif
hour
later
direct
plate
quantit
cultur
observ
cut
point
cfuml
determin
posit
qsc
result
sputum
sampl
neg
cultur
techniqu
ten
cultur
display
mix
growth
two
organ
bacteria
posit
sputum
cultur
observ
haemophilu
influenza
common
isol
follow
streptococcu
pneumonia
branhamella
catarrhali
quantit
urin
microscopi
quick
reliabl
examin
bacteriuria
mhalla
ferjani
n
hannechi
j
boukadida
souss
tn
object
diagnosi
treatment
urinari
infect
often
delay
caus
renal
damag
larg
unavail
quick
accur
diagnost
examin
aim
studi
compar
accuraci
diagnos
signific
bacteriuria
quantit
urin
microscopi
gramstain
method
method
urin
sampl
obtain
fresh
urin
specimen
sent
laboratori
month
octob
urin
sampl
examin
signific
bacteriuria
use
standard
cultur
examin
use
gramstain
method
quantit
urin
microscopi
mallassez
cell
particl
could
distinguish
definit
bacilli
quantit
microscopi
urin
examin
use
oil
immers
microscopi
magnif
result
signific
bacteriuria
detect
bacteri
cultur
urin
sampl
use
quantit
microscopi
rod
found
cocci
cluster
cocci
chain
one
indefinit
particl
sampl
indefinit
sampl
oilimmers
microscopi
abl
distinguish
rod
cocci
cluster
one
neg
confirm
cultur
rod
staphylococci
neg
respect
quantit
microscopi
method
reliabl
sensit
specif
diagnos
signific
bacteriuria
compar
gramstain
method
sensit
specif
conclus
quantit
urin
microscopi
confirm
oilimmers
quick
reliabl
method
diagnosi
signific
bacteriuria
consid
use
earli
diagnosi
urinari
infect
detect
extendedspectrum
betalactamas
among
enterobacteriacea
use
autom
microbiolog
system
manual
detect
procedur
object
reliabl
autom
antibiot
suscept
test
system
detect
extendedspectrum
betalactamas
esbl
among
enterobacteriacea
crucial
optim
patient
therapi
outbreak
manag
serratia
marcescen
test
three
autom
microbiolog
system
compar
phoenix
tm
autom
microbiolog
system
bd
diagnost
system
spark
md
system
marci
letoil
franc
microscan
si
dade
behr
inc
convent
phenotyp
confirmatori
test
nccl
doubl
disk
synergi
test
dd
disk
approxim
method
dam
etest
esbl
ab
biodisk
solna
sweden
also
evalu
combin
use
isoelectr
focus
pcr
procedur
detect
tem
shv
gene
andor
dna
sequenc
use
refer
method
result
total
isol
esbl
produc
determin
refer
method
isol
exclud
due
indetermin
result
remain
isol
identifi
nonesbl
produc
sensit
specif
neg
npv
posit
ppv
predict
valu
determin
conclus
result
indic
phoenix
system
offer
highest
sensit
accept
specif
among
autom
suscept
test
system
detect
esbl
product
clinic
import
enterobacteriacea
reliabl
overal
perform
achiev
esbl
etest
assess
delay
report
blood
cultur
result
develop
method
identifi
defect
qualiti
u
saarela
p
h
sarkkinen
lahti
fi
object
wellknown
fact
earli
report
posit
blood
cultur
result
ration
treatment
patient
sepsi
one
might
expect
earli
report
neg
blood
cultur
well
impact
clinic
assess
treatment
patient
symptom
infect
previous
analys
posit
blood
cultur
flag
posit
autom
blood
cultur
system
within
two
day
incub
base
defin
maxim
delay
time
two
day
first
report
blood
cultur
whether
posit
neg
verifi
laboratori
practic
compli
guidelin
audit
blood
cultur
report
method
blood
cultur
report
includ
analysi
blood
cultur
bottl
incub
bact
biomerieux
autom
blood
cultur
system
posit
accord
document
procedur
posit
result
report
phone
laboratori
inform
system
effica
microbiolog
tietoen
immedi
gramstain
preliminari
identif
directli
blood
cultur
bottl
neg
result
report
first
time
two
day
incub
final
five
day
implement
report
system
expect
report
delay
analys
use
develop
report
gener
includ
effica
microbiolog
softwar
exclud
variou
variat
due
workflow
laboratori
accept
delay
set
three
day
instead
two
result
mean
delay
time
report
first
result
whether
posit
neg
day
standard
deviat
median
day
minimum
day
maximum
day
result
report
within
three
day
found
case
report
delay
exceed
predefin
time
seven
report
consid
error
differ
ground
case
accept
reason
delay
found
regard
human
error
conclus
report
delay
import
qualiti
indic
microbiolog
laboratori
number
result
report
fals
later
three
day
begin
incub
small
n
develop
report
gener
describ
abl
detect
outlier
thu
improv
qualiti
report
valid
commerci
kit
detect
antibodi
legionella
p
elverd
sa
uldum
copenhagen
dk
object
valid
four
commerci
kit
detect
antibodi
legionella
l
pneumophila
comparison
inhous
legionella
ifa
assay
threekit
indirect
enzymelink
immunosorb
assay
elisa
one
kit
indirect
immunofluoresc
antibodi
assay
ifa
studi
kit
test
sera
test
posit
bacteria
legionella
inhous
ifa
assay
posit
sera
patient
l
pneumophila
infect
method
seventyf
sera
test
posit
bacteria
campylobact
helicobact
riskettsia
mycoplasma
pneumonia
chlamydia
group
pseudomona
aeruginosa
coxiella
legionella
one
hundr
inhous
ifa
assay
posit
sera
titr
patient
l
pneumophila
infect
confirm
one
follow
method
pcr
cultur
legionella
urinari
antigen
test
inhous
ifa
assay
heat
inactiv
l
pneumophila
serogroup
l
micdadei
l
bozemanii
use
antigen
kit
valid
focu
diagnost
ifa
kit
l
pneumophila
serogroup
ii
serion
elisa
classic
l
pneumophila
igm
kit
iii
serion
elisa
classic
l
pneumophila
igg
kit
iv
zeu
scientif
inc
l
pneumophila
serogroup
elisa
kit
result
tabl
seen
sensit
highest
focu
diagnost
kit
kit
also
next
highest
fals
posit
rate
properli
caus
crossreact
compar
serion
elisa
classic
kit
kit
igm
igg
result
combin
kit
detect
iggigmiga
serion
elisa
classic
kit
sensit
fals
posit
rate
two
kit
igm
igg
result
combin
tabl
numer
percent
sensit
crossreact
kit
lat
conclus
focu
diagnost
serion
elisa
classic
zeu
scientif
inc
elisa
kit
rel
sensit
focu
diagnost
zeu
scientif
inc
elisa
kit
high
fals
posit
rate
best
kit
compar
inhous
assay
serion
elisa
classic
kit
igm
igg
result
combin
best
combin
rel
high
sensit
low
fals
posit
rate
intrathec
synthesi
antiborrelia
antibodi
multipl
sclerosi
j
bednarova
p
stourac
brno
cz
object
multipl
sclerosi
ms
chronic
inflammatori
demyelin
diseas
autoimmun
origin
common
caus
neurolog
disabl
young
adult
intrathec
synthesi
specif
igg
antibodi
measl
rubella
varicella
zoster
virus
call
mrz
reaction
report
ms
patient
part
oligoclon
polyspecif
immun
respons
ms
intrathec
synthesi
specif
igg
antibodi
herp
simplex
viru
toxoplasma
also
report
aim
studi
investig
frequenc
intrathec
synthesi
specif
igg
antibodi
borrelia
burgdorferi
ms
method
investig
cohort
patient
patient
diagnos
multipl
sclerosi
patient
diagnos
neuroborreliosi
nb
patient
neurolog
diseas
ond
serum
csf
sampl
analys
patient
diagnost
kit
testlin
compani
clinic
diagnost
czech
republ
eia
borrelia
garinii
igg
use
detect
specif
antibodi
absolut
valu
absorb
convert
arbitrari
unit
au
intrathec
synthesi
evalu
specif
antibodi
index
ai
accord
reiber
method
valu
ai
indic
posit
intrathec
synthesi
statist
signific
confirm
spearman
rank
coeffici
wilcoxon
test
result
intrathec
synthesi
specif
igg
antibodi
bburgdorferi
detect
ms
patient
ai
rang
csf
arbitrari
unit
antibodi
bburgdorferi
rang
au
median
au
mean
intrathec
synthesi
specif
igg
antibodi
b
burgdorferi
detect
nb
patient
ai
rang
csf
arbitrari
unit
antibodi
bburgdorferi
rang
au
median
au
mean
oneond
patient
posit
intrathec
synthesi
bburgdorferi
ai
low
antiborrelia
au
ms
patient
reflect
polyspecif
immun
respons
ms
compar
high
antiborrelia
au
nb
patient
indic
immun
respons
bburgdorferi
caus
agent
nb
conclus
detect
posit
intrathec
synthesi
specif
igg
antibodi
bburgdorferi
ms
patient
specif
intrathec
synthesi
infecti
agent
ms
part
polyspecif
immun
respons
chronic
autoimmun
diseas
nervou
system
antimicrobi
suscept
complementari
diagnost
tool
identif
rare
encount
nonfer
gramneg
bacteria
glupczynski
g
detri
c
berhin
janssen
g
wauter
yvoir
brussel
object
gramneg
nonferment
gnnf
pseudomona
aeruginosa
acinetobact
spp
increasingli
implic
variou
differ
type
nosocomi
infect
commerci
avail
identif
method
limit
perform
convent
method
despit
improv
accuraci
difficult
implement
routin
diagnost
laboratori
occurr
wide
variat
natur
antimicrobi
resist
pattern
among
differ
genu
andor
speci
rare
encount
gnnf
aim
assess
antibiogram
auxillari
aid
identif
method
clinic
strain
refer
strain
belong
differ
genera
speci
rare
encount
gnnf
identifi
speci
level
convent
method
andor
sequenc
rrna
gene
test
disk
diffus
agent
repres
class
antibiot
suscept
categor
made
accord
clsi
interpret
criteria
nonferment
except
colistin
interpret
resist
basi
absenc
zone
size
result
maltophilia
c
meningosepticum
anthropi
display
multiresist
profil
besid
colistin
fosfomycin
suscept
resist
pattern
specif
betalactam
agent
see
tabl
found
use
complementari
tool
identif
suscept
aztreonam
temocillin
found
burkholderia
deftia
comamona
speci
resist
carbapenem
sometim
dissoci
imipenem
meropenem
encount
stenotrophomona
chryseobacterium
burkholderia
ralstonia
synergi
betalactamas
inhibitor
betalactam
seen
stenotrophomona
chryseobacterium
myroid
spp
rhizobium
spp
imag
cephalosporinas
induct
cephamycin
carbapenem
betalactambetalactamas
inhibitor
typic
seen
ochrobactrum
anthropi
conclus
overal
natur
antibiot
resist
pattern
sever
gnnf
genusspeci
group
appear
may
appear
valuabl
use
complementari
identif
organ
improv
protocol
serolog
diagnosi
atyp
pneumonia
c
jenkin
balakrishnan
london
uk
object
royal
free
hospit
microbiolog
depart
receiv
approxim
request
atyp
pneumonia
serolog
test
year
prior
april
sera
atyp
pneumonia
serolog
request
analys
antibodi
mycoplasma
pneumonia
chlamydia
pneumonia
coxiella
burnetti
legionella
pneumophila
detect
use
urinari
antigen
test
includ
studi
howev
test
acutestag
sera
neither
exclud
specif
aetiolog
neg
result
firmli
establish
detect
antibodi
earli
sampl
test
pair
sera
use
inher
delay
reduc
valu
result
case
manag
method
april
clinician
request
provid
detail
date
onset
patient
symptom
sampl
taken
less
seven
day
onset
symptom
date
onset
test
save
c
seven
day
report
issu
state
serum
save
pleas
phone
microbiolog
specimen
taken
day
ill
send
followup
specimen
day
parallel
test
indic
request
atyp
pneumonia
serolog
compar
sent
determin
whether
new
protocol
reduc
number
test
perform
improv
servic
provid
result
review
period
request
atyp
pneumonia
serolog
sent
compar
sixtysix
request
receiv
test
immedi
fulfil
test
criteria
test
clinician
provid
requir
inform
feedback
receiv
request
clinician
sampl
test
infecti
diseas
ward
respond
inform
often
wherea
accid
emerg
least
like
respond
conclus
april
septemb
test
perform
sampl
due
chang
protocol
result
reduct
expenditur
workload
signific
reduct
number
request
sent
without
date
onset
patient
symptom
despit
proactiv
approach
howev
increas
number
clinician
respond
request
inform
addit
new
protocol
improv
qualiti
servic
ration
diagnosi
atyp
pneumonia
potenti
antigen
determin
chlamydia
trachomati
major
outer
membran
protein
model
overlap
recombin
protein
background
major
outer
membran
protein
momp
primari
target
specif
antichlamydia
trachomati
antibodi
protein
perform
import
structur
immunityrel
role
contain
variabl
segment
vs
ii
iii
iv
previous
shown
immunoreact
antigen
epitop
locat
within
vs
ii
iv
object
purpos
studi
determin
potenti
antigen
epitop
encod
open
read
frame
major
outer
membran
protein
chlamydia
trachomati
model
use
overlap
recombin
protein
amino
acid
aa
method
sever
antigen
determin
chlamydia
trachomati
momp
predict
bioinformat
analysi
six
pair
primer
design
produc
six
overlap
dna
fragment
genom
dna
chlamydia
trachomati
use
pcr
reaction
recombin
gene
encod
select
amino
acid
sequenc
aa
overlap
aa
synthes
protein
express
escherichia
coli
hybrid
protein
glutathion
stransferas
tag
studi
antigen
properti
new
protein
well
defin
posit
n
neg
n
serum
sampl
test
serum
sampl
previous
characteris
three
commerci
avail
assay
detect
igg
antichlamydia
trachomati
result
six
cluster
potenti
antigen
determin
predict
within
major
outer
membran
protein
chlamydia
trachomati
recombin
gene
encod
predict
amino
acid
sequenc
momp
posit
aa
aa
aa
aa
aa
aa
synthesis
pure
sampl
protein
obtain
affin
chromatographi
protein
immunoreact
demonstr
differ
specif
activ
antichlamydia
trachomati
antibodi
serum
sampl
aa
protein
show
highest
level
immunoreact
antigen
epitop
compris
vs
iii
conclus
predict
antigen
epitop
locat
within
aa
demonstr
signific
diagnost
potenti
candid
develop
diagnost
assay
detect
antichlamydia
trachomati
igg
activ
serum
specimen
evalu
giardiastrip
vitro
immunochromatograph
test
detect
giardia
lamblia
cyst
faecal
specimen
object
giardiasi
diarrhoeal
ill
caus
giardia
lamblia
onecel
parasit
live
intestin
human
anim
diseas
diagnos
microscop
identif
cyst
trophozoit
faec
use
direct
mount
well
concentr
procedur
sinc
analys
labourintens
requir
skill
microscopist
antigen
detect
test
direct
fluoresc
antibodi
dfa
enzym
immunoassay
eia
rapid
dipsticklik
test
develop
altern
evalu
perform
commerci
avail
onestep
immunochromatograph
membran
test
use
specif
monoclon
antibodi
cyst
membran
antigen
g
lamblia
giardiastrip
corisbioconcept
method
test
perform
evalu
known
posit
n
neg
n
stool
specimen
g
lamblia
test
standard
ova
parasit
p
examin
golden
standard
faec
parasit
endolimax
nana
entamoeba
coli
entamoeba
histolytica
ancylostoma
staphylococcu
aureu
includ
evalu
specif
test
fresh
unpreserv
sampl
obtain
laboratori
uz
gasthuisberg
medisch
centrum
voor
huisartsen
leuven
frozen
maintain
prior
test
giardiastrip
use
accord
manufactur
instruct
result
giardiastrip
known
posit
specimen
posit
giardianeg
sampl
neg
sensit
specif
posit
predict
valu
neg
predict
valu
compar
p
consid
refer
method
giardia
falseposit
discrep
sampl
came
patient
holiday
tunisia
microscopi
control
sampl
patient
remain
neg
miss
posit
specimen
giardiastrip
contain
mani
cyst
crossreact
parasit
aureu
observ
studi
conclus
giardiastrip
excel
sensit
specif
detect
g
lamblia
stool
test
easi
perform
concentr
prior
test
suitabl
singl
sampl
analysi
short
turnaroundtim
minut
diagnost
kit
may
benefici
absenc
train
microscopist
howev
substitut
routin
ps
g
lamblia
detect
use
tube
test
set
paediatr
tuberculosi
clinic
j
paton
c
luca
c
william
glasgow
uk
object
assess
feasibl
use
perform
spot
tb
test
within
paediatr
tb
clinic
monitor
level
agreement
tuberculin
skin
test
tst
spot
tb
test
method
tspot
oxford
immunotec
directli
detect
individu
activ
effector
tcell
via
secret
cytokin
use
elispot
enzym
link
immunosorb
spot
assay
assay
base
upon
principl
cell
individu
sensit
tuberculosi
antigen
produc
reencount
mycobacteri
antigen
antigen
specif
tuberculosi
earli
secretori
antigen
target
cultur
filtrat
protein
use
stimul
cell
remov
patient
blood
specif
tuberculosi
ppd
share
bcg
substrain
non
tubercul
mycobacterium
ntm
speci
except
kansasii
marinum
szulgai
perform
elispot
test
result
compar
elispot
tst
case
result
technic
failur
test
case
commonest
caus
test
insuffici
cell
proceed
assay
gener
good
agreement
neg
elispot
tst
patient
histori
bcg
vaccin
agreement
case
howev
patient
posit
tst
elispot
posit
patient
histori
bcg
vaccin
posit
tst
posit
elispot
conclus
use
spot
test
practic
paediatr
tb
clinic
assay
high
degre
concord
neg
test
absenc
bcg
vaccin
also
use
previou
bcg
vaccin
given
howev
ongo
evalu
methodolog
paediatr
outpati
set
need
object
bacteri
infect
remain
major
caus
morbid
mortal
despit
continu
develop
antibiot
prognosi
infect
variabl
depend
host
bacteri
specif
factor
role
crp
wbc
count
prognost
factor
controverci
studi
measur
hyaluran
ha
level
effort
find
new
prognost
factor
could
defin
clinic
outcom
bacteri
infect
patientsmethod
june
octob
immunocompet
adult
confirm
bacteri
infect
includ
cholecyst
pneumonia
pyelonephr
admit
hospit
patient
monitor
least
day
level
ha
crp
wbc
count
well
temperatur
measur
day
hospit
level
ha
measur
use
elisa
normal
limit
ngml
day
patient
ha
level
higher
ngml
rest
ha
level
within
normal
rang
group
similar
mean
valu
age
admiss
temperatur
admiss
serum
crp
wbc
count
result
day
hospit
patient
group
complet
remiss
infect
develop
septic
syndrom
die
mortal
patient
group
improv
develop
septic
syndrom
die
mortal
wbc
level
group
significantli
lower
second
group
p
likewis
signific
reduct
serum
crp
first
group
compar
second
one
temperatur
patient
group
return
normal
limit
group
remain
high
p
mean
ha
level
remain
high
patient
group
patient
group
remain
within
normal
limit
p
conclus
data
indic
ha
could
use
prognost
factor
determin
outcom
bacteri
infect
studi
need
confirm
find
establish
mechan
ha
might
influenc
evolut
bacteri
infect
find
exact
mechan
could
help
design
new
therapeut
strategi
evalu
new
chromogen
medium
chromagar
salmonella
plu
detect
salmonella
speci
includ
salmonella
typhi
salmonella
lactos
plu
rambach
q
tran
ac
le
dantec
pari
fr
infect
due
salmonella
continu
major
problem
throughout
world
cultur
media
sever
advantag
comparison
pcr
immunolog
method
cultur
media
allow
antibiot
suscept
studi
epidemiolog
studi
detect
strain
addit
live
bacteria
detect
recent
sever
new
chromogen
media
improv
detect
salmonella
studi
pure
strain
new
chromogen
media
chromagar
salmonella
plu
chromagar
franc
hour
incub
detect
salmonella
speci
includ
salmonella
typhi
salmonella
lactos
plu
first
result
comparison
hektoen
enter
agar
bd
oscm
oxoid
show
chromagar
salmonella
plu
allow
detect
salmonella
spp
salmonella
typhi
salmonella
lactos
plu
hea
oscm
fail
detect
mani
lactos
posit
salmonella
preliminari
result
show
chromagar
salmonella
plu
conveni
rapid
sensit
specif
medium
detect
three
type
salmonella
speci
next
step
studi
evalu
chromagar
salmonella
plu
routin
detect
background
definit
communityacquir
infect
cai
need
reformul
increas
outpati
manag
nurs
care
facil
etc
characterist
healthcareassoci
infect
hcai
similar
nosocomi
infect
nci
sever
studi
investig
characterist
hcai
caus
aureu
e
coli
method
four
hundr
twenti
two
adult
patient
admit
jan
june
sever
hospit
seoul
korea
bloodstream
infect
bsi
caus
aureu
ecoli
studi
character
healthcareassoci
bloodstream
infect
caus
aureu
ecoli
investig
comorbid
medic
condit
predispos
factor
site
infect
resist
pattern
inhospit
mortal
epidemiolog
categori
nci
hcai
cai
result
among
patient
patient
saureu
bsi
ecoli
bsi
one
hundr
sixti
five
patient
met
criteria
nci
hcai
cai
hcai
similar
nosocomi
infect
term
frequenc
malign
predispos
factor
sourc
infect
inhospit
mortal
mrsa
preval
hcai
similar
nci
versu
p
similar
cai
versu
p
ecoli
resist
pattern
hcai
similar
cai
versu
p
ampicillinsulbactam
versu
p
cefotaxim
versu
p
esblproduc
similar
nci
versu
p
ampicillinsulbactam
versu
p
cefotaxim
versu
p
esblproduc
preval
quinolon
resist
ecoli
order
follow
nci
hcai
cai
conclus
hcai
similar
nci
clinic
characterist
mrsa
preval
similar
resist
pattern
ecoli
consider
need
definit
hcai
regard
gramneg
infect
object
antimicrobi
resist
one
challeng
issu
modern
medicin
sought
evalu
secular
trend
rel
frequenc
blood
isol
pattern
vitro
antimicrobi
suscept
hospit
last
four
half
year
method
focus
gramneg
gramposit
bacteri
isol
cultur
blood
specimen
suscept
test
perform
vitek
system
appli
criteria
suggest
clinic
laboratori
standard
institut
clsi
follow
isol
bacteria
compar
antimicrobi
resist
blood
isol
two
period
first
period
isol
second
period
isol
result
overal
data
regard
rel
frequenc
blood
isol
newli
found
hospit
differ
significantli
hospit
function
much
longer
period
time
bacteri
isol
coagulas
neg
staphylococci
commonest
blood
isol
total
rel
frequenc
gramposit
gramneg
microorgan
follow
descend
order
escherichia
coli
staphylococcu
aureu
pseudomona
aeruginosa
klebsiella
spp
acinetobact
baumannii
enterococcu
faecali
noteworthi
emerg
problem
increas
antimicrobi
resist
gramneg
bacteria
mainli
acinetobact
baumannii
klebsiella
pneumonia
variou
class
antibiot
acinetobact
baumannii
isol
show
increas
resist
amikacin
p
ciprofloxacin
p
imipenem
p
piperacillintazobactam
p
first
second
period
studi
conclus
alarm
increas
antimicrobi
resist
note
studi
gramneg
bacteria
especi
acinetobact
baumannii
klebsiella
pneumonia
object
isol
frequenc
resist
profil
commonest
bacteraemiarel
organ
retrospect
studi
throughout
period
cover
decad
sotiria
chest
diseas
hospit
athen
method
bacteraemia
consid
nosocomi
sinc
occur
least
hour
patient
admiss
hospit
case
analys
relat
respons
organ
antibiot
resist
profil
hospit
period
patient
develop
nosocomi
bacteraemia
period
b
result
period
b
isol
frequenc
gram
organ
respect
aureu
epidermidi
cn
pneumonia
e
faecali
e
faecium
k
pneumonia
e
coli
p
aeruginosa
baumanii
maltophilia
respectivelyth
main
characterist
antibiot
profil
period
b
includ
mrsa
occurr
oxacillinresist
pneumonia
gre
faecali
gre
faecium
esblproduc
k
pneumonia
esblproduc
e
coli
mblproduc
k
pneumonia
carbapenemresist
p
aeruginosa
carbapenemresist
baumanii
respect
conclus
worthi
remark
excess
rise
bacteraemia
case
period
b
could
partli
attribut
recent
develop
oncolog
unit
well
univers
intern
medicin
unit
hospit
decreas
frequenc
mrsa
isol
probabl
due
control
measur
taken
increas
incid
oxacillinresist
pneumonia
recent
occurr
glycopeptideresist
enterococci
emerg
highli
resist
organ
esblproduc
enterobacteriacea
mblproduc
k
pneumonia
carbapenemresist
p
aeruginosa
baumanii
strike
incid
maltophilia
consid
seriou
nosocomi
pathogen
object
purpos
studi
determin
spectrum
microorgan
isol
posit
central
venou
cathet
cvc
cultur
assess
correl
bacteremia
posit
cvc
cultur
method
januari
juli
total
cvc
sent
microbiolog
analysi
studi
cathet
tip
consid
infect
yield
equal
coloni
use
semi
quantit
maki
method
blood
cultur
perform
use
bactalert
autom
system
identif
microorgan
perform
use
vitek
autom
system
biomerieux
result
among
cvc
cultur
consid
posit
microbi
agent
isol
posit
cvc
cultur
staphylococcu
epidermidi
acinetobact
baumannii
pseudomona
aeruginosa
klebsiella
pneumonia
coagulaseneg
staphylococci
enterococcu
faecali
staphylococcu
aureu
gram
neg
bacteria
genu
enterobacteriacea
furthermor
posit
blood
cultur
drawn
peripher
vein
patient
posit
cvc
cultur
studi
order
evalu
cvc
sourc
bloodstream
infect
case
microorgan
isol
cvc
blood
cultur
demonstr
cathet
previou
colon
microorgan
skin
flora
well
nosocomi
pathogen
entri
site
bacteremia
common
microorgan
recov
blood
cultur
follow
baumannii
epidermidi
p
aeruginosa
kpneumonia
e
faecali
enterobacteriacea
conclus
sepidermidi
mainli
respons
catheterrel
infect
hospit
ii
catheterrel
bacteremia
consid
iii
asept
techniqu
well
continu
microbiolog
surveil
studi
lead
effect
empir
treatment
catheterrel
infect
requir
laboratorybas
epidemiolog
nosocomi
candidaemia
tertiari
teach
hospit
lgo
cardoso
p
trabasso
campina
br
object
describ
epidemiolog
nosocomi
candidemia
teach
hospit
method
prospect
follow
patient
posit
blood
cultur
candida
speci
done
search
underli
diseas
presenc
central
venou
line
use
antibiot
antifung
drug
prior
candidemia
treatment
perform
outcom
surviv
thirti
day
candidemia
death
result
seventythre
patient
candidemia
follow
male
mean
age
year
rang
previou
episod
bacteremia
occur
isol
candida
site
candidemia
present
patient
frequent
underli
diseas
cancer
diagnos
diabet
mellitu
cardiopathi
nephropathi
pulmonari
neurolog
diseas
present
less
case
almost
half
patient
submit
surgeri
last
three
month
antifung
prophylaxi
fluconazol
receiv
antibiot
hour
previous
use
case
moment
candidemia
mechan
ventil
present
patient
parenter
nutrit
central
venou
line
hemodyalisi
hour
candidemia
perform
case
candida
isol
c
albican
c
nonalbican
c
tropicali
c
parapsilosi
c
glabrata
none
risk
factor
underli
diseas
statist
relat
speci
candida
antifung
therapi
hour
given
patient
overal
mortal
thirti
day
antifung
treatment
day
variabl
associ
lower
mortal
differ
mortal
rate
detect
differ
candida
speci
infect
conclus
candidemia
frequent
seriou
nosocomi
infect
high
mortal
frequenc
nonalbican
speci
candida
high
identif
speci
lower
suscept
fluconazol
common
antifung
treatment
day
associ
lower
mortal
death
first
hour
treatment
rare
reinforc
import
suspicion
candidemia
risk
patient
earli
start
therapi
nosocomi
bloodstream
infect
follow
cardiac
surgeri
children
n
jashiashvili
nanuashvili
chkhaidz
tbilisi
ge
object
hospit
infect
continu
major
problem
caus
high
morbid
mortal
surgic
clinic
significantli
increas
length
hospit
cost
treatment
nosocomi
bloodstream
infect
repeatedli
identifi
frequent
type
nosocomi
infect
pediatr
patient
although
known
frequenc
infecti
complic
well
etiolog
rather
differ
variou
geograph
region
sometim
even
concret
hospitalsth
aim
studi
determin
frequenc
etiolog
hospit
bloodstream
infect
follow
cardiac
surgeri
children
find
whether
emerg
oper
increas
frequenc
bloodstream
infect
method
studi
patient
paediatr
cardiac
surgeri
clinic
oper
period
januari
till
decemb
age
patient
vari
day
year
case
oper
plane
casesemerg
result
patient
hospit
infect
occur
patient
frequenc
infecti
complic
follow
pneumonia
bloodstream
infect
wound
infect
urinari
tract
infect
endocardit
pericard
non
differenti
site
infect
case
bloodstream
infect
occur
children
year
age
bloodstream
infect
case
caus
gramneg
bacteria
klebsiella
pneumonia
serratia
marcescen
acinetobact
baumanni
case
gramposit
bacteria
staphilococcu
epidermidi
streptococcu
salivari
rate
bloodstream
infect
follow
plane
oper
emerg
conclus
bloodstream
infect
second
frequent
infecti
complic
follow
cardiac
surgeri
children
etiolog
bloodstream
infect
frequent
gramposit
bacterium
staphilococcu
epidermidi
frequent
gramneg
bacteriaenterobacteriacea
frequenc
bloodstream
infect
signific
differ
emerg
plane
oper
result
episod
nosocomi
bloodstream
infect
admiss
bloodstream
infect
secondari
infecti
bodi
site
lower
respiratori
tract
wound
urinari
tract
episod
catheterrel
case
unknown
origin
cellwal
defici
form
preval
microorgan
strain
revert
classic
state
gramposit
cocci
gramposit
bacilli
gramneg
bacilli
anaerob
lstabl
follow
staphylococcu
aureu
coagulaseneg
staphylococci
strain
gramposit
bacilli
fungi
hacek
group
gramneg
bacilli
enterococcu
spp
strain
streptococcu
pneumonia
anaerob
proport
polymicrobi
episod
staphylococcu
aureu
haemophilu
paraphrophilu
h
parainfluenza
enterococcu
faecali
fatal
conclus
found
high
proport
cell
wall
defici
form
rare
report
may
due
blood
cultur
collect
antimicrobi
therapi
p
especi
betalactam
adequ
method
blood
cultur
process
sucros
enrich
media
hemolin
perform
duo
biomerieux
franc
acridin
orang
stain
microscopi
blood
cultur
rifampin
minocyclin
impregn
central
venou
cathet
metaanalysi
randomis
control
trial
assess
cathet
colonis
catheterrel
bloodstream
infect
falaga
k
fragouli
blizioti
chatzinikola
athen
gr
object
use
antimicrobialimpregn
central
venou
cathet
cvc
prevent
cvc
microbi
colon
catheterrel
bloodstream
infect
crbsi
controversi
subject
perform
metaanalysi
randomis
control
trial
rct
cvc
coat
rifampinbas
antimicrobi
combin
order
evalu
subject
method
assess
primari
outcom
microbi
colon
cvc
crbsi
analys
secondari
outcom
occurr
advers
event
emerg
resist
organ
caus
mortal
main
analysi
includ
rct
compar
efficaci
cvc
impregn
rifampin
minocyclin
nonimpregn
antibiot
cvc
result
rct
fulfil
inclus
criteria
compar
cvc
impregn
rifampinbas
antimicrobi
combin
nonimpregn
antibiot
cvc
primari
analysi
show
rifampinminocyclin
impregn
cvc
associ
lesser
rate
colon
ci
crbsi
ci
sub
analys
studi
compar
rifampinminocyclin
impregn
cvc
nontunnel
nonantimicrobialimpregn
cvc
studi
demonstr
superior
impregn
cathet
prevent
colon
ci
crbsi
ci
analysi
rct
compar
cvc
impregn
rifampinbas
combin
antimicrobi
nonimpregn
antibiot
cvc
rct
demonstr
superior
rifampinbas
combin
reduc
colon
ci
crbsi
ci
none
rct
report
signific
increas
mortal
toxic
emerg
resist
studi
group
conclus
rifampinminocyclin
impregn
cvc
safe
effect
reduc
rate
cvc
colon
crbsi
addit
rct
need
provid
inform
cost
analysi
possibl
emerg
microbi
resist
evalu
benefit
longterm
catheteris
compar
versu
new
gener
chss
coat
cvc
infect
relat
tunel
haemodialysi
cathet
r
luqu
mj
marco
blanco
j
ibea
e
bouza
red
ola
de
n
en
infecciosa
reipi
introduct
spain
everi
year
cvc
insert
patient
hd
tunnel
tc
infect
second
lead
caus
death
popul
catheterrel
bacteremia
crb
major
caus
hospitalis
object
ass
incid
epidemiolog
risk
factor
crb
patient
tc
hd
know
length
tc
use
cathet
surviv
patient
method
prospect
analys
consecut
tc
insert
four
spanish
hospit
sep
use
idsa
definit
intravascular
catheterrel
infect
cid
characterist
patient
tc
risk
factor
associ
crb
insert
remov
analys
patient
follow
crb
death
remov
tc
time
end
studi
one
year
data
collet
onlin
databas
system
quantit
variabl
express
median
rang
chisquar
tstudent
test
use
statist
analysi
result
one
hundr
twentyeight
tc
insert
patient
male
age
year
previou
time
hd
tc
insert
day
cathet
surviv
day
tunnel
cathet
use
vascular
access
patient
six
episod
crb
observ
incid
catheterday
total
time
catheterday
caus
bacteria
e
faecali
n
aureu
ms
n
aureu
mr
n
three
tunnel
infect
report
two
develop
crb
time
sinc
cathet
insert
onset
crb
day
thirtytwo
tc
remov
although
crb
insert
femor
subclavian
vein
rr
ci
p
previou
hospitalis
rr
ci
p
surgic
procedur
rr
ci
p
associ
crb
outcom
regist
one
death
one
relaps
later
die
two
metastat
infect
septic
arthriti
vertebr
osteomyel
two
dead
crbrelat
anoth
dead
observ
noncrb
group
oneyear
followup
rr
ci
conclus
incid
crb
tc
low
howev
mortalityrel
high
risk
factor
associ
cbr
nonjugular
vein
insert
previou
hospitalis
surgic
procedur
perform
bacillu
spp
bacteraemia
children
parenter
nutrit
object
studi
epidemiolog
clinic
data
concern
bacteremia
due
bacillu
spp
associ
total
parenter
nutrit
tpn
fouryear
period
method
patient
present
clinic
sign
bacteremia
receiv
tpn
blood
andor
tpn
solut
cultur
posit
bacillu
spp
includ
blood
drawn
peripher
vein
sampl
discontinu
tpn
solut
cultur
bactalert
system
biomerieux
franc
tpn
solut
also
cultur
quantit
identif
microorgan
carri
use
gram
stain
coloni
morpholog
motil
test
lecithinas
product
egg
yolk
agar
oxoid
england
bbl
crystal
posit
id
kit
becton
dickinson
usa
andor
biomerieux
franc
three
epidemiolog
environ
survey
tpn
prepar
room
ppr
perform
accord
hospit
infect
control
guidelin
cluster
episod
occur
sept
jun
oct
result
studi
period
episod
occur
patient
rang
age
day
year
bacteremia
due
bacillu
spp
document
posit
blood
cultur
case
tpn
discontinu
case
tpn
solut
found
contamin
organ
bacillu
spp
also
isol
tpn
solut
involv
episod
neg
n
perform
n
blood
cultur
b
cereu
strain
b
megaterium
strain
common
speci
isol
follow
b
pumilu
strain
brevibacillu
brevi
strain
implic
organ
also
recov
laminar
flowhood
ppr
abrupt
onset
present
fever
andor
chill
occur
patient
accompani
vomit
diarrhoea
one
case
thrombophleb
one
case
dramat
clinic
respons
observ
discontinu
infus
death
observ
conclus
isol
bacillu
spp
laminar
flowhood
tpn
solut
suggest
inus
contamin
prepar
compound
admixtur
bacillu
spp
due
spore
format
resist
disinfect
emphas
need
stringent
asepsi
hospit
pharmaci
order
avoid
contamin
infus
potenti
pathogen
wide
distribut
environ
bacillu
spp
object
studi
aim
survey
preval
virul
factor
enterococci
clinic
isol
related
vancomycin
resist
impact
clinic
outcom
furthermor
elucid
role
pathogenesi
blood
stream
infect
enterococci
cathol
hsct
center
method
collect
enterococcu
isol
blood
neutropen
patient
hematolog
diseas
januari
decemb
vancomycin
resist
enterococci
vre
isol
rectum
patient
time
vre
bacteremia
screen
presenc
virul
factor
gene
cytolysin
cyla
gelatinas
gele
aggreg
substanc
enterococc
surfac
protein
esp
hyluronidas
hyl
pcr
pfge
isol
blood
rectum
patient
done
evalu
genet
related
result
collect
isol
blood
isol
rectum
patient
time
vre
bateremia
among
isol
blood
e
faecium
account
n
e
faecali
n
proport
vancomycin
resist
isol
n
e
faecium
n
e
faecali
esp
gene
hyl
gene
detect
isol
e
faecium
gene
gele
cyla
detect
among
strain
e
faecali
n
posit
esp
n
posit
gele
n
n
cyla
n
hyl
none
virul
factor
associ
vancomycin
resist
none
virul
factor
directli
influenc
clinic
outcom
thirteen
rectal
isol
vr
e
faecium
posit
esp
n
posit
hyl
pfge
pair
isol
blood
rectum
reveal
pair
genet
match
conclus
virul
factor
associ
vancomycin
resit
influenc
clinic
outcom
high
related
rectal
blood
isol
higher
preval
esp
hyl
rectal
isol
suggest
intestin
tract
could
import
focu
bacteremia
neutropen
patient
anoth
factor
esp
hyl
might
associ
invas
e
faecium
bloodstream
role
virul
factor
e
faecium
need
elucid
futur
object
surveil
blood
cultur
accuraci
evalu
treatment
efficaci
predict
death
patient
staphylococcu
aureu
bacteremia
remain
unclear
furthermor
whether
inform
standard
clinic
biolog
follow
determin
final
mssa
mrsa
bacteremia
consid
separ
sinc
differ
pharmacolog
properti
betalactamin
glycopeptid
may
influenc
length
bacteremiaw
evalu
accuraci
posit
surveil
blood
cultur
detect
treatment
failur
predict
mortal
patient
mrsa
bacteremia
compar
standard
clinic
biolog
followup
fever
sign
sepsi
leukocytosi
c
reactiv
protein
level
method
prospect
casecontrol
studi
realis
octob
may
pitaux
universitair
de
strasbourg
surveil
blood
cultur
systemat
perform
hour
presum
activ
antibiot
treatment
patient
follow
day
result
fifti
patient
present
mrsa
bacteremia
includ
studi
eighteen
patient
posit
surveil
blood
cultur
main
factor
associ
breakthrough
bacteremia
presenc
central
vascular
devic
cvd
particularli
consid
portal
entri
bacteremia
p
convers
patient
treat
teicoplanin
less
like
posit
surveil
blood
cultur
p
compar
treat
vancomycin
mortal
rate
case
sustain
bacteremia
vs
case
nonsustain
bacteremia
p
posit
predict
valu
ppv
death
isol
breakthrough
bacteremia
howev
consid
bacteremia
develop
anoth
portal
entri
cvd
ppv
increas
aggrav
standard
clinic
biolog
data
hour
treatment
strongli
correl
mortal
p
ppv
npv
death
good
independ
factor
conclus
posit
surveil
blood
cultur
predict
factor
mortal
mrsa
bacteremia
justifi
treatment
reconsider
portal
entri
cvd
howev
case
appear
inform
standard
clinic
biolog
followup
methicillin
resist
risk
factor
mortal
staphylococcu
aureu
bacteraemia
analysi
earss
enhanc
bacteraemia
surveil
ireland
oza
murchan
r
cunney
behalf
irish
earss
steer
group
object
uncertainti
literatur
contribut
methicillin
resist
mortal
associ
staphylococcu
aureu
bloodstream
infect
bsi
examin
risk
factor
mortal
among
irish
patient
aureu
bsi
method
set
irish
hospit
laboratori
provid
enhanc
clinic
demograph
risk
factor
data
episod
bsi
report
european
antimicrobi
resist
surveil
system
earss
outcom
data
includ
inhospit
mortal
also
report
subset
laboratori
sinc
begin
examin
inhospit
mortal
vs
surviv
end
earss
survey
period
day
logist
regress
surviv
analysi
result
episod
aureu
bsi
report
inhospit
death
discharg
still
hospit
end
survey
period
factor
examin
length
stay
lo
prior
bsi
age
meticillin
resist
signific
predictor
inhospit
mortal
mortal
among
patient
mrsa
bsi
n
significantli
higher
among
patient
mssa
bsi
n
cox
regress
control
lo
age
demonstr
methicillin
resist
signific
contributor
mortal
hr
ci
baselin
surviv
curv
shown
conclus
methicillin
resist
remain
signific
risk
factor
inhospit
mortal
among
patient
aureu
bsi
control
age
lo
mortal
sepsi
russia
identifi
gap
epidemiolog
data
object
avail
epidemiolog
data
sepsi
russia
contain
scarc
clinic
inform
low
report
mortal
rate
lead
underestim
real
figur
studi
design
investig
incid
clinic
trait
sepsi
accord
autopsi
record
larg
citi
central
russia
comparison
offici
statist
method
autopsi
protocol
popul
citi
smolensk
deceas
undergon
post
mortem
examin
year
inclus
assess
protocol
sepsi
post
mortem
diagnosi
major
caus
death
complic
underli
diseas
regist
process
use
sa
version
softwar
sa
institut
usa
data
compar
report
depart
health
smolensk
region
result
overal
autopsi
protocol
evalu
autopsi
record
patient
die
sepsi
men
women
mean
age
year
septic
patient
die
hospit
set
length
hospitalis
death
day
day
took
death
post
mortem
evalu
sepsi
primari
diagnosi
record
complic
underli
condit
patient
deviat
clinic
diagnosi
note
patient
overal
mortal
rate
autopsi
record
case
per
popul
comparison
case
per
popul
offici
data
fiveyear
studi
period
conclus
although
demonstr
differ
mortal
rate
sepsi
reach
statist
differ
p
show
superior
incid
accord
autopsi
protocol
comparison
offici
data
possibl
explain
lack
implement
common
definit
inadequ
diseas
registr
recommend
russia
close
gap
epidemiolog
data
action
reinforc
use
unifi
sepsi
diagnost
criteria
requir
nationwid
level
object
find
clinic
epidemiolog
featur
associ
aureu
bacteraemia
resist
phenotyp
materi
method
retrospect
studi
aureu
bacteraemia
occur
januari
septemb
hospit
aureu
isol
patient
blood
cultur
process
system
becton
dickinson
antimicrobi
sucept
carri
microscan
walkaway
autom
system
resist
cloxacillin
verifi
salin
mh
cloxacillin
etest
statist
studi
carri
spss
result
patient
studi
men
women
averag
age
year
old
case
medic
servic
emerg
intens
care
unit
surgic
servic
averag
number
day
hospit
day
case
monomicrobian
bacteraemia
infect
intrahospitalarian
origin
patient
progress
case
toward
exitu
averag
resist
cloxacillin
clo
period
even
though
increas
clear
year
go
resist
rate
studi
period
erythromycin
e
ciprofloxacin
ci
clindamycin
cc
gentamicin
g
rifampin
r
resist
clo
relat
age
studi
increas
found
elderli
age
group
year
old
year
old
year
old
increas
resist
clo
intrahospitalarian
strain
found
compar
extrahospitalarian
resist
clo
studi
relat
age
sex
hospitalis
day
hospit
depart
author
nt
found
signific
differ
resist
phenotyp
mostli
found
clo
cc
follow
clo
ci
clo
e
moreov
strain
show
clo
cc
e
clo
cc
e
ci
phenotyp
strain
sensit
glycopeptid
conclus
aureu
bacteraemia
frequent
men
averag
age
year
old
came
medic
depart
intrahospitalarian
origin
resist
cloxacillin
increas
six
point
sinc
case
cloxacillin
resist
strain
also
resist
clindamicin
eritromicin
ciprofloxacin
object
aim
studi
know
rate
ni
nosocomi
infect
patient
admit
icu
januari
june
compar
result
last
nni
report
nation
nosocomi
infect
surveillanceoctob
patient
method
patient
locat
medic
icu
patient
admit
coronari
icu
oper
open
heart
surgeri
januari
june
includ
patient
prospect
studi
sinc
day
admit
end
episod
infect
control
team
variabl
surveil
number
invas
devic
oropharing
tube
urinari
cathet
arteri
venou
central
cathet
sitespecif
infect
rate
associ
devic
use
denomin
number
patient
risk
patientday
deviceday
ventil
associ
pneumonia
vap
urinari
tract
infect
uti
central
line
bacteremia
clb
secondari
bacteremia
osb
primari
bacteremia
pb
microorgan
antibiot
suscept
treatment
outcom
comput
base
surveil
system
envinuci
use
result
vap
uti
clb
osb
diagnos
medic
icu
vap
uti
clb
pb
osb
coronari
icu
densiti
incid
rate
medic
icu
vap
uti
svcb
total
bacteremia
coronari
icu
valu
vap
vap
arriv
postop
period
openheart
surgeri
uti
clb
total
bacteremia
microorgan
coronari
icu
bacteremia
candida
spp
aureu
epidermidi
uti
candida
spp
vap
aureu
marcencen
microorgan
medic
icu
bacteremia
candida
spp
aureu
e
coli
uti
candida
spp
e
coli
morganii
p
aeruginosa
k
pneumonia
vap
aureu
p
aeruginosa
maltophilia
k
oxytoca
h
influenza
conclus
compar
data
densiti
incid
deviceassoci
infect
nni
report
result
concord
except
vap
case
data
higher
nni
data
even
coronari
icu
rate
coronari
icu
without
postoper
patient
percentil
nniss
report
even
target
prevent
vap
coronari
icu
hospit
must
group
patient
undergo
openheart
surgeri
infect
intens
care
unit
admit
multipl
trauma
patient
incid
risk
factor
mortal
rate
object
improv
resuscit
manag
patient
sustain
multipl
trauma
increas
surviv
rate
still
suffer
infect
cours
recoveri
hospit
purpos
studi
survey
incid
site
infect
defin
risk
factor
infect
mortal
icu
admittedmultipl
trauma
patient
method
prospect
record
apach
ii
score
day
day
conduct
multipl
trauma
patient
admit
surgic
icu
ajou
univers
hospit
june
may
patient
transfer
hospit
oper
hour
care
age
exclud
review
medic
record
imag
studi
retrospect
result
total
patient
male
mean
age
year
year
includ
mean
apach
ii
score
common
caus
trauma
blunt
injuri
patient
like
traffic
accid
fall
total
infect
occur
patient
incid
patientday
site
infect
lower
respiratori
tract
skinsoft
tissu
intraabdomen
central
venou
cathet
urinari
tract
surgic
site
other
mean
onset
time
infect
day
day
mean
onset
time
accord
infect
site
order
follow
intraabdomen
day
lower
respiratori
tract
day
skinsoft
tissu
day
surgic
site
day
central
venou
cathet
day
urinari
tract
day
mortal
rate
death
attribut
infect
four
patient
multivari
analysi
patient
infect
like
prolong
hospit
care
odd
ratio
p
longterm
ventil
care
p
open
fractur
p
apach
ii
score
p
durat
mechan
ventil
p
contribut
death
independ
conclus
multipl
trauma
patient
high
risk
infect
common
infect
lower
respiratori
tract
infect
apach
ii
score
risk
factor
infect
risk
factor
death
object
studi
identifi
incid
risk
factor
ni
cost
nicu
stay
attribut
ni
turkish
nicu
method
prospect
cohort
studi
conduct
novemb
may
nicu
eskisehir
osmangazi
univers
hospit
academ
tertiari
care
centr
nicu
exposur
variabl
matern
newborn
data
prospect
collect
daili
visit
diagnos
ni
base
recommend
centr
diseas
control
statist
analysi
perform
softwar
program
spss
version
result
patient
survey
acquir
ni
common
site
ni
found
urinari
tract
eyeearnosethroat
skin
soft
tissu
blood
stream
relationship
ni
probabl
risk
factor
prolong
hospit
stay
day
low
birth
weight
previou
antimicrobi
usag
corticosteroid
treatment
intub
mechan
ventil
cpap
surgeri
total
parenter
nutrit
enter
nutrit
polycytemia
found
statist
signific
relationship
ni
sex
gestat
age
twin
birth
rout
deliveri
home
birth
low
apgar
score
statist
signific
common
nosocomi
pathogen
escherichia
coli
staphylococcu
aureu
enterococci
klebsiella
spp
addit
hospit
stay
ni
day
median
cost
found
euro
newborn
without
ni
euro
newborn
ni
conclus
risk
factor
ni
detect
nicu
similar
defin
worldwid
gramneg
bacteria
lead
caus
ni
increas
medic
cost
due
ni
remark
colonis
surveil
predict
microbi
aetiolog
infect
critic
ill
icu
microbi
colon
respiratori
gastrointestin
tract
rt
gt
frequent
preced
invas
infect
retrospect
studi
abil
colon
surveil
predict
microbi
etiolog
subsequ
infect
method
studi
perform
medicalsurg
icu
new
univers
hospit
novemb
octob
infect
control
polici
includ
weekli
surveil
cultur
bronchial
secret
urin
stool
sampl
record
case
ventilatorassoci
pneumonia
vap
bloodstream
infect
bsi
base
data
patient
file
microbiolog
laboratori
relationship
infecti
etiolog
recent
colon
analys
base
speci
antimicrobi
suscept
pattern
molecular
type
reppcr
select
isol
result
record
vap
bsi
case
catheterrel
pathogen
isol
vap
case
correl
bronchial
stool
colon
prior
rt
colon
seem
import
acinetobact
sp
colon
rt
predict
vap
etiolog
sensit
specif
primari
gram
bsi
pathogen
recent
colon
case
associ
gt
rt
klebsiella
sp
colon
gt
predict
gram
bsi
etiolog
sensit
specif
catheterrel
isol
relationship
observ
gram
prior
colon
howev
gram
previous
colon
bronchial
secret
stool
reppcr
techniqu
confirm
pathogen
colon
concord
case
test
case
pathogencolon
discord
due
either
miss
surveil
cultur
growth
inhibit
sensit
strain
antimicrobialcontain
media
use
stool
surveil
empir
antibiot
treatment
base
colon
result
permit
adequaci
vap
primari
bacteremia
treatment
conclus
rt
gt
colon
strongli
relat
microbi
etiolog
subsequ
infect
systemat
weekli
colon
surveil
rt
gt
specimen
could
help
implement
prompt
empir
antimicrobi
therapi
especi
multidrug
resist
gram
pathogen
icu
administr
antibiot
via
respiratori
tract
prevent
icuacquir
pneumonia
metaanalysi
compar
trial
falaga
siempo
blizioti
k
rello
michalopoulo
athen
gr
object
administr
prophylact
antibiot
via
respiratori
tract
one
sever
strategi
prevent
icuacquir
pneumonia
infect
consider
morbid
mortal
sought
systemat
examin
avail
evid
regard
effect
prophylact
antibiot
administ
via
respiratori
tract
develop
icuacquir
pneumonia
mortal
colon
respiratori
tract
emerg
antimicrobi
resist
toxic
method
relev
studi
identifi
pub
med
search
refer
relev
articl
trial
includ
analysi
provid
compar
data
regard
abovement
outcom
two
independ
investig
perform
data
extract
calcul
effect
studi
intervent
clinic
relev
outcom
result
eight
compar
trial
studi
gentamicin
studi
polymyxin
studi
tobramycin
studi
ceftazidim
studi
studi
patient
includ
metaanalysi
icuacquir
pneumonia
ci
colon
respiratori
tract
p
aeruginosa
ci
less
common
group
patient
receiv
antibiot
prophylaxi
differ
mortal
found
compar
group
ci
seriou
drugrel
toxic
note
conclus
prophylact
administr
antibiot
via
respiratori
tract
patient
icu
set
associ
reduct
occurr
icuacquir
pneumonia
despit
valid
concern
develop
dissemin
bacteria
antimicrobi
resist
evid
support
investig
consider
prevent
strategi
least
icu
patient
high
risk
develop
icuacquir
pneumonia
background
diagnos
ventilatorassoci
pneumonia
vap
remain
difficult
without
exist
clinic
avail
gold
standard
gener
vap
diagnos
upon
combin
clinic
radiolog
bacteriolog
criteria
describ
clinic
pulmonari
infect
score
cpi
mani
physician
includ
creactiv
protein
crp
clinic
judgement
importantli
temporari
trend
variabl
frequent
use
daili
practic
though
diagnost
properti
dynam
valu
cpi
crp
compar
diagnost
perform
static
valu
therefor
aim
compar
diagnost
perform
static
dynam
valu
cpi
crp
diagnos
vap
method
consecut
patient
previous
includ
randomis
vapintervent
trial
need
mechan
ventil
studi
cpi
crp
obtain
daili
valu
determin
day
diagnosi
consid
static
valu
dynam
valu
defin
differ
day
diagnosi
day
patient
develop
vap
patient
notdevelop
vap
cpi
crp
day
consid
static
calcul
possibl
sequenti
day
refer
diagnosi
vap
base
upon
clinic
judgement
respons
physician
independ
adjud
intensivist
result
patient
develop
vap
static
cpi
score
vapfre
patient
day
day
vap
diagnosi
area
curv
auc
receiv
oper
characterist
roc
ci
optim
cpi
cutoff
sen
spec
temporari
trend
cpi
discern
patient
develop
notdevelop
vap
wherea
cpi
score
clearli
increas
toward
day
vap
diagnosi
yet
auc
cpi
valu
ci
ci
compar
static
cpi
although
static
crp
higher
patient
vap
versu
mgl
p
auc
static
crp
ci
diagnost
properti
increas
use
dynam
crp
valu
auc
ci
ci
resp
conclus
use
tempor
trend
cpi
improv
diagnost
perform
neither
static
dynam
crpvalu
appear
reliabl
vap
diagnosi
aetiolog
time
bloodstream
infect
liver
intens
care
unit
f
pink
e
sizer
w
bernal
g
auzing
j
wendon
eltringham
london
uk
object
determin
aetiolog
time
bloodstream
infect
adult
liver
intens
care
unit
compar
result
previous
publish
data
unit
method
retrospect
studi
adult
patient
admit
liver
intens
care
unit
hour
januari
juli
apach
ii
risk
score
admiss
clinic
data
relat
aetiolog
liver
failur
transplant
mortal
collect
addit
blood
cultur
organ
identif
antimicrobi
suscept
standard
criteria
adopt
definit
bacteraemia
chisquar
fisher
exact
test
use
determin
associ
categor
variabl
result
patient
one
bacteraemia
total
isol
includ
repeat
episod
speci
mean
time
admiss
licu
first
signific
bacteraemia
day
isol
gram
posit
gram
neg
yeast
median
time
first
bacteraemia
differ
organ
follow
escherichia
coli
meticillinsensit
staphylococcu
aureu
day
enterococcu
faecali
day
multiresist
acinetobact
baumanii
day
mrsa
coagulaseneg
staphylococci
yeast
enterococcu
faecium
day
klebsiella
sp
day
stenotrophomona
maltophilia
day
enterobact
sp
day
pseudomona
sp
day
number
organ
differ
reach
statist
signific
mean
apach
ii
score
admiss
develop
bacteraemia
compar
conclus
compar
earlier
studi
centr
data
suggest
signific
differ
time
sequenc
organ
isol
septic
patient
licu
studi
infect
member
enterobacteriacea
gramposit
organ
appear
later
may
reflect
chang
preval
differ
speci
strain
andor
impact
earli
preemptiv
use
antibiot
develop
infect
liver
failur
patient
signific
term
manag
sepsi
discuss
isra
gener
intens
care
unit
analysi
mashiach
h
sprecher
r
finkelstein
haifa
il
object
evalu
epidemiolog
featur
nosocomi
bloodstream
infect
bsi
observ
gener
intens
care
unit
uti
medic
centr
past
year
method
data
collect
retrospect
computer
record
octob
potenti
skin
contamin
includ
episod
caus
one
posit
blood
cultur
yield
coagulaseneg
staphylococci
exclud
multipl
cultur
speci
consid
singl
infect
result
studi
period
episod
bsi
aerob
gramposit
organ
account
case
aerob
gramneg
organ
account
caus
fungi
caus
divers
organ
includ
anaerob
common
organ
coagulaseneg
staphylococci
klebsiella
spp
aureu
acinetobact
spp
resist
rate
pathogen
increas
gradual
strikingli
period
rate
mrsa
increas
increas
rate
resist
klebsiella
gener
cephalosporin
increas
increas
resist
pseudomona
acinetobact
imipenem
increas
increas
increas
respect
multipl
drug
resist
among
acinetobact
spp
studi
period
rang
surprisingli
rate
vre
remain
low
mean
rang
conclus
data
may
allow
clinician
better
target
empir
therapi
bloodstream
infect
intens
care
unit
well
understand
danger
relationship
antibiot
use
resist
set
object
order
identifi
assess
appli
relev
evid
better
health
care
decisionmak
studi
address
evalu
whether
pseudomona
aeruginosa
associ
nosocomi
infect
ni
intens
care
unit
icu
origin
mainli
patient
endogen
flora
exogen
crosstransmiss
determin
occurr
p
aeruginosa
carriag
admiss
ii
icuacquir
p
aeruginosa
infect
colonis
rate
site
iii
impact
crosstransmiss
use
molecular
type
data
involv
microrgan
method
six
month
activ
surveil
survey
perform
icu
italian
hospit
accord
helic
protocol
carriag
colon
definit
describ
bertrand
et
al
molecular
type
perform
macro
restrict
analysi
speidigest
genom
dna
interpret
genom
related
perform
use
wellestablish
criteria
presenc
two
indistinguish
strain
two
patient
consid
one
episod
crosstransmiss
result
survey
period
total
patient
admit
icu
incid
p
aeruginosa
carriag
colonizationinfect
admiss
patient
respect
icuacquir
colon
rate
patient
incid
densiti
patientday
icuacquir
infect
rate
patient
incid
densiti
patientday
icuacquir
pneumonia
vap
confirm
first
p
aeruginosaspecif
infect
type
follow
uti
local
cvc
relat
infect
nineteen
distinct
clone
identifi
macro
restrict
analysi
impact
p
aeruginosa
crossinfect
estim
least
figur
higher
crosscolon
includ
thu
defin
prevent
proport
p
aeruginosasustain
crosstransmiss
episod
conclus
p
aeruginosa
infect
icu
suggest
repres
tip
iceberg
wherea
colon
reflect
submerg
part
epidemiolog
scenario
depict
analysi
show
crosstransmiss
import
mean
p
aeruginosa
infect
highlight
occurr
silent
epidem
mainli
sustain
multiresist
clone
absenc
epidemiolog
screen
would
remain
submerg
part
iceberg
metaanalys
impact
inappropri
antibiot
therapi
mortal
patient
ventilatorassoci
pneumonia
bloodstream
infect
e
gillespi
patel
c
coleman
hartford
us
object
sever
studi
found
initi
treatment
ventilatorassoci
pneumonia
vap
blood
stream
infect
bsi
inappropri
antimicrobi
therapi
associ
higher
rate
mortal
addit
studi
fail
confirm
find
provid
stronger
quantit
basi
address
postul
associ
conduct
seri
metaanalys
exist
relev
studi
method
three
investig
systemat
search
databas
review
citat
relev
articl
identifi
studi
met
follow
inclus
criteria
randomis
observ
trial
compar
patient
receiv
appropri
antimicrobi
therapi
defin
antibiot
regimen
demonstr
vitro
activ
identifi
bacteri
speci
associ
infect
inappropri
antimicrobi
therapi
set
vap
bsi
report
data
incid
mortal
conduct
mortal
analys
without
adjust
confound
factor
randomeffect
model
util
analys
result
studi
includ
observ
natur
metaanalysi
vap
studi
util
unadjust
mortal
data
n
studi
demonstr
inappropri
antimicrobi
therapi
significantli
increas
patient
odd
mortal
odd
ratio
ci
q
statist
pvalu
similar
result
seen
upon
metaanalysi
adjust
mortal
data
n
studi
ci
q
statist
pvalu
metaanalysi
bsi
studi
util
unadjust
mortal
data
n
studi
demonstr
inappropri
antimicrobi
therapi
significantli
increas
patient
odd
mortal
ci
q
statist
pvalu
similar
result
seen
upon
metaanalysi
includ
adjust
mortal
data
n
studi
ci
q
statist
pvalu
assess
funnel
plot
egger
weight
regress
statist
pvalu
demonstr
low
probabl
signific
public
bia
vap
bsi
analys
conclus
appear
associ
inappropri
antimicrobi
therapi
higher
mortal
patient
vap
bsi
thu
emphas
critic
import
earli
appropri
antimicrobi
therapi
background
nosocomi
infect
patient
admit
intens
care
unit
icu
frequent
caus
potenti
resist
pathogen
rp
present
studi
aim
determin
influenc
antibiot
resist
outcom
identifi
risk
factor
develop
icuacquir
pneumonia
rp
method
patient
sever
pneumonia
admit
icu
prospect
includ
studi
clinic
data
marker
infect
crp
leukocyt
differenti
blood
count
purul
secret
quantit
cultur
respiratori
sampl
bronchoalveolar
lavag
protect
specimen
brush
endotrach
aspir
bacteri
diagnost
blood
cultur
record
consid
distinguish
colonis
infect
rp
defin
pathogen
resist
least
two
major
antibiot
group
result
patient
total
patient
femal
mean
age
year
pneumonia
microbi
growth
respiratori
secret
patient
rp
note
furthermor
patient
rp
could
isol
icustay
mortal
rate
patient
evid
rp
significantli
higher
comparison
patient
infect
suscept
pathogen
versu
p
factor
associ
infect
rp
mechan
ventil
p
renal
failur
p
sepsi
p
mean
durat
treatment
significantli
longer
patient
rp
comparison
group
suscept
pathogen
microbi
growth
versu
respect
day
p
conclus
patient
sever
pneumonia
resist
pathogen
significantli
higher
mortal
rate
factor
associ
acquir
pneumonia
resist
pathogen
mechan
ventil
renal
failur
sepsi
antimicrobi
resist
pattern
gramneg
bacteria
isol
intens
care
unit
greek
hospit
object
purpos
studi
determin
antimicrobi
resist
gramneg
rod
caus
infect
patient
intens
care
unit
icu
tertiari
care
hospit
northern
greec
method
januari
decemb
total
clinic
specimen
icu
patient
admit
laboratori
specimen
inocul
onto
routin
cultur
media
blood
cultur
perform
use
bactalert
autom
system
infect
character
nosocomi
accord
cdc
criteria
identif
microorgan
suscept
test
perform
use
vitek
autom
system
biomerieux
franc
result
clinic
specimen
posit
cultur
one
multipl
microorgan
respiratori
tract
infect
frequent
follow
bloodstream
infect
urinari
tract
infect
surgic
site
infect
gramneg
bacteria
respons
infect
icu
acinetobact
baumannii
frequent
isol
gram
neg
speci
n
follow
pseudomona
aeruginosa
n
klebsiella
spp
n
escherichia
coli
n
proteu
mirabili
n
enterobact
cloaca
n
resist
rate
gram
neg
microorgan
present
tabl
total
klebsiella
spp
e
coli
p
mirabili
resist
third
gener
cephalosporin
demonstr
extend
spectrum
beta
lactamas
esbl
posit
phenotyp
conclus
acinetobact
baumannii
predomin
pathogen
follow
paeruginosa
high
resist
rate
observ
investig
drug
esbl
product
appear
major
mechan
resist
beta
lactam
imipenem
appear
activ
agent
major
isol
incid
methicillinresist
aureu
prospect
studi
critic
patient
result
threeyear
period
patient
isol
aureu
detect
studi
repres
total
patient
attend
critic
care
unit
nt
observ
signific
chang
studi
period
isol
rate
methicillinresist
aureu
methicillin
suscept
aureu
n
n
respect
patient
whose
mean
age
slightli
superior
inpati
mrsa
isol
versu
n
male
n
femal
patient
prospect
includ
exhaust
studi
infect
defin
hospit
acquir
n
commun
acquir
n
frequent
underli
diseas
heart
diseas
n
trauma
n
infecti
diseas
n
neurolog
diseas
n
neoplasm
n
risk
factor
detect
mechan
ventil
n
venou
central
cathet
n
thorac
tube
n
surgeri
n
mortal
inpati
mrsa
isol
versu
inpati
methicillinsuscept
aureu
conclus
aureu
commonli
isol
critic
ill
patient
knowledg
epidemiolog
clinic
characterist
may
allow
optimis
manag
treatment
reduc
morbid
mortal
critic
care
unit
prevent
increas
methicillinresist
aureu
isol
screen
mrsa
nasal
swab
admitt
intens
care
unit
object
aureu
well
document
nosocomi
pathogen
respons
seriou
system
infect
recommend
perform
screen
mrsa
admitt
intens
care
unit
tradit
search
mrsa
involv
detect
aureu
evalu
suscept
profil
oxacilin
procedur
take
least
h
provid
rel
late
answer
clinician
chromagar
mrsa
chromogen
medium
isol
specimen
allow
direct
differenti
methicillin
resist
aureu
coloni
colour
decid
compar
tradit
way
search
mrsa
use
cromogen
medium
materi
method
nasal
swab
cultur
columbia
blood
sheep
agar
difco
chromagar
mrsa
medium
bd
incub
h
h
coloni
compat
staphylococcu
blood
agar
plate
submit
confirmatori
test
like
catalas
coagulas
test
posit
disk
diffus
test
perform
evalu
suscept
profil
oxacilin
chromagar
medium
look
mauv
coloni
clearli
differenti
bacteri
speci
result
blue
colourless
coloni
mauv
coloni
methicillin
resist
aureu
later
confirm
use
classic
methodolog
result
posit
case
nasal
carriag
mrsa
detect
use
blood
agar
h
take
one
day
need
isol
coloni
mix
gram
neg
bacilli
nine
addit
posit
case
detect
chromagar
mrsa
medium
confirm
classic
identif
method
h
conclus
regard
detect
mrsa
chromagar
mrsa
cultur
show
sensit
method
give
reliabl
faster
result
comparison
convent
medium
thu
allow
tremend
save
labour
time
genotyp
characteris
epidemiolog
analysi
vancomycinresist
enterococci
isol
patient
intens
care
unit
lambias
del
pezzo
f
rossano
napl
past
decad
rapid
rise
number
seriou
nosocomi
infect
caus
enterococci
resist
multipl
antibiot
enterococci
highlevel
gentamicin
resist
becam
major
concern
begin
subsequ
ampicillinresist
enterococci
includ
blactamaseproduc
noproduc
strain
isol
mani
hospit
recent
year
glycopeptideresist
enterococci
report
european
north
american
hospit
itali
problem
vre
vancomycinresistantenterococci
emerg
present
therapeut
problem
object
present
studi
describ
molecular
character
clinic
isol
vrenterococcu
faecium
obtain
patient
intens
care
unit
icu
napl
materi
method
period
januari
isol
vre
faecium
examin
resist
vancomycin
teicoplanin
determin
standard
dilut
micro
method
accord
nccl
guidelin
strain
obtain
sever
biolog
sampl
includ
urin
blood
cathet
respiratori
sampl
icu
patient
van
genotyp
vana
vanb
vanc
determin
use
pcr
therefor
isol
type
puls
field
gel
electrophoresi
pfge
smai
restrict
enzym
result
studi
demonstr
preval
genotyp
vana
strain
strain
vanb
genotyp
analysi
pfge
comparison
smai
band
profil
show
isol
belong
uniqu
pfge
group
group
pattern
differ
two
three
band
accord
tenov
criteria
one
strain
belong
uniqu
pfge
profil
strain
b
uniqu
strain
b
group
five
strain
vanb
genotyp
conclus
presenc
vrefaecium
relat
risk
factor
immunosuppress
organ
recipi
statu
exposur
antibiot
result
studi
suggest
intrahospit
spread
vre
faecium
occur
knowledg
epidemiolog
essenti
control
spread
use
chef
electrophoresi
might
help
clinician
initi
effect
infect
control
measur
contain
spread
organ
object
norovirus
nv
identifi
import
caus
gastroenter
human
virus
also
lead
caus
food
born
waterborn
outbreak
infecti
intestin
diseas
genogroup
ii
gii
gi
associ
human
infect
viru
transmit
contamin
food
water
directli
person
person
contact
contamin
surfac
aim
studi
investig
nv
caus
acut
nonbacteri
gastroenter
northern
greec
method
total
faecal
specimen
patient
children
adult
male
femal
acut
gastroenter
studi
major
criterion
choic
sampl
initi
exclus
bacteri
natur
diseas
detect
nv
antigen
faecal
specimen
ideiatm
test
dakocytom
perform
test
util
gi
gii
specif
monoclon
antibodi
solidphas
sandwich
enzym
immunoassay
detect
gi
gii
nv
specimen
found
posit
ideiatm
test
n
examin
presenc
nv
rna
rtpcr
use
three
differ
pair
primer
rna
extract
perform
qiagen
spin
column
techniqu
qia
amp
rna
kit
viral
rna
specimen
amplifi
use
two
pair
primer
rna
polymeras
gene
pcr
pcr
b
one
pair
locat
near
end
genom
pcr
c
result
faecal
specimen
patient
children
adult
found
posit
ideiatm
test
gi
gii
gi
gii
repres
total
specimen
pcr
show
posit
result
specimen
pcr
b
pcr
c
specimen
posit
three
pcr
specimen
posit
pcr
b
specimen
posit
pcr
c
specimen
posit
pcr
conclus
present
find
show
nv
frequent
caus
acut
nonbacteri
gastroenter
northern
greec
knowledg
first
report
studi
investig
nv
caus
gastroenter
greec
result
obtain
suggest
season
distribut
diseas
wherea
signific
differ
among
age
pcr
sensit
three
pcr
appli
studi
set
describ
epidemiolog
noroviru
outbreak
island
ireland
oneyear
period
studi
commenc
epidemiolog
data
outbreak
collect
electron
databas
establish
project
link
share
epidemiolog
virolog
data
establish
lead
enhanc
data
set
sampl
outbreak
republ
ireland
sent
nation
viru
refer
laboratori
univers
colleg
dublin
confirm
diagnosi
rtpcr
revers
transcript
polymeras
chain
reaction
due
enhanc
surveil
studi
period
high
rate
submiss
sampl
north
ireland
sampl
sent
region
viru
refer
laboratori
royal
victoria
hospit
belfast
nest
pcr
use
diagnosi
noroviru
sequenc
carri
pcr
product
determin
circul
strain
noroviru
ireland
oneyear
period
noroviru
outbreak
report
republ
ireland
north
ireland
period
outbreak
noroviru
infect
report
region
viru
refer
laboratori
result
far
indic
major
report
outbreak
island
ireland
associ
hospit
residenti
institut
republ
ireland
norovirus
associ
major
outbreak
new
variant
genogroup
known
jam
strain
small
number
norovirus
associ
outbreak
republ
ireland
belong
genogroup
databas
use
sourc
data
food
born
virus
europ
network
safefoodth
food
safeti
promot
board
fund
research
emerg
vibrio
cholera
biotyp
el
tor
serotyp
inaba
last
summer
outbreak
iran
object
cholera
endem
diseas
iran
aim
studi
determin
epidemiolog
antimicrobi
suscept
pattern
vibrio
cholera
biotyp
el
tor
serotyp
inab
isol
recent
outbreak
iran
method
stool
sampl
collect
patient
suspect
cholera
admit
hospit
clinic
specimen
examin
convent
bacteriolog
method
isol
sent
cholera
refer
laboratori
confirm
stereotyp
suscept
test
antimicrobi
suscept
test
perform
disk
diffus
method
recommend
nccl
antimicrobi
drug
includ
ampicillin
ciprofloxacin
ci
cotrimoxazol
sxt
tetracyclin
tc
erythromycin
em
nalidix
acid
na
furazolidon
f
etest
mic
method
use
detect
minim
inhibitori
concentr
mic
cotrimoxazol
nalidix
acid
erythromycin
result
total
patient
diagnos
clinic
laboratori
confirm
cholera
diseas
report
twentysix
provinc
major
case
tehran
qum
hamadan
case
respect
patient
year
old
patient
male
femal
patient
iranian
nation
afghanistan
pakistan
patient
hospitalis
outpati
case
fatal
rate
isol
inaba
serotyp
case
ogawa
serotyp
studi
reveal
origin
vibrio
cholera
consumpt
raw
veget
water
swage
also
isol
v
cholera
swage
isol
resist
cotrimoxazol
nalidix
acid
furazolidon
intermedi
chloramphenicol
isol
suscept
tetracyclin
ciprofloxacin
erythromycin
mic
cotrimoxazol
nalidix
acid
lgml
lgml
erythromycin
antimicrobi
result
show
isol
suscept
pattern
conclus
studi
reveal
recent
outbreak
caus
v
cholera
el
tor
serotyp
inaba
isol
resist
cotrimoxazol
nalidix
acid
furazolidon
method
data
two
ongo
project
surveil
infecti
diseas
netherland
use
cover
million
inhabit
respect
incid
resist
rate
analys
time
region
level
urban
season
variat
recent
travel
histori
result
incid
cultureproven
campylobact
infect
show
incident
decreas
year
time
relat
avian
flu
outbreak
poultri
patient
age
group
test
frequent
found
posit
age
group
year
highest
percentag
posit
cultur
incid
campylobact
infect
highest
southern
part
netherland
per
south
versu
averag
per
part
netherland
incid
much
lower
rural
urban
area
high
stabl
rate
resist
observ
fluoroquinolon
resist
erythromycin
low
increas
year
highest
resist
rate
erythromycin
found
south
netherland
resist
rate
increas
increas
urban
level
invers
relat
observ
incid
infect
high
summer
low
winter
resist
fluoroquinolon
macrolid
rel
high
rate
winter
resist
predominantli
fluoroquinolon
consider
higher
travelrel
infect
compar
endem
one
conclus
found
region
differ
incid
resist
rate
highest
south
netherland
furthermor
found
invers
relationship
resist
rate
fluoroquinolon
macrolid
incid
campylobacteriosi
explan
could
winter
month
poultri
import
sourc
campylobact
infect
summer
isol
sourc
associ
low
rate
fluoroquinolon
resist
becom
import
high
resist
rate
fluoroquinolon
warrant
reconsider
use
drug
first
choic
empir
treatment
presum
campylobact
infect
epidemiolog
clinic
present
hydatid
cyst
diseas
patient
imam
sina
shariati
paediatr
medic
centr
hospit
z
abdi
liae
soudbakhsh
solemani
k
kiyani
tehran
ir
background
hydatid
diseas
zeonot
diseas
seriou
diseas
human
import
hygien
problem
area
world
endem
iran
possibl
parasit
continu
life
cycl
must
differenti
diagnosi
list
patient
cystic
lesion
method
review
epidemiolog
clinic
present
patient
admit
treat
imam
sina
shariati
paediatr
medic
centr
hospit
hydat
diseas
result
diseas
involv
person
decad
sex
prefer
household
women
patient
group
patient
live
citi
common
involv
organ
liver
lung
liver
right
lobe
involv
left
lobe
lung
left
lower
lobe
involv
other
kidney
cn
bone
heart
spleen
organ
involv
rare
laboratori
chang
meaning
patient
eosinophilia
may
help
diagnosi
patient
research
ct
scan
use
modal
diagnosi
help
diagnosi
option
hydatid
serolog
ifa
surgeri
therapeut
choic
patient
diseas
season
distribut
time
prefer
seen
infect
cyst
common
complic
conclus
hydatidosi
low
mortal
rate
chronic
diseas
high
morbid
rate
import
diagnos
earli
treat
soon
possibl
reason
patient
symptom
sign
rise
suspicion
space
occupi
lesion
hydatidosi
must
one
major
diseas
think
rule
prove
appropri
modal
echinococcu
granulosu
lethal
effect
low
voltag
direct
electr
current
hydatid
cyst
protoscolec
r
ghasemikhah
h
ghasemikhah
sharbatkhori
tehran
ir
object
studi
smallscal
method
kill
hydatid
cyst
protoscolec
use
low
voltag
direct
electr
current
method
collect
hydatid
cyst
infect
organ
slaughter
anim
protoscolec
cultur
four
differ
media
hydatid
cyst
fluid
rpmi
normal
salin
tri
buffer
respect
protoscolec
media
transfer
electrolysi
devic
differ
electr
current
densiti
appli
measur
surviv
rate
protoscolec
flame
cell
movement
eosin
stain
use
result
result
show
surviv
rate
protoscolec
hydatid
fluid
depend
electr
current
densiti
time
appli
current
current
densiti
macm
v
macm
v
macm
v
min
respect
kill
parasit
hydatid
fluid
conclus
howev
current
densiti
macm
v
rpmi
medium
min
effect
singl
multipl
pyogen
liver
abscess
aetiolog
clinic
cours
treatment
object
aim
present
studi
evalu
differ
etiolog
clinic
cours
treatment
patient
singl
multipl
pyogen
liver
abscess
pla
method
multicent
retrospect
review
pla
diagnost
eight
spanish
hospit
januari
decemb
case
includ
abscess
confirm
imag
well
either
document
organ
recov
abscess
site
resolut
symptom
sign
treatment
statist
analysi
perform
spss
softwar
packag
result
total
patient
pla
manag
present
singl
abscess
sa
multipl
abscess
median
age
sem
male
affect
hepatomegali
frequent
p
serum
level
alkalin
phosphatas
p
neutrophil
count
p
significantli
higher
patient
sa
sa
usual
larger
cm
smaller
cm
sa
locat
right
side
liver
case
locat
right
side
case
sa
cryptogen
origin
case
biliari
origin
case
respons
microorgan
identifi
case
patient
sa
case
patient
chisquar
p
eschericia
coli
common
etiolog
agent
identifi
cultur
blood
abscess
aspir
pla
percutan
drenaig
antibiot
therapi
use
treatment
type
abscess
abscess
relat
morbid
rate
higher
overal
mortal
higher
sa
conclus
result
suggest
biliari
origin
show
hepatomegali
neutrophillia
rise
alkalin
phosphatas
clinic
present
frequent
sa
microbiolog
identif
higher
patient
patient
sa
comparison
pyogen
liver
abscess
caus
nonescherichia
coli
e
coli
object
aim
present
studi
compar
pyogen
liver
abscess
pla
caus
nonescherichia
coli
escherichia
coli
method
multicent
retrospect
review
pla
diagnos
treat
eight
spanish
hospit
januari
decemb
case
includ
abscess
confirm
imag
well
either
document
organ
recov
abscess
site
resolut
symptom
sign
treatment
statist
analysi
perform
spss
softwar
packag
result
total
patient
pla
manag
escherichia
coli
speci
commonli
isol
cultur
blood
abscess
aspir
abscess
caus
escherichia
coli
account
case
organ
recov
differ
epidemiolog
characterist
durat
fever
admiss
initi
laboratori
valu
durat
antibiot
therapi
mean
age
femal
gender
higher
escherichia
coli
pla
rr
ci
commonli
identifi
underli
caus
biliari
diseas
recoveri
escherichia
coli
guid
biliari
origin
rr
ci
compar
size
escherichia
coli
versu
caus
pla
escherichia
coli
pla
greater
nonescherichia
coli
abscess
p
differ
diamet
averag
cm
ci
frequent
locat
right
lobe
correl
microbiolog
find
presenc
solitari
multipl
abscess
therapeut
modal
percutan
drenaig
antibiot
therapi
carri
two
group
significantli
differ
neither
hospit
stay
morbid
mortal
rate
conclus
result
suggest
pla
caus
escherichia
coli
compris
diseas
biliari
origin
higher
age
femal
gender
escherichia
coli
pla
greater
nonescherichia
coli
abscess
diabet
mellitu
risk
prognost
factor
pyogen
liver
abscess
denmark
rw
thomsen
p
jepsen
ht
aalborg
aarhu
dk
object
pyogen
liver
abscess
pla
rare
lifethreaten
diseas
rise
incid
rate
report
unit
state
europ
taiwan
diabet
mellitu
emerg
overwhelm
risk
factor
pla
wherea
epidemiolog
studi
diabet
risk
factor
pla
western
popul
spars
method
examin
diabet
risk
factor
prognost
factor
pla
denmark
period
use
larg
nationwid
data
set
base
administr
registri
identifi
patient
diagnosi
pla
nation
registri
patient
randomli
select
fifti
genderand
agematch
popul
control
case
use
condit
logist
regress
estim
odd
ratio
or
pla
accord
diabet
adjust
medic
surgic
risk
factor
among
patient
pla
compar
adjust
mortal
odd
ratio
diabet
patient
result
studi
includ
patient
first
hospitalis
pla
median
age
rang
year
men
total
patient
pla
diabet
record
match
date
compar
control
subject
adjust
potenti
confound
factor
pla
person
diabet
ci
day
discharg
mortal
diabet
patient
nondiabet
patient
pla
adjust
mortal
odd
ratio
diabet
patient
ci
conclus
nationwid
studi
found
fourfold
increas
risk
poorer
outcom
pla
associ
diabet
mellitu
object
spontan
bacteri
periton
sbp
major
complic
liver
cirrhosi
data
prognost
signific
bacteremia
patient
sbp
perform
retrospect
studi
determin
influenc
bacteremia
mortal
patient
sbp
method
patient
sbp
microorgan
isol
ascit
andor
blood
identifi
retrospect
review
clinic
laboratori
record
seoul
nation
univers
hospit
korea
januari
decemb
classifi
bacterem
group
nonbacterem
group
underli
liver
function
determin
meld
model
endstag
liver
diseas
score
microbiolog
respons
rate
ascit
polymorphonuclear
leukocyt
count
reduct
rate
sbprelat
mortal
compar
two
group
identifi
independ
risk
factor
mortal
multipl
logist
regress
model
use
control
effect
confound
variabl
result
total
patient
enrol
studi
among
patient
bacterem
nonbacterem
escherichia
coli
common
etiolog
organ
follow
klebsiella
pneumonia
distribut
etiolog
organ
differ
two
group
stratifi
meld
score
show
signific
differ
two
group
microbiolog
respons
rate
versu
p
ascit
polymorphonuclear
leukocyt
count
reduct
rate
versu
p
differ
bacterem
nonbacterem
group
sbprelat
mortal
bacterem
group
significantli
higher
nonbacterem
group
versu
p
bacteremia
ci
p
meld
score
ci
p
independ
risk
factor
multipl
logist
regress
analys
sbp
relat
mortal
conclus
bacteremia
independ
risk
factor
mortal
sbp
object
etiolog
analysi
sputum
cultur
regard
season
fluctuat
famili
practition
patient
method
studi
group
includ
primari
care
clinic
diagnos
patient
sputum
examin
order
perform
silesian
analyt
laboratori
period
subject
regist
famili
practis
hospitalis
silesian
area
includ
criteria
activ
infect
lower
respiratori
tract
intak
transport
final
identif
materi
compli
laboratori
standard
result
number
posit
cultur
sputum
sampl
taken
primari
care
hospitalis
patient
account
respect
common
pathogen
primari
care
patient
order
preval
exclud
streptococcu
viridan
moraxella
catarrhali
ecoli
staphaureu
klebspneumonia
pseud
aeruginosa
proteu
mirabili
clinic
diagnos
patient
moraxella
catarrhali
kleb
pneum
e
coli
pseudomona
aeruginosa
staphaureu
str
spp
str
pneumonica
season
fluctuat
among
primari
care
patient
higher
number
posit
sampl
note
april
octob
least
june
juli
august
result
detail
analysi
primari
care
sampl
show
higher
percentag
moraxella
catarrhali
strain
dec
jan
least
may
month
rang
higher
percentag
ecoli
isol
observ
may
mar
jun
dec
absent
staphylococcu
aureu
frequent
detect
state
mar
respect
wherea
emerg
summer
month
june
sep
higher
emerg
pseudomona
aeruginosa
observ
june
kleb
pneumonia
isol
test
posit
mainli
spring
summer
period
conclus
prefer
empir
therapi
diagnost
procedur
examin
sputum
seldom
order
famili
physician
moraxella
catarrhali
isol
common
pathogen
isol
materi
subject
lower
respiratori
tract
infect
tend
preval
winter
month
obtain
data
may
use
famili
practis
select
optim
treatment
lower
respiratori
tract
infect
chronic
exposur
smoke
risk
factor
communityacquir
pneumonia
elderli
popul
object
relationship
cigarett
smoke
risk
communityacquir
pneumonia
cap
elderli
peopl
remain
controversi
age
gender
match
casecontrol
studi
analys
associ
cigarett
smoke
risk
hospitalis
cap
elderli
peopl
perform
method
elig
cohort
n
deriv
korean
elderli
pharmacoepidemiolog
cohort
n
populationbas
dynam
cohort
cohort
member
year
age
live
busan
metropolitan
citi
beneficiari
korean
medic
insur
corpor
kmic
inform
smoke
statu
alcohol
consumpt
pastmed
histori
height
weight
perform
statu
daili
life
relat
variabl
age
year
collect
selfadminist
mail
questionnair
potenti
case
n
hospitalis
cap
collect
kmic
medic
claim
databas
januari
decemb
incid
case
hospitalis
cap
n
confirm
medic
record
four
control
match
case
randomli
use
age
gender
year
questionnair
survey
n
adjust
odd
ratio
aor
calcul
condit
logist
regress
analysi
adjust
confound
effect
smoke
alcohol
consumpt
bodi
mass
index
bmi
perform
statu
underli
lung
cerebrovascular
diseas
result
median
age
case
patient
year
patient
male
underli
lung
diseas
aor
ci
alcohol
exdrink
aor
ci
age
year
associ
higher
risk
hospitalis
cap
smoke
total
amount
cigarett
smoke
durat
smoke
age
year
significantli
relat
risk
hospitalis
cap
factor
includ
perform
statu
bmi
underli
diseas
associ
risk
hospitalis
cap
conclus
underli
lung
diseas
alcohol
exdrink
age
year
independ
risk
factor
hospitalis
cap
elderli
peopl
later
period
chronic
previou
exposur
smoke
howev
risk
factor
hospitalis
cap
peopl
suggest
chronic
respiratori
damag
due
cigarett
smoke
might
influenc
occurr
acut
lower
respiratori
tract
infect
commun
environ
similar
trend
also
observ
high
level
p
resist
respect
although
high
among
pen
ir
isol
overal
resist
erythromycin
minim
variat
differ
period
time
mlsb
tpe
resist
domin
among
er
isol
shown
phenotyp
test
pzr
resist
levofloxacin
detect
mc
isol
suscept
amoxyclav
amc
fluoroquinolon
cefaclor
small
increment
blactamas
posit
seen
year
hi
isol
also
univers
sensit
gen
cephalosporin
amc
blactamas
product
rang
nil
hand
trimetoprimsulfamethoxazol
sxt
resist
high
among
speci
still
low
rate
resist
commonli
use
antibiot
among
respiratori
pathogen
increas
resist
penicillin
note
sp
sxt
three
speci
differ
bedouin
jewish
popul
clinic
characterist
patient
admit
communityacquir
pneumonia
v
novack
l
avnon
k
riesenberg
f
schlaeffer
beer
sheva
il
object
ethnic
group
differ
inher
risk
factor
contract
communityacquir
pneumonia
cap
southern
israel
popul
two
ethnic
group
live
side
side
predominantli
urban
jewish
popul
popul
arab
bedouin
popul
social
transit
desert
nomad
settl
lifestyleth
object
studi
evalu
differ
characterist
outcom
cap
two
popul
patient
hospitalis
one
winter
season
method
conduct
hospit
base
prospect
observ
studi
soroka
univers
medic
centr
bed
tertiari
care
hospit
serv
region
hospit
southern
israel
period
assess
clinic
well
demograph
characterist
patient
hospitalis
cap
result
patient
enrol
bedouin
bedouin
patient
younger
rest
cohort
vs
year
p
lower
rate
cardiovascular
diseas
ischem
heart
diseas
cerebrovascular
diseas
vs
p
bedouin
higher
smoke
rate
vs
p
higher
preval
copd
vs
p
diabet
vs
p
differ
pneumonia
patient
outcom
research
team
port
score
bedouin
jewish
popul
admiss
median
point
vs
point
p
bedouin
patient
lower
rate
prehospitalis
antibiot
therapi
compar
rest
vs
p
differ
length
hospitalis
median
day
p
mortal
rate
bedouin
jewish
patient
vs
p
conclus
number
differ
clinic
characterist
bedouin
jewish
patient
admit
hospit
cap
higher
smoke
copd
rate
bedouin
patient
may
affect
microbiolog
cap
pathogen
taken
consider
therapeut
decis
made
despit
socioeconom
differ
two
ethnic
group
differ
sever
cap
clinic
outcom
object
examin
mortal
hospitalis
pneumonia
within
day
followup
among
patient
haematolog
nonhaematolog
malign
method
conduct
populationbas
cohort
studi
three
danish
counti
popul
million
region
hospit
discharg
registri
identifi
adult
year
firsttim
hospit
discharg
diagnosi
pneumonia
n
furthermor
obtain
inform
previou
discharg
diagnos
includ
haematolog
nonhaematolog
malign
patient
follow
mortal
danish
civil
registr
system
estim
mortal
ratio
mrr
use
cox
regress
analysi
adjust
calendar
year
age
gender
comorbid
result
among
patient
hospitalis
pneumonia
haematolog
malign
nonhaematolog
malign
diagnos
prior
hospitalis
pneumonia
anoth
patient
haematolog
nonhaematolog
malign
cumul
mortal
follow
pneumonia
patient
without
malign
vs
patient
haematolog
malign
patient
nonhaematolog
malign
compar
patient
without
malign
adjust
mrr
ci
patient
haematolog
malign
ci
patient
nonhaematolog
malign
conclus
among
patient
firsttim
hospitalis
pneumonia
haematolog
nonhaematolog
malign
associ
substanti
increas
mortal
outbreak
three
relat
case
psittacosi
detect
realtim
pcr
object
psittacosi
life
threaten
zoonosi
caus
infect
oblig
intracellular
microorgan
chlamydophila
psittaci
although
major
patient
present
typic
symptom
like
abrupt
onset
fever
rigor
sweat
promin
headach
couch
percent
show
respiratori
symptom
cultur
difficult
time
consum
isol
c
psittaci
highli
infecti
isol
handl
biosafeti
level
condit
molecular
techniqu
like
real
time
pcr
therefor
ideal
altern
detect
c
psittaci
aid
diagnosi
psittacosi
method
develop
intern
control
real
time
pcr
system
target
ribosom
intergen
spacer
c
psittaci
pcr
assay
valid
set
clinic
sampl
serolog
confirm
patient
psittacosi
control
result
use
pcr
system
detect
outbreak
psittacosi
among
member
veterinari
unit
one
member
admit
icu
multi
organ
failur
conclus
new
develop
realtim
pcr
c
psittaci
abl
identifi
three
patient
psittacosi
relat
common
sourc
symptom
patient
vari
mild
sever
realtim
pcr
c
psittaci
enabl
diagnosi
psittacosi
prior
clinic
undetect
case
audit
sputum
sampl
nation
smoke
ban
j
fennel
b
cryan
g
corcoran
cork
ie
object
smoke
associ
increas
morbid
mortal
cancer
cardiovascular
diseas
smoke
also
associ
infect
tb
exacerb
copd
meningococc
diseas
march
ireland
becam
nation
enforc
univers
smoke
ban
workplac
provid
uniqu
opportun
assess
whether
chang
popul
smoke
practic
affect
number
respiratori
tract
infect
epidemiolog
respiratori
pathogen
would
help
show
smoke
ban
provid
shorterterm
benefit
predict
longterm
benefit
cancer
cardiovascular
diseas
may
suggest
reduct
smoke
protect
specif
pathogen
method
cork
univers
hospit
tertiari
referr
centr
serv
popul
sampl
evenli
divid
inpati
gp
sampl
sputum
sampl
cultur
sensit
june
month
month
imposit
smoke
ban
examin
inform
smoke
pattern
provid
offic
tobacco
control
sputum
sampl
tracheal
aspir
bronchial
wash
process
use
standard
accredit
laboratori
method
result
log
apex
isoft
databas
queri
use
cogno
databas
analysi
softwar
analys
use
excel
microsoft
result
children
posit
patient
discard
monthli
total
number
posit
sampl
streptococci
pneumonia
staphylococcu
aureu
haemophilu
influenza
moraxella
catarrhali
assess
analys
result
sampl
process
posit
number
posit
sampl
june
april
april
monthli
mean
number
select
speci
smoke
ban
shown
conclus
smoke
ban
associ
substanti
chang
preval
certain
bacteria
notabl
pneumonia
chang
commun
mirror
oppos
chang
hospit
sputa
result
work
requir
see
chang
reflect
mortal
morbid
respiratori
tract
infect
period
explain
appar
invers
relationship
chang
commun
hospit
specimen
pneumonia
prognost
factor
patient
pneumococc
bacteraemia
counti
teach
hospit
spain
object
despit
medic
advanc
pneumococc
bacteremia
import
mortal
prognost
factor
address
sever
studi
howev
data
provid
studi
develop
univers
hospit
high
incid
co
morbid
prognost
factor
obtain
univari
analysi
method
case
pneumonia
bacteremia
detect
januari
june
identifi
use
microbiolog
laboratori
databas
standard
data
collect
form
use
review
hospit
record
statist
analys
student
test
use
comparison
mean
valu
chi
squar
test
fisher
exact
test
comparison
categor
data
two
tail
stepwis
logist
regress
analysi
progress
condit
incorpor
variabl
perform
multivari
analysi
result
case
bacteremia
detect
studi
period
die
pneumococc
bacteremia
commun
acquir
univari
analysi
factor
associ
mortal
age
yr
among
surviv
vs
yr
among
die
durat
ill
admiss
day
vs
day
absenc
fever
vs
absenc
chill
vs
presenc
sever
sepsi
shock
vs
presenc
bilater
pneumonia
vs
multivari
analysi
factor
associ
mortal
presenc
bilater
pneumonia
p
absenc
fever
p
durat
ill
admiss
p
reach
statist
borderlin
signific
conclus
among
patient
pneumococc
bacteremia
mortal
low
durat
ill
admiss
presenc
bilater
pneumonia
absenc
fever
prognost
factor
ambulatori
treatment
telithromycin
versu
clarithromycin
communityacquir
pneumonia
spain
b
puchad
valencia
es
object
assess
efficaci
safeti
telithromycin
versu
clarithromycin
ambulatori
treatment
communityacquir
pneumonia
patient
requir
hospitalis
patient
method
outpati
fine
ii
communityacquir
pneumonia
randomis
receiv
telithromycin
mg
od
day
patient
clarithromycin
mg
bid
day
patient
patient
requir
admiss
hospit
includ
visit
perform
posttreat
final
evalu
perform
day
inclus
studi
failur
consid
one
follow
condit
present
persist
progress
cap
signsymptom
xray
death
sever
advers
event
preclud
treatment
complianc
need
differ
antimicrobi
agent
result
patient
rang
year
age
male
femal
patient
signific
differ
p
success
rate
ci
treatment
found
final
clinic
assess
telithromycin
versu
clarithromycin
failur
rate
telithromycin
clarithromycin
distribut
failur
clarithromycin
asymmetr
first
h
telithromycin
failur
occur
first
h
differ
found
respect
frequenc
sever
advers
event
studi
drug
conclus
telithromycin
day
show
higher
efficaci
clarithromycin
day
empir
ambulatori
treatment
fine
ii
communityacquir
pneumonia
spain
need
cover
atyp
pneumonia
addit
penicillinmacrolid
resist
pneumococci
drug
equal
well
toler
connect
seem
use
estim
influenc
antibiot
longterm
prognosi
patient
aecb
ie
length
symptomfre
period
diseas
exacerb
method
open
randomis
compar
studi
patient
aecb
least
three
exacerb
per
year
includ
studi
one
group
patient
aecb
treat
levofloxacin
lfx
mg
per
day
day
groupbi
macrolid
antibiot
azithromycin
clarithromycin
day
treatment
patient
follow
month
result
total
patient
aecb
includ
studi
treat
lfx
macrolid
antibiot
averag
age
patient
correspondingli
year
length
chronic
year
number
aecb
previou
year
similar
group
clinic
cure
rate
estim
day
end
treatment
lfx
macrolid
erad
rate
caus
microorgan
haemophilu
influenza
main
pathogen
correspondingli
regress
rate
main
symptom
exacerb
cough
dyspnoea
sputum
volum
higher
lfx
therapi
followup
period
month
incid
aecb
requir
prescript
antibiot
group
patient
prescrib
lfx
group
patient
treat
macrolid
antibiot
p
averag
length
symptomfre
period
lfx
macrolid
treatment
correspondingli
day
p
conclus
lfx
superior
macrolid
longterm
prognosi
aecb
prolong
symptomfre
period
retrospect
review
use
standard
questionnair
result
thirtyfour
men
women
identifi
suffer
h
influenza
lrti
median
age
rang
year
major
patient
smoke
histori
well
underli
condit
chronic
obstruct
pulmonari
diseas
frequent
patient
infect
manifest
pneumonia
among
lobar
segment
opacif
chest
xray
pleural
effus
accompani
parenchym
lesion
observ
patient
patient
treat
empir
antibiot
base
result
sputum
cultur
regimen
proven
appropri
patient
thirtysix
h
influenza
isol
resist
amoxycillin
coamoxiclav
ciprofloxacin
forti
patient
infect
favour
outcom
five
patient
die
pneumonia
respiratori
failur
sever
underli
condit
conclus
lrti
due
h
influenza
occur
popul
underli
diseas
high
rate
amoxycillin
resist
alarm
increas
resist
antibiot
use
observ
object
assess
variat
outcom
patient
hospitalis
communityacquir
pneumonia
cap
accord
pneumonia
sever
index
psi
categori
method
retrospect
review
chart
patient
admit
hospit
diagnosi
cap
period
geograph
scatter
hospit
spain
knowledg
largest
singleyear
seri
spain
one
largest
world
largest
adjust
popul
result
overal
patient
cap
initi
includ
studi
psi
score
properli
record
patient
proport
pretreat
blood
cultur
higher
among
patient
lowrisk
class
iiii
patient
highrisk
class
ivv
vs
p
wherea
proport
blood
cultur
posit
result
lower
former
group
vs
p
signific
differ
class
also
observ
proport
diagnost
techniqu
appli
sputum
cultur
vs
p
legionella
urinari
antigen
assay
vs
p
pneumococc
urinari
antigen
assay
vs
p
outcom
accord
psi
categori
shown
tabl
conclus
diagnost
workup
perform
frequent
lowrisk
patient
highrisk
patientsin
spite
at
idsa
guidelin
recommend
carri
legionella
urinari
antigen
sever
cap
studi
test
perform
frequent
lowrisk
patient
vs
p
result
suggest
sever
case
antibacteri
therapi
prioritis
microbiolog
andor
wider
bacteri
spectrum
cover
empir
therapi
provid
physician
lower
need
obtain
etiolog
diagnos
factor
influenc
length
hospit
stay
larg
singleyear
seri
communityacquir
pneumonia
object
identifi
variabl
associ
length
hospit
stay
lo
patient
communityacquir
pneumonia
cap
discharg
hospit
method
retrospect
review
chart
patient
admit
hospit
diagnosi
cap
period
geograph
scatter
hospit
spain
data
avail
patient
patient
die
remov
analysi
multivari
cox
regress
analysi
perform
assess
factor
independ
associ
prolong
lo
result
overal
mean
lo
day
ci
median
day
day
day
rang
day
ninetysix
point
two
patient
stay
day
sitespecif
mean
lo
rang
day
tabl
show
result
obtain
differ
variabl
assess
conclus
admiss
icu
posit
blood
cultur
hypoxia
multilobar
xray
involv
age
absenc
fever
comorbid
alcohol
abus
know
criteria
sever
increas
significantli
lo
neither
empir
antibiot
choic
idsaat
guidelin
etiolog
diagnosi
nursinghom
stay
activ
smoker
insignific
influenc
lo
survivedlikewis
hospit
centr
independ
factor
associ
lo
variat
among
centr
suggest
increas
medic
care
cost
hospit
largest
lo
identif
factor
increas
lo
patient
cap
especi
attribut
differ
patient
characterist
opportun
modifi
could
mean
import
save
object
assess
physician
belief
respiratori
tract
infect
guidelin
g
whether
affect
choic
regimen
method
four
differ
staff
meet
hospit
base
physician
hbp
two
educ
meet
commun
practic
physician
cpp
question
regard
attitud
toward
g
choic
regimen
scenario
pneumonia
hbp
pharyng
nonadmiss
warrant
pneumonia
cpp
collect
anonym
achiev
ballot
vote
hbp
interact
repli
system
cpp
regimen
choic
check
concord
major
idsa
bt
hellen
id
g
applic
data
collect
date
result
total
hbp
cpp
repli
collect
analyz
overal
favour
attitud
toward
g
state
hbp
declar
alway
frequent
follow
g
respect
rate
cpp
analysi
select
regimen
howev
display
discrep
statement
hbp
choic
pneumonia
concord
current
g
penicillin
scenario
streptococc
pharyng
chosen
cpp
choic
pneumonia
concord
g
repli
clinic
microbiolog
infect
volum
supplement
conclus
physician
tend
express
overal
favour
attitud
toward
guidelin
choic
regimen
reflect
either
superfici
g
knowledg
limit
accept
accord
belief
prefer
influenc
aetiolog
diagnosi
mortal
hospitalis
patient
communityacquir
pneumonia
result
larg
singleyear
seri
j
garau
f
baquero
e
jl
c
behalf
nacer
group
object
identifi
variabl
influenc
earli
late
mortal
patient
communityacquir
pneumonia
cap
method
retrospect
review
chart
patient
admit
hospit
diagnosi
cap
period
nov
oct
geograph
scatter
hospit
spain
data
avail
patient
multivari
logist
regress
analysi
perform
assess
factor
independ
associ
earli
within
day
late
day
mortal
result
overal
mortal
subject
admit
hospit
cap
die
day
deceas
subject
repres
total
mortal
seri
sitespecif
mortal
rate
rang
result
shown
tabl
conclus
admiss
icu
multilobar
xray
involv
age
independ
associ
earli
late
mortal
contrast
empir
treatment
choic
idsaat
guidelin
fever
etiolog
diagnosi
activ
smoke
associ
lower
late
mortal
wherea
posit
blood
cultur
presenc
comorbid
associ
increas
late
mortal
hypoxia
resid
nurs
home
associ
earli
mortal
seri
set
etiolog
diagnosi
independ
protector
factor
late
mortal
earli
mortal
object
optim
manag
parapneumon
effus
ppe
empyema
children
remain
controversi
current
insuffici
evid
give
clear
guidanc
therapi
aim
studi
delin
biochem
characterist
examin
effect
differ
therapeut
strategi
ultrasound
stage
ppe
method
retrospect
chart
review
tertiari
pediatr
refer
center
juli
juli
patient
pneumococc
pneumonia
complic
parapneumon
effus
empyema
underw
realtim
chest
sonographi
thoracentesi
biochem
analysi
includ
ultrason
appear
classifi
accord
deposit
fibrin
format
fibrin
septat
stage
ultrason
appear
ppe
use
correl
hematolog
biochem
variabl
pleural
effus
clinic
outcom
respect
therapeut
strategi
variou
stage
ppe
also
analys
result
total
eightyon
patient
enrol
present
studi
chest
ultrasound
perform
result
stratifi
anecho
fluid
stage
n
float
fibrin
strand
stage
n
septat
fibrin
stage
n
mean
day
fever
elaps
detect
stage
appear
higher
advanc
stage
p
univari
analysi
reveal
wbc
platelet
count
hemogram
ph
glucos
ldh
protein
pleural
effus
significantli
associ
stage
ppe
multivari
analysi
reveal
ph
protein
mgdl
pleural
fluid
two
independ
predict
factor
progress
ppe
trend
rate
success
tube
drainag
decreas
advanc
stage
ppe
especi
patient
initi
chest
tube
drainag
p
total
durat
fever
hospit
stay
significantli
shorter
children
initi
videoassist
thorac
surgeri
vat
compar
initi
chest
tube
drainag
p
conclus
chest
sonographi
well
discrimin
progress
stage
bacteri
ppe
children
progress
ppe
fibrin
format
earli
aggress
tube
drainag
may
avoid
subsequ
surgic
intervent
children
fibrin
septat
ppe
initi
vat
recommend
shorten
durat
fever
hospit
stay
method
prospect
nonintervent
multicentr
studi
includ
outpati
diagnosi
aecb
mcl
therapi
last
aecb
current
aecb
either
treat
mfx
tablet
mcl
po
decis
drug
prescrib
well
dose
durat
therapi
attend
physician
document
compris
patient
characterist
diseas
treatment
histori
cours
current
aecb
treat
mfx
mcl
well
final
assess
efficaci
toler
result
total
patient
includ
analysi
patient
treat
mxf
mcl
clarithromycin
ccr
roxithromycin
rox
azithromycin
azm
patient
characterist
differ
markedli
two
treatment
group
mxf
mean
age
year
mean
bmi
kgm
current
smoker
mcl
mean
age
year
mean
bmi
kgm
current
smoker
patient
least
one
concomit
diseas
mostli
cardiovascular
mxf
group
mcl
group
patient
group
suffer
chronic
bronchiti
year
year
mean
number
aecb
last
month
respect
mxf
patient
treatment
appli
day
main
therapi
regimen
mcl
patient
ccr
mg
day
rox
mg
day
azm
mg
day
symptom
relief
group
last
followup
shown
figur
mean
durat
overal
improv
cure
aecb
day
sd
day
sd
mxf
patient
compar
day
sd
day
sd
bulstar
nation
longitudin
surveil
system
monitor
isol
antimicrobi
suscept
import
clinic
signific
microorgan
blood
cultur
cerebrospin
fluid
upper
lower
respiratori
tract
urin
wound
sampl
particip
microbiolog
laboratori
one
hundr
three
microbiolog
laboratori
public
hospit
privat
laboratori
counti
republ
bulgaria
particip
bulstar
data
communityacquir
pneumonia
base
outpati
lower
respiratori
tract
sampl
particip
laboratori
use
clinic
laboratori
standard
institut
clsi
methodolog
number
clinic
signific
isol
among
lead
pathogen
streptococcu
pneumonia
follow
staphylococcu
aureu
klebsiella
pneumonia
moraxella
catarrhali
haemophilu
influenza
preval
penicillin
nonsuscept
streptococcu
pneumonia
resist
erythromycin
levofloxacin
number
methicillinresist
staphylococcu
aureu
among
gramneg
bacteria
sensit
frequent
use
antibiot
moder
streptococcu
pneumonia
common
caus
bacteri
pneumonia
children
past
sever
year
frequenc
children
pneumococc
pneumonia
complic
necrosi
empyema
increas
studi
undertaken
evalu
clinic
characterist
children
pneumococc
pneumonia
especi
complic
pneumon
hospit
children
diagnosi
pneumococc
pneumonia
januari
octob
enrol
patient
fulfil
least
one
evid
spneumonia
infect
cultur
blood
pleural
fluid
yield
spneumonia
posit
result
detect
antigen
pleural
fluid
complic
pneumonia
defin
presenc
pleural
fluid
paramet
consist
empyema
andor
ct
imag
compat
necrot
pneumon
fiftytwo
patient
elig
studi
femal
mean
age
month
fever
cough
common
symptom
significantli
high
crp
mgl
found
patient
case
suffer
complic
pneumonia
analysi
clinic
characterist
occurr
complic
pneumonia
associ
longer
durat
fever
length
hospit
longer
time
defervesc
antibiot
treatment
signific
differ
note
except
crp
laboratori
find
patient
without
complic
mic
test
show
signific
differ
regard
rate
penicillin
nonsuscept
group
isol
patient
complic
pneumonia
empir
treat
thirdgener
cephalosporin
highdos
penicillin
regimen
adjust
accord
patientsclin
respons
besid
case
complic
pneumonia
manag
includ
decort
endotrach
tube
intub
intens
care
picu
perform
respect
fatal
case
note
seri
conclus
children
complic
pneumococc
pneumonia
may
prolong
cours
hospit
febril
durat
longer
time
defever
antibiot
treatment
antibioticsresist
spneumonia
commonli
isol
patient
complic
diseas
clinic
outcom
appear
correl
patient
clinic
present
suscept
pneumococcu
elderli
patient
hospitalis
communityacquir
pneumonia
valid
compar
evalu
prognost
rule
object
identifi
prognost
factor
cap
elderli
patient
gener
discrimin
rule
predict
hospit
clinic
microbiolog
infect
volum
supplement
mortal
valid
evalu
compar
wide
use
prognost
index
cap
gener
popul
method
elderli
patient
admit
cap
select
multivari
analys
deriv
cohort
n
identifi
factor
associ
hospit
mortal
predict
model
mortal
establish
test
valid
cohort
n
predict
rule
compar
other
prognost
indic
cap
american
thorac
societi
british
thorac
societi
pneumonia
patient
outcom
research
team
result
hospit
mortal
rate
deriv
valid
cohort
similar
vs
identifi
prognost
factor
odd
ratio
confid
interv
bilater
radiograph
infiltr
blood
urea
nitrogen
mmoll
absenc
fever
respiratori
rate
confus
shock
discrimin
rule
predict
hospit
mortal
compris
three
factor
specif
neg
predict
valu
greater
overal
accuraci
other
gener
prognost
index
at
bt
port
p
valid
cohort
conclus
simpl
discrimin
rule
incorpor
prognost
factor
identifi
power
predictor
hospit
mortal
wide
accept
prognost
indic
cap
could
adequ
elderli
patient
heart
failur
mortal
within
day
hospitalis
pneumonia
populationbas
cohort
studi
object
examin
prognost
impact
heart
failur
day
mortal
hospit
pneumonia
method
conduct
populationbas
cohort
studi
three
danish
counti
north
jutland
aarhu
viborg
adult
hospit
firsttim
diagnosi
pneumonia
identifi
hospit
discharg
registri
categor
accord
whether
previou
discharg
diagnosi
heart
failur
danish
civil
registr
system
retriev
inform
mortal
inform
potenti
confound
obtain
hospit
discharg
registri
populationbas
prescript
databas
use
cox
regress
analysi
compar
mortal
rate
patient
without
heart
failur
adjust
calendar
year
gender
age
comorbid
alcoholrel
disord
preadmiss
antibiot
immunosuppress
drug
use
result
studi
includ
adult
firsttim
hospit
pneumonia
diagnosi
heart
failur
overal
day
mortal
increas
patient
heart
failur
adjust
mortal
rate
ratio
mrr
pneumonia
heart
failur
patient
compar
nonheart
failur
patient
ci
adjust
mmr
increas
ci
among
heart
failur
patient
receiv
thiazidebas
regimen
ci
among
heart
failur
patient
receiv
loopdiureticbas
regimen
includ
spironolacton
treatment
adjust
mrr
pneumonia
furthermor
higher
heart
failur
patient
diagnosi
heart
valv
diseas
ci
heart
failur
patient
atrial
fibril
ci
previou
myocardi
infarct
ci
conclus
among
patient
hospit
pneumonia
heart
failur
appear
associ
increas
mortal
elev
sever
heart
failur
may
associ
wors
pneumonia
outcom
rise
incid
persist
high
mortal
hospitalis
pneumonia
populationbas
studi
denmark
object
littl
known
tempor
trend
incid
mortal
pneumonia
gener
popul
conduct
populationbas
cohort
studi
three
danish
counti
popul
million
examin
chang
incid
mortal
associ
hospit
pneumonia
method
adult
hospit
firsttim
diagnosi
pneumonia
n
identifi
hospit
discharg
registri
follow
mortal
danish
civil
registri
system
determin
agestandard
incid
rate
adjust
mortal
rate
associ
calendar
year
gender
age
comorbid
result
incid
hospit
pneumonia
among
adult
increas
per
personyear
per
personyear
equival
agestandard
incid
rate
ratio
cumul
mortal
within
day
admiss
respect
rang
mortal
patient
age
year
age
advanc
age
import
poor
prognost
factor
follow
high
comorbid
score
male
gender
adjust
mortal
rate
ratio
among
patient
hospit
pneumonia
compar
ci
day
ci
day
conclus
incid
hospit
pneumonia
denmark
increas
consider
last
year
combin
persist
high
mortal
rate
clinic
public
health
concern
daili
sequenti
intravenousor
ivpo
moxifloxacin
equival
iv
ceftriaxon
plu
twice
daili
ivpo
levofloxacin
treatment
sever
communityacquir
pneumonia
requir
hospitalis
motiv
studi
object
determin
efficaci
safeti
daili
mg
sequenti
ivpo
moxifloxacin
mxf
vs
high
dose
ceftriaxon
ctx
plu
high
dose
levofloxacin
lfx
treatment
patient
sever
communityacquir
pneumonia
cap
requir
hospit
parenter
treatment
patient
method
prospect
random
multicentr
multin
thirdparti
blind
doubledummi
trial
compar
efficaci
safeti
ivpo
mxf
mg
od
day
iv
ctx
g
od
plu
iv
lfx
mg
bid
follow
oral
lfx
mg
bid
day
lfx
dose
adjust
renal
function
patient
stratifi
either
pneumonia
sever
index
psi
class
iii
popul
class
ivv
primari
endpoint
clinic
cure
test
cure
day
final
dose
n
number
subject
clinic
cure
bacteriolog
success
n
total
number
subject
conclus
daili
mg
sequenti
ivpo
mxf
shown
equival
highdos
ctxlfx
treatment
sever
cap
even
sever
psi
ivv
group
antibiot
therapi
acut
lower
respiratori
tract
infect
within
slovakia
k
banasova
h
hupkova
v
foltan
bratislava
sk
background
acut
lower
respiratori
tract
infect
lrti
common
condit
manag
primari
care
although
benefit
antibiot
therapi
question
prescript
often
object
assess
antibiot
prescript
assum
aetiolog
antibiot
group
prescrib
lrti
acut
bronchiti
superinfect
acut
bronchiti
bronchopneumonia
atyp
pneumonia
method
multicentr
prescript
studi
acut
respiratori
tract
infect
four
week
novemb
slovak
citi
protocol
methodolog
appli
paediatrician
regist
patient
characterist
gender
age
weight
diagnosi
assum
aetiolog
antibiot
therapi
prescrib
antibiot
risk
factor
patient
allergi
penicillin
dysimmun
chronic
respiratori
tract
diseas
etc
result
four
week
novemb
patient
suffer
lrti
common
acut
bronchiti
patient
second
superinfect
acut
bronchiti
patient
third
bronchopneumonia
patient
less
frequent
pneumonia
patient
incid
lrti
vari
age
group
risk
age
group
patient
preschool
age
patient
antibiot
treatment
indic
patient
pneumonia
superinfect
ac
bronchiti
therapi
acut
bronchiti
ac
bronchiti
superinfect
coaminopenicillin
indic
antibiot
group
respect
macrolid
use
treat
bronchopneumonia
pneumonia
respect
gp
conceiv
mainli
bacteri
aetiolog
infect
viral
aetiolog
assum
acut
bronchiti
case
pneumonia
bronchopneumonia
estim
either
viral
bacteri
case
conclus
although
lower
respiratori
tract
infect
caus
mainli
virus
antibiot
therapi
domin
part
treatment
cutdown
antibiot
prescript
possibl
accomplish
use
time
laboratori
examin
settl
specif
etiolog
agent
infect
result
epidemiolog
occurr
rtisti
kosova
period
present
realiti
epidemiolog
situat
lack
report
rti
sti
case
report
total
case
report
surveil
system
identifi
syndrom
diagnos
case
neisseria
gonorrhea
laboratori
diagnost
extrem
limit
possibl
state
etiolog
profil
preval
sti
sinc
decemb
confirm
aid
case
death
regist
institut
public
health
iph
pristina
kosovo
aid
case
report
six
aid
case
case
previou
year
period
twothird
report
case
male
conclus
specif
rtisti
programm
establish
march
gap
identifi
variou
compon
sti
prevent
care
gnostic
uniform
current
standard
provid
perceiv
lack
privaci
confidenti
sti
care
due
limit
suppli
reagent
sti
diagnost
limit
longterm
plan
data
need
essenti
direct
program
work
ribeiroayeh
labeith
u
frank
mannheim
freiburg
ibr
object
investig
correl
cervic
dysplasia
sociodemograph
immunolog
determin
hiv
posit
women
method
women
admit
univers
hospit
inpati
studi
period
includ
studi
data
abstract
clinic
chart
individu
divid
two
group
normal
pap
iii
abnorm
pap
iiiiv
cervic
cytolog
screen
result
statist
method
use
compar
sociodemograph
clinic
variabl
analysi
perform
use
statist
packag
social
scienc
spss
result
cohort
women
test
posit
human
immunodefici
viru
hiv
includ
studi
mean
age
rang
fiftyon
individu
origin
europ
africa
eight
asia
overal
preval
abnorm
cytolog
smear
studi
period
present
normal
abnorm
smear
women
cytolog
evid
human
papilloma
viru
infect
hpv
herp
simplex
viru
infect
detect
seven
women
trichomona
vaginali
chlamydia
five
seven
respect
compar
group
signific
associ
found
sociodemograph
determin
presenc
dysplasia
howev
signific
determin
hpv
infect
immunosuppress
cd
cell
count
vs
viral
load
vs
rna
copiesl
number
cytolog
chang
due
hpv
infect
occur
frequent
group
cytolog
evid
infect
vs
condylomata
acuminata
vs
conclus
cervic
dysplasia
due
hpv
infect
appear
highli
correl
immunosupress
hiv
posit
women
localis
rest
patient
treat
differ
antiretrovir
combin
monitoris
treat
patient
untreat
present
herp
recurr
mean
vs
recurr
frequent
sever
immunosuprest
patient
vs
p
recurr
ratio
nt
modifi
patient
good
immun
respons
therapi
recurr
less
frequent
patient
undetect
viral
load
vs
detect
p
conclus
antiretrovir
therapi
immun
restor
influenc
rate
herpet
reactiv
preval
hiv
hepat
b
c
syphili
risk
behaviour
among
drug
user
insid
outsid
prison
object
purpos
studi
evalu
potenti
risk
transmiss
bloodborn
sexual
transmit
infect
dutch
prison
high
proport
prison
mani
countri
use
drug
among
inject
drug
user
iud
infect
like
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
preval
method
drug
user
recruit
differ
assembl
point
streetwalk
district
methadon
provid
point
homeless
shelter
inject
noninject
drug
user
elig
use
least
one
day
week
particip
given
facetofac
questionnair
sociodemograph
prison
histori
drug
use
behaviour
sexual
practic
serum
sampl
test
follow
infect
marker
antihiv
hbsag
antihbc
antihcv
tppa
hiv
antibodi
confirm
westernblot
characterist
sourc
popul
represent
region
drug
use
popul
male
mean
age
year
sd
rang
dutch
origin
ever
use
drug
intraven
use
heroin
use
cocain
use
methadon
use
benzodiazepin
recent
inject
heroin
last
month
en
recent
inject
cocain
result
compar
two
group
particip
never
imprison
b
drug
user
imprison
least
two
time
often
mani
time
group
b
ever
inject
drug
prison
recent
sex
group
b
differ
significantli
higher
preval
hiv
antihiv
vs
hepat
b
hbsag
vs
antihbc
vs
hepat
c
antihcv
vs
found
syphili
tppa
significantli
differ
two
group
although
preval
suggest
direct
vs
studi
popul
recent
sex
last
month
usual
unprotect
sex
money
often
without
condom
discuss
high
observ
inprison
preval
viral
infect
consequ
prison
transmiss
potenti
transmiss
infect
could
prevent
hepat
b
vaccin
among
prison
popul
prison
staff
needl
exchang
condom
use
shortag
cell
dutch
prison
nation
polici
chang
put
one
prison
cell
two
polici
might
creat
addit
risk
transmiss
antimicrobi
resist
neisseria
gonorrhoea
northeast
romania
badescu
enach
z
petrescu
buiuc
iasi
ro
object
emerg
gonococc
isol
reduc
suscept
resist
antimicrobi
agent
signific
concern
whole
world
studi
aim
character
current
antimicrobi
susceptibilityresist
pattern
n
gonorrhoea
isol
northeast
romania
method
septemb
octob
total
isol
n
gonorrhoea
collect
male
patient
urethr
femal
patient
cervicovagin
attend
sexual
transmit
diseas
clinic
iasi
specimen
patient
inocul
directli
onto
thayermartin
select
agar
incub
h
atmospher
identif
suspect
coloni
base
upon
presenc
gramneg
oxidaseposit
superoxolposit
diplococci
typic
enzym
pattern
isol
also
test
betalactamas
product
antimicrobi
agent
test
penicillin
tetracyclin
ciprofloxacin
cefixim
ceftriaxon
spectinomycin
suscept
test
perform
agar
diffus
method
gc
agar
base
vitox
accord
clsi
recommend
result
test
isol
resist
penicillin
betalactamas
product
betalactamas
neg
strain
demonstr
intermedi
resist
tetracyclin
resist
observ
isol
intermedi
resist
strain
resist
ciprofloxacin
show
intermedi
resist
studi
strain
demonstr
tripl
resist
penicillin
tetracyclin
ciprofloxacin
isol
found
resist
ceftriaxon
cefixim
spectinomycin
conclus
penicillin
tetracyclin
ciprofloxacin
longer
recommend
treatment
gonorrhea
area
ceftriaxon
cefixim
spectinomycin
consid
antimicrobi
choic
sinc
test
gonococc
isol
resist
three
antibiot
monitor
resist
antimicrobi
agent
n
gonorrhoea
must
establish
romania
perman
basi
order
adjust
standard
treatment
regimen
introduct
syphili
incid
increas
dramat
amsterdam
case
may
due
increas
unsaf
sexual
behaviour
homosexu
men
result
diminish
perceiv
threat
hivaid
tp
surfac
protein
encod
repeat
gene
tpr
l
polymorph
involv
partial
host
immun
object
develop
type
techniqu
tp
track
syphili
transmiss
method
studi
case
primari
syphili
men
swab
genit
lesion
use
tp
pcr
diagnost
posit
isol
thereaft
use
sequenc
analysi
tprk
gene
span
variabl
domain
phylogenet
tree
amino
acid
sequenc
allow
cluster
analysi
structur
questionnair
use
amsterdam
sti
clinic
collect
socioepidemiolog
inform
routin
contact
trace
perform
result
four
patient
two
anatom
locat
tppcr
posit
one
visit
patient
visit
clinic
twice
recidivist
studi
period
result
nucleic
acid
isol
singl
tprk
sequenc
type
obtain
isol
either
tprk
pcr
neg
sequenc
impli
presenc
least
two
tprk
type
isol
patient
dual
posit
lesion
reveal
ident
sequenc
howev
one
patient
two
differ
tprk
type
found
isol
recidivist
also
show
two
differ
tprk
gene
despit
fact
none
tppatient
known
sexual
partner
identifi
cluster
ident
isol
cluster
size
vari
patient
cluster
may
reveal
link
remain
unknown
classic
contact
trace
conclus
type
domain
tprk
gene
show
potenti
identifi
transmiss
rout
syphili
aim
studi
retrospect
review
epidemiolog
clinic
featur
mammalassoci
injuri
travel
report
geosentinel
surveil
network
characterist
examin
includ
type
anim
countri
exposur
provis
rabi
postexposur
prophylaxi
pep
occurr
relat
infect
may
may
animalassoci
injuri
report
geosentinel
femal
predomin
amongst
injur
travel
mf
ratio
averag
age
year
predomin
region
animalassoci
injuri
report
includ
asia
latin
america
africa
anim
speci
associ
injuri
known
case
dog
involv
case
monkey
cat
human
bat
mice
predomin
particular
speci
differ
geograph
region
rabi
pep
given
case
howev
inform
remain
miss
report
either
rabi
tularaemia
travel
cat
scratch
diseas
report
complic
infect
report
animalassoci
injuri
account
total
report
health
problem
travel
seen
travel
patient
seen
travel
proportion
morbid
sustain
anim
bite
higher
amongst
travel
visit
asia
compar
africa
latin
america
australianew
zealand
north
america
west
europ
p
victim
anim
injuri
younger
ill
travel
vs
year
old
p
frequent
femal
p
final
proportion
morbid
sustain
anim
bite
higher
children
less
year
p
data
show
animalassoci
injuri
uncommon
complaint
among
travel
present
geosentinel
site
highest
proport
record
travel
asia
mostli
region
endem
rabi
led
requir
pep
preexposur
rabi
prophylaxi
must
consid
travel
region
world
appropri
pep
avail
addit
pretravel
consult
also
includ
advic
regard
animalassoci
injuri
risk
rabi
associ
infect
pep
travel
highrisk
region
use
saliva
sooth
bloodsuck
arthropod
bite
transmiss
human
herpesviru
object
transmiss
previous
consid
sexual
transmit
viru
sometim
appear
strictli
relat
child
hypersensit
respons
bite
blood
feed
arthropod
mother
caregiv
habit
attempt
reliev
itch
reduc
scratch
contamin
bite
site
infect
saliva
coluzzi
et
al
saliva
seem
play
major
role
viral
transmiss
appear
reservoir
bodi
fluid
taylor
et
al
order
confirm
promot
arthropod
hypothesi
carri
survey
questionnair
method
two
anonym
questionnair
women
reproduct
age
student
test
sampl
three
differ
region
itali
veneto
tuscani
latium
region
palestinian
territori
gaza
strip
africa
uganda
cameroon
result
frequenc
use
saliva
among
student
age
significantli
differ
three
italian
region
tuscani
latium
veneto
case
tuscani
mother
also
interview
close
correspond
result
student
mean
frequenc
compar
frequenc
record
gaza
strip
show
statist
signific
differ
p
rel
low
rate
record
gaza
rather
surpris
sinc
socioeconom
statu
popul
notori
one
worst
mediterranean
area
howev
import
note
among
palestinian
cultur
tend
avoid
use
saliva
consid
impolit
frequenc
record
itali
palestin
compar
uganda
show
high
statist
signific
differ
p
similar
data
also
obtain
comparison
preliminari
result
cameroon
background
hepat
e
gener
regard
selflimit
rel
mild
diseas
nonpregn
travel
diseas
thought
least
part
zoonosi
one
sourc
transmiss
may
uncook
meat
wild
anim
fulmin
case
rare
report
non
pregnant
patient
nonendem
area
japan
case
report
old
paediatrician
travel
old
husband
old
sister
three
week
cashmer
india
suffer
diarrhoea
last
week
return
germani
week
present
malais
headach
fatigu
anoth
two
week
hospit
symptom
acut
hepat
within
week
show
sign
acut
liver
failur
liver
transplant
prepar
total
durat
four
week
howev
symptom
sign
fulmin
acut
hepat
decreas
anoth
week
patient
feel
well
discharg
hospit
although
husband
sister
share
meal
patient
travel
togeth
time
stay
without
clinic
symptom
test
neg
antibodi
hev
neg
hevrna
rtnpcr
hepat
e
patient
diagnos
detect
antibodi
hev
enzymeimmunoassay
immunoblot
assay
stool
specimen
serum
sampl
repetit
test
hevrna
rtnpcr
assum
hevviremia
last
long
week
hevrna
detect
long
week
stool
sampl
conclus
patient
remark
develop
fulmin
hepat
e
without
pregnant
shed
viral
rna
stool
long
nine
week
first
present
hepat
symptom
durat
hevviremia
detect
hevrtnpcr
estim
least
week
first
clinic
symptom
hepat
case
indic
hev
may
present
patient
blood
stool
sampl
prolong
period
time
dengu
fever
associ
sever
reactiv
thrombocytosi
gangren
toe
case
report
sk
surrun
da
kandiah
singapor
sg
introduct
present
patient
dengu
fever
associ
sever
reactiv
thrombocytosi
gangren
toe
condit
knowledg
describ
case
report
chines
ladi
without
previou
signific
medic
histori
admit
fever
chill
myalgia
skin
rash
day
durat
clinic
examin
unremark
except
peticha
rash
leg
arm
blood
investig
reveal
mild
thrombocytopaenia
platelet
count
drop
l
posit
pair
dengu
serolog
hospit
stay
develop
sever
pain
bluish
discolor
middl
three
toe
feet
progress
patch
superfici
gangren
platelet
count
increas
maximum
l
echocardiogram
ct
scan
aorta
normal
duplex
scan
arteri
leg
normal
distal
end
posterior
tibiali
dorsali
pedi
full
autoimmun
serolog
neg
complement
level
normal
clopidogrel
pentoxyphyllin
start
skin
lesion
platelet
count
improv
significantli
discuss
progress
thrombocytopaenia
sever
thrombocytosi
dengu
fever
uncommon
event
though
mani
type
skin
lesion
known
occur
dengu
fever
gangren
document
far
case
unusu
associ
thrombocytosi
gangren
toe
forc
us
exclud
differenti
like
embol
phenomena
atherosclerosi
immunolog
disord
investig
neg
diagnosi
dengu
fever
associ
sever
reactiv
thrombocytosi
gangren
toe
one
exclus
though
thrombocytosi
clinic
condit
respond
clopidogrel
pentoxyphyllin
spontan
resolut
could
still
occur
conclus
sever
reactiv
thrombocytosi
gangren
toe
rare
complic
dengu
fever
complic
occur
even
mild
case
dengu
fever
repeat
full
blood
count
episod
dengu
fever
thu
paramount
import
object
rift
valley
fever
rvf
import
diseas
domest
livestock
subsaharan
africa
caus
acut
febril
diseas
abort
death
also
human
diseas
usual
show
influenzalik
clinic
sign
howev
epidem
rvf
may
complic
hemorrhag
syndrom
enceph
blind
death
rvfv
belong
genu
phleboviru
famili
bunyavirida
rna
genom
consist
three
segment
two
segment
larg
l
medium
repres
neg
strand
rna
small
ambisens
rna
known
mice
conveni
model
studi
viru
laboratori
purpos
studi
detect
rvfv
organ
blood
infect
mice
use
develop
pcr
test
method
vero
cell
infect
rvfv
entebb
strain
isol
rna
monolay
use
life
technolog
usa
method
rna
isol
base
nonorgan
carrier
conduct
pcr
nest
modif
develop
research
primer
design
base
sequenc
nucleocapsid
protein
n
gene
follow
align
differ
rvfv
sequenc
genbank
databas
version
clustal
w
result
evalu
specif
develop
system
differ
relat
phlebovirus
test
follow
arbija
corfou
karimabad
sandfli
fever
sicilian
sf
sandfli
fever
napl
sfn
salehabad
toscana
result
indic
crossreact
relat
phlebovirus
therefor
develop
pcr
test
possess
high
specif
determin
viru
local
differ
organ
spleen
liver
brain
muscl
lung
blood
infect
adult
mice
test
use
develop
pcr
test
isol
viru
organ
tissu
infect
mous
conduct
two
differ
method
extract
nonorgan
carrier
show
best
result
viru
detect
type
tissu
extract
method
use
allow
detect
viru
lung
spleen
conclus
confirm
viru
present
test
organ
blood
experiment
infect
mice
also
high
specif
develop
pcr
test
shown
introduct
although
brucellosi
worldwid
exist
zoononi
preval
mediterranean
region
skin
lesion
brucellosi
rare
report
approxim
patient
lesion
nonspecif
often
transient
pityriasi
rosea
symmetr
erythemat
squamat
diseas
commonli
seen
young
adult
although
aetiolog
unknown
hypersensit
reaction
human
herp
viru
suspect
histopatholog
find
pithyriasi
rosea
pathognomon
promin
featur
microscob
vesicl
oedema
papillar
dermi
perivascular
infiltr
lymphocyt
histiocyt
extravascular
erythrocyt
dermal
papilla
epidermi
seen
case
twentynin
year
old
male
patient
admit
hospit
complaint
annular
erythemat
rash
extrem
buttock
month
fever
knee
pain
last
two
week
investig
vascul
brucella
standard
tube
agglutin
test
found
posit
titr
brucella
spp
isol
blood
cultur
pityriasi
rosea
found
histopatholog
examin
skin
lesion
start
rifampisin
mgday
doxycyclin
mgday
fever
return
normal
sixth
day
treatment
complet
day
outpati
basi
skin
lesion
resolv
complet
treatment
relap
seen
month
follow
conclus
literatur
coexist
brucellosi
pityriasi
rosea
report
earlier
although
coexist
may
coincident
hypersensit
reaction
brucella
spp
might
caus
pityriasi
rosea
result
brucellosi
must
one
diseas
differenti
diagnosi
patient
present
rash
fever
especi
endem
area
physic
examin
chest
radiographi
electrocardiographi
ecg
perform
case
radiograph
contrast
studi
oesophagu
colon
echocardiographi
perform
patient
symptom
ecg
abnorm
result
ten
case
chaga
diseas
identifi
latin
american
immigr
seven
submit
blood
bank
posit
elisa
screen
mean
age
year
gender
femal
male
seven
patient
aquir
infect
bolivia
argentina
chile
serolog
result
see
tabl
polymeras
chain
reaction
avail
case
posit
one
nine
patient
indetermin
chronic
form
one
mix
chronic
cardiac
digest
form
chest
radiographi
normal
patient
right
bundl
branch
hemiblock
detect
two
patient
left
anterior
fascicular
hemiblock
one
case
identifi
ten
patient
import
chaga
diseas
januari
octob
one
chronic
cardiac
digest
form
nine
indetermin
form
chaga
diseas
emerg
diseas
europ
migratori
movement
situat
requir
improv
clinic
diagnost
knowledg
special
blood
bank
determin
prioriti
prevent
assistenci
need
object
acanthamoeba
spp
caus
agent
granulomat
amoeb
enceph
frequent
kerat
case
minor
corneal
surfac
injuri
caus
contact
len
agent
effect
therapi
patholog
improv
new
drug
need
particularli
resist
classic
therapeut
encount
azol
antifung
alreadi
use
differ
clinic
situat
evalu
effect
caspofungin
new
antifung
belong
echinocandin
trophozoit
cyst
three
strain
acanthamoeba
method
trophozoit
cyst
castellani
atcc
polyphaga
atcc
culbertsoni
atcc
expos
solut
lgml
lgml
caspofungin
h
trophozoit
h
cyst
viabil
trophozoit
determin
toluidin
blue
stain
cystic
form
resuspend
contact
caspofungin
medium
allow
viabl
microorgan
excyst
replic
subsequ
trophozoit
observ
microscop
day
experi
repeat
three
time
result
activ
caspofungin
trophozoit
growth
depend
test
concentr
concentr
lgml
viabil
trophozoit
reduc
castellanii
polyphaga
concentr
lgml
observ
viabil
trophozoit
three
test
strain
cyst
castellanii
polyphaga
sensit
concentr
lg
ml
caspofungin
matter
fact
trophozoit
recov
day
incub
percentag
viabl
form
increas
concentr
caspofungin
decreas
concern
culbertsoni
highest
concentr
use
studi
prevent
excyst
weak
percentag
treat
cyst
form
conclus
result
indic
caspofungin
show
vitro
activ
trophozoit
cyst
stage
test
acanthamoeba
strain
new
antimicrobi
agent
could
promis
treat
alon
associ
acanthamoeba
kerat
cyclospora
cayetenensi
infect
five
immunocompet
patient
turkish
univers
hospit
b
sancak
akyon
erguven
ankara
tr
object
cyclospora
cayetanensi
c
cayetanensi
newli
recogn
coccidian
parasit
emerg
import
caus
epidem
endem
diarrhoeal
diseas
human
present
five
immunocompet
patient
infect
c
cayetanensi
sought
medic
care
hacettep
univers
hospit
method
three
stool
sampl
collect
three
day
consecut
evalu
parasitolog
laboratori
routin
ova
parasit
examin
sampl
ova
found
neg
stain
modifi
acid
fast
stain
one
reveal
pink
reddish
stain
oval
round
organ
lm
diamet
diagnos
cyclospora
cayetanensi
oocyst
modifi
acid
fast
stain
sulphur
acid
use
decolouris
result
microscop
examin
faecal
sampl
leucocyt
erythrocyt
seen
bacteriolog
stool
cultur
found
neg
detect
c
cayetensi
oocyst
modifi
acid
fast
stain
five
patient
none
patient
immunodefici
determin
patient
treat
trimethoprim
mg
sulfamethoxazol
mg
bid
day
treatment
clinic
symptom
patient
disappear
seven
day
conclus
cyclospora
isol
chronic
diarrhoea
immunocompet
patient
therefor
infect
must
taken
consider
especi
patient
prolong
diarrhoea
coccidi
infect
could
detect
modifi
acidfast
stain
routin
perform
malaria
rare
diseas
latvia
present
malaria
patient
regist
octob
increas
tourist
travel
guest
worker
flow
spread
diseas
across
border
aim
studi
character
malaria
case
novel
malaria
tendenc
latvia
patient
method
analysi
case
record
malaria
patient
treat
infectolog
center
latvia
perform
malaria
plasmodia
diagnos
use
thin
thick
blood
smear
result
obtain
data
show
grow
malaria
patient
number
latvia
particularli
plasmodium
falciparum
caus
case
epidemiolog
anamnes
patient
suggest
patient
present
malaria
endem
region
prior
affect
import
malaria
one
case
nonimport
malaria
local
malaria
result
pfalciparum
transmiss
import
case
establish
sourc
infect
could
either
contact
person
transmiss
mechan
mosquito
genu
anophel
inhabit
latvia
howev
sexual
contact
use
intraven
drug
exclud
infect
mosquito
travel
malaria
endem
area
patient
worker
railway
station
one
case
sever
pfalciparum
malaria
broad
spectrum
complic
cerebr
malaria
acut
renal
failur
acut
respiratori
distress
syndrom
gastroenter
hypoglycemia
fatal
outcom
due
late
hospit
day
ill
hyperparasitemia
particular
clinic
interest
possibl
resist
chloroquin
receiv
malaria
prevent
establish
affect
conclus
continu
increas
malaria
throughout
world
hasten
malaria
spread
latvia
last
year
number
malaria
particularli
p
falciparum
caus
malaria
case
rise
case
local
p
falciparum
malaria
detect
latvia
increas
drugresist
malaria
world
promot
increas
import
drug
resist
malaria
latvia
take
account
widespread
distribut
malaria
world
gener
unconvent
transmiss
rout
emerg
latvia
primari
health
care
physician
readi
detect
malaria
seemingli
nontyp
case
correl
serum
bilirubin
level
mortal
p
falciparum
malaria
ak
aribandi
ms
albur
sheffield
uk
accord
sever
hepat
dysfunct
encephalopathi
unusu
malariahowev
literatur
review
shown
recent
evid
correl
sever
falciparum
malaria
liver
dysfunct
object
studi
liver
function
abnorm
patient
falciparum
malaria
present
jaundic
assess
prognosi
p
falciparum
malaria
relat
liver
function
abnorm
method
prospect
studi
done
tertiari
referr
hospit
teach
southcentr
india
period
year
patient
smear
posit
p
falciparum
present
jaundic
includ
studi
clinic
present
along
laboratori
find
note
patient
histori
excess
consumpt
alcohol
hepatotox
drug
known
liver
diseas
andor
posit
viral
hepat
serolog
exclud
studi
result
total
number
patient
includ
studi
age
rang
yr
mean
age
male
femal
clinic
patient
jaundic
fever
chillsrigor
patient
pallor
hepatomegali
splenomegali
patient
hepatosplenomegali
renal
failur
patient
alter
sensorium
base
serum
bilirubin
level
mg
normal
rang
patient
categor
group
patient
serum
bilirubin
mg
group
b
patient
serum
bilirubin
mg
group
c
patient
serum
bilirubin
level
mg
group
patient
serum
bilirubin
mg
major
patient
conjug
hyperbilirubinaemia
serum
alt
level
iudl
normal
rang
rang
ast
alkalin
phosphatas
ka
unit
normal
rang
albumin
gramsdl
normal
rang
overal
mortal
studi
follow
tabl
show
correl
serum
bilirubin
level
mortal
rate
conclus
patient
p
falciparum
malaria
abnorm
liver
function
also
featur
sever
malaria
renal
failur
ard
alter
sensorium
high
mortal
mortal
rate
set
correl
serum
bilirubin
level
object
clinic
epidemiolog
therapeut
studi
case
leishmaniasi
travel
endem
area
hospit
constana
romania
diagnosi
histolog
microbiolog
confirm
treatment
consist
sodium
stiboglucon
one
case
meglumin
antimon
case
amphotericin
b
one
case
clinic
followup
conduct
daili
treatment
month
afterward
result
diagnosi
cutan
leishmaniasi
patient
male
one
femal
viscer
leismaniasi
one
patient
femal
age
patient
year
old
travel
endem
area
examin
show
nodular
lesion
depress
central
ulcer
bodi
lesion
clinic
manifest
viscer
leishmaniasi
improv
end
therapi
patient
treat
amphotericin
b
brown
spot
appear
hand
sole
end
therapi
like
advers
event
disappear
one
week
conclus
romania
endem
area
leishmaniasi
last
year
case
relat
person
circul
tourist
profession
humanitarian
purpos
object
classic
viscer
leishmaniasi
present
fever
hepatosplenomegali
pancytopenia
fever
almost
alway
present
time
medic
consult
present
case
leishmaniasi
without
fever
immunocompet
individu
clinic
microbiolog
infect
volum
supplement
case
report
man
admit
depart
due
fatigu
splenomegali
elev
serum
igg
never
fever
ill
neighbourhood
dog
medic
histori
note
mild
diabet
mellitu
gastriti
appendicectomi
surgic
extract
gall
bladder
thrombocytosi
unknown
origin
year
yield
without
treatment
upon
admiss
temperatur
physic
examin
reveal
slight
pale
spleen
enlarg
left
costal
margin
small
nontend
cervic
lymphnod
maculopapular
rash
front
thorac
side
blood
analysi
reveal
hematocrit
haemoglobin
leucocyt
granulocut
platelet
serious
decreas
compar
year
erythrocyt
sediment
rate
mmh
creactiv
protein
mgdl
serum
igg
mgdl
small
iggk
band
chest
radiograph
bone
scan
normal
ct
scan
chest
abdomen
show
splenomegali
bone
marrow
biopsi
aspir
reveal
haematolog
malign
bone
marrow
smear
reveal
good
deal
leishmania
amastigot
pcr
leishmania
bone
marrow
also
posit
leishmania
serum
fluoresc
antibodi
posit
patient
administ
liposom
amphotericinb
mgkgday
day
anoth
mgkg
eight
day
later
month
patient
well
spleen
lymphnod
palpabl
rash
disappear
laboratori
valu
within
normal
rang
conclus
mild
leishmaniasi
one
describ
abovei
becom
frequent
develop
develop
world
therefor
unexplain
constitut
symptom
appear
within
two
year
exposur
endem
area
might
warrant
investig
infect
leishmania
efficaci
medic
treatment
hydatid
diseas
dumitru
rugina
e
dumitru
e
dumea
constanta
ro
object
analyz
efficaci
medic
treatment
hydat
diseas
materi
method
perform
studi
patient
admit
depart
parasitolog
last
year
diagnosi
base
elisa
reaction
echinococcu
granulosu
chest
xray
ultrasonographi
comput
tomographi
treatment
involv
albendazol
mgday
day
separ
two
week
interv
minimum
three
cure
case
giant
liver
cyst
cm
cm
perform
percutan
ultrasonographyquid
punctur
cyst
fluid
aspir
pair
follow
medic
treatment
result
echinococcosi
differ
locat
involv
liver
lung
spleen
kidney
brain
pericardi
mediastin
peritoneum
retro
peritoneum
muscl
bone
parotid
gland
secondari
hydatidosi
report
case
multipl
cyst
found
case
liver
pulmonari
muscular
bone
periton
parotid
gland
hydatidosi
multipl
locat
case
begin
therapi
cyst
less
cm
dimens
medic
treatment
notic
regress
cyst
dimens
cyst
wall
calcif
case
signific
chang
observ
muscular
bone
cyst
requir
surgic
intervent
conclus
albendazol
elect
therapi
cyst
dimens
less
cm
pair
good
choic
solitari
giant
liver
cyst
vitro
effect
levamisol
praziquantel
combin
echinococcu
granulosu
protoscolic
guvenli
hokelek
samsun
tr
object
larval
metasestod
form
echinococcu
granulosu
brought
exist
zoonot
infect
human
call
cystic
echinococcosi
ce
ce
wide
part
world
also
import
human
health
anim
health
economi
aim
studi
investig
protoscolicid
activ
levamisol
lvm
praziquantel
pz
metronidazol
mz
interact
e
granulosu
protoscolic
vitro
incub
method
e
granulosu
protoscolic
asept
remov
liver
hydatid
cyst
obtain
anim
slaughter
privat
abattoir
samsun
turkey
viabl
protoscolic
cultur
medium
three
day
three
drug
ad
combin
separ
medium
comparison
result
use
follow
final
concentr
drug
lvm
alon
lg
ml
pz
alon
lgml
lvm
lgml
pz
lgml
mz
alon
lgml
respect
protoscolicid
activ
assess
minut
postincub
result
signific
protoscolicid
effect
obtain
lvm
pz
combin
minut
protoscolic
minim
protoscolicid
effect
found
mz
concentr
conclus
result
show
lvm
pz
combin
significantli
deadli
protoscolic
studi
regard
use
lvm
pz
combin
anim
model
e
granulosu
may
help
design
new
treatment
regimen
ce
human
multipl
hydatid
cyst
left
main
pulmonari
arteri
extrem
rare
locat
ok
ariba
e
turkariba
f
kanat
erayman
yuksek
konya
tr
hydatid
cyst
may
seldom
develop
within
pulmonari
arteri
ruptur
cardiac
hepat
cyst
report
case
multipl
hydatid
cyst
within
pulmonari
arteri
necessit
left
pneumonectomi
present
femal
patient
symptom
haemoptysi
patient
describ
fever
cough
attack
control
medic
therapi
within
previou
year
past
histori
reveal
hepat
hydatid
cyst
oper
year
ago
physic
examin
unremark
except
diminish
pulmonari
sound
inspiratori
rate
left
lung
esr
mmhour
iha
test
echinococcosi
highli
posit
chest
xray
reveal
enlarg
left
hilu
linear
heterogen
infiltr
left
lower
zone
paracardiac
pulmonari
nodul
right
lower
zone
chest
ct
scan
disclos
cm
diamet
cystic
septat
mass
lesion
obliter
lie
downward
within
trace
right
main
pulmonari
arteri
widespread
tubular
dilat
peribronchi
thicken
left
lower
lobe
bronchi
two
small
neighbour
nodul
right
lower
lobe
probabl
crescent
moon
appear
seen
within
left
inferior
pulmonari
arteri
contrast
enhanc
chest
magnet
reson
imag
reveal
multipl
cystic
lesion
left
main
left
lower
lobe
pulmonari
arteri
magnet
reson
angiographi
show
amput
left
inferior
pulmonari
arteri
ventilationperfus
lung
scan
confirm
perfus
defect
left
lower
lobe
echocardiographi
normal
abdomin
ultrasonographi
reveal
heterogen
hypoecho
calcifi
area
left
liver
lobe
oper
sequela
patient
underw
left
pneumonectomi
irrevers
pulmonari
arteri
wall
pulmonari
parenchym
destruct
via
median
sternotomi
total
circulatori
arrest
prevent
contralater
hydatid
cyst
embol
numer
intact
ruptur
hydatid
cyst
variou
size
within
pulmonari
arteri
observ
pulmonari
arteri
dissect
resect
specimen
intim
destruct
promin
dilat
thin
pulmonari
arteri
wall
albendazol
treatment
given
patient
sinc
procedur
perform
hydatid
cyst
right
side
believ
albendazol
prophylaxi
given
patient
surgic
intervent
hepat
cyst
year
ago
life
threaten
unusu
present
hydatid
cyst
might
seen
patient
might
save
pulmonari
resect
extrem
rare
locat
cardiac
hydatid
cyst
interventricular
septum
erayman
e
turk
ariba
avcu
bitirgen
konya
tr
hydatid
csyt
zoonosi
human
diseas
may
usual
manifest
lung
liver
involv
cardiac
involv
rare
clinic
pictur
depend
localis
ill
diamet
cyst
complic
echocardiographi
radiolog
imag
reliabl
method
describ
anatom
localis
serolog
test
support
role
diagnosi
surgic
resect
well
albendazol
treatment
suggest
treatment
present
describ
case
respond
month
medic
therapi
case
diagnos
cardiac
hydatid
cyst
locat
interventricular
septum
reevalu
use
transoesophag
echocardiographi
multislic
comput
tomographi
recent
introduc
countri
year
old
male
patient
appli
patient
clinic
cardiolog
depart
complaint
chest
pain
palpit
abdomin
pain
patient
take
albendazol
mgday
twenti
one
day
transoesophag
echocardiographi
reveal
cm
hydatid
cyst
locat
interventricular
septum
multislic
comput
tomographi
demonstr
cm
hydatid
cyst
locat
interventricular
septum
echinoccocu
specif
ige
rais
time
normal
six
cycl
chemotherapi
consist
albendazol
mgkgday
four
week
follow
day
drug
free
interv
prescrib
studi
intestin
parasitosi
gener
hospit
piraeu
greec
object
determin
incid
intestin
parasit
citizen
piraeu
analyz
differ
nativ
immigr
come
develop
countri
major
nativ
hospit
area
low
socialeconom
statu
method
year
period
faecal
sampl
nativ
foreign
examin
hospit
laboratori
intestin
parasitosi
inpati
hospit
outpati
outpati
worker
examin
order
obtain
health
clearanc
certif
specimen
examin
direct
microscopi
use
wet
mount
formalineeth
concentr
trichrom
stain
pcr
method
result
examin
specimen
found
posit
pathogen
intestin
parasit
entamoeba
hystolytica
dispar
giardia
lamblia
ancylostoma
duodenal
patient
foreign
ascari
lumbricoid
enterobiu
vermiculari
taenia
sagginata
incid
pathogen
parasit
greek
citizen
foreign
citizen
conclus
frequenc
intestin
parasitosi
greec
gener
low
recent
year
mani
immigr
introduc
new
parasit
necessari
public
health
servic
prevent
parasit
spread
carrier
healthi
popul
take
measur
prevent
right
inform
introduct
west
africa
filariasi
endem
chronic
diseas
prioriti
public
health
program
control
carri
last
year
order
errad
diseas
purpos
studi
investig
preval
import
microfilari
immigr
come
africa
endem
area
last
year
area
method
blood
skin
sampl
immigr
subject
collect
hospit
januari
novemb
knott
concentr
techniqu
observ
skin
snip
use
detect
microfilaria
sampl
field
stain
use
confirm
diagnosi
result
total
blood
sampl
skin
sampl
buttock
scapula
thigh
analys
sampl
subject
come
equatori
guinea
found
posit
sampl
filaria
blood
skin
preval
speci
obtain
report
case
coinfect
one
speci
filaria
blood
skin
sampl
conclus
although
recent
review
impact
control
program
indic
effect
observ
relev
preval
filariasi
among
patient
come
african
endem
area
routin
examin
must
perform
peopl
subsaharian
africa
hepatobiliari
ascariasi
case
report
cholecyst
acut
cholang
obstruct
jaundic
acut
pancreat
hepat
liver
abscess
gain
entri
ampullari
orific
worm
freeli
move
biliari
tree
time
diseas
symptomless
ultrasound
excel
modal
diagnos
follow
hepatobiliari
ascariasi
ultrasound
also
use
confirm
exit
worm
biliari
tree
case
year
old
male
patient
admit
jaundic
complaint
begun
day
ago
physic
examin
skin
sclera
icter
abdomen
examin
normal
laboratori
examin
reveal
ast
ul
normal
rang
alt
ul
normal
rang
alkalin
phosphatas
ul
normal
rang
total
bilirubin
mgdl
normal
rang
direct
bilirubin
mgdl
normal
rang
viral
marker
acut
hepat
neg
abdomin
ultrasound
show
two
polyp
size
neck
gall
bladder
wall
oedema
follow
noninfecti
reason
jaundic
research
patient
vomit
ascari
lumbricoid
measur
cm
length
liver
enzym
jaundic
regress
day
vomit
alumbricoid
serum
transaminas
obtain
alt
ul
ast
ul
total
bilirubin
control
abdomin
ultrasound
tomographi
complet
normal
polyp
interpret
ascariasi
disappear
patient
treat
mebendazol
mg
day
one
year
follow
patient
complaint
alt
ast
level
normal
conclus
ascariasi
reason
obstruct
jaundic
clinician
awar
possibl
especi
endem
region
pinworm
enterobiu
sp
infect
lung
mimick
tuberculoma
case
report
h
v
adamson
p
naaber
tartu
ee
object
report
case
human
enterobiu
infect
lung
initi
misdiagnos
pulmonari
tuberculosi
histolog
find
case
report
femal
work
food
market
routin
check
tuberculosi
xray
march
chest
radiograph
show
presenc
two
round
opac
lower
lobe
left
lung
latest
chest
xray
year
without
patholog
find
patient
seen
pulmonologist
consult
xray
find
confirm
ctscan
diagnost
hypothesi
pulmonari
tuberculosi
diagnosi
confirm
despit
repeat
cultur
sputum
mycobacteria
march
march
april
patient
hospitalis
diagnost
videothoracosopi
materi
lesion
left
lung
sent
histopatholog
investig
cito
preliminari
find
show
chronic
granulomat
process
necrosi
characterist
tuberculoma
antituberculot
treatment
initi
final
histopatholog
find
demonstr
two
granuloma
includ
enterobiu
vermiculari
egg
addit
analysi
rectal
swab
faec
neg
enterobiu
discuss
pinworm
enterobiu
vermiculari
tuberculosi
common
diseas
estonia
granuloma
format
around
pinworm
egg
quit
often
report
appendix
abdomin
pelvic
peritoneum
peritoneum
small
larg
intestin
granuloma
form
around
degener
adult
worm
around
discreat
egg
around
cluster
egg
probabl
around
migrat
worm
granuloma
case
cm
across
necrosi
centr
way
nonspecif
except
find
egg
centr
accident
enterobiu
transmiss
via
oral
rout
respiratori
tract
suspect
like
emphas
need
character
pathogenesi
common
parasit
like
enterobiu
organ
rare
involv
case
enterobiu
involv
lung
tissu
character
medic
literatur
far
malnutrit
children
nairobi
slum
kolenova
ondrusova
trnava
sk
even
today
malnutrit
major
problem
develop
countri
third
world
children
suffer
degre
malnutrit
malnutrit
defin
defici
protein
energi
micronutri
commonest
nutrit
problem
gener
defici
food
malnutrit
increas
mortal
common
childhood
diseas
malnutrit
problem
nutrit
social
famili
problem
well
sinc
januari
nairobi
record
children
year
clinic
examin
laboratori
test
accord
strict
indic
place
children
supplementari
feed
program
measur
weight
arm
circumfer
begin
everi
week
end
program
check
vaccin
scheme
social
histori
observ
clinic
statu
risk
factor
durat
program
age
children
laboratori
result
especi
hiv
tb
stool
parasit
specifi
criterion
leav
program
mother
wellinform
condit
program
breastfeed
nutrit
treatment
vaccin
got
breast
milk
substitut
multivitamin
case
ill
children
got
examin
treatment
accord
clinic
statu
children
finish
program
main
indic
malnutrit
accord
weight
age
second
contraind
breastfeed
hiv
mother
frequent
group
children
year
test
children
posit
hiv
tb
commonest
diseas
respiratori
infect
intestin
infect
skin
chang
other
main
intestin
parasit
gardia
main
risk
factor
low
birth
weight
children
leav
program
optim
weight
good
clinic
statu
inadequ
cooper
mother
die
move
countrysid
children
often
sick
intestin
parasit
monitor
higher
morbid
complic
mortal
especi
children
hiv
properli
monitor
treatment
educ
achiev
nice
success
almost
half
children
leav
normal
weight
good
clinic
statu
still
larg
number
mother
nt
care
nt
understand
problem
properli
nutrit
matter
import
know
hiv
statu
start
haart
get
properli
educ
treat
infect
object
observ
studi
present
incid
infecti
diseas
therapi
dor
dioces
rumbek
univers
trnava
clinic
mapuordit
south
sudan
patient
file
analysi
period
januari
june
monitor
antimalari
drug
effici
popul
vulner
group
stabl
malaria
area
method
case
histori
clinic
examin
laboratori
diagnosi
determin
diagnosi
data
collect
laboratori
regist
hospit
clinic
record
process
median
test
verif
data
level
coincid
test
comparison
two
sizeabl
independ
file
mention
period
patient
examin
patient
present
infecti
diseas
result
number
malaria
case
fever
unknown
origin
age
categori
month
year
sever
malaria
complic
record
case
malari
case
cerebr
malaria
diagnos
case
pulmonari
oedema
case
macroscop
haemoglobinuria
case
generalis
convuls
case
partial
convuls
case
sever
anaemia
case
hyperparasitemia
diagnos
case
categori
month
year
case
respiratori
tract
infect
diagnos
patient
sexual
transmit
diseas
urinari
tract
infect
diagnos
patient
intestin
parasitosi
patient
repres
ankylostomiasi
diarrhoeal
diseas
patient
skin
infect
patient
onchocercosi
patient
wuchereriosi
patient
dracunculosi
patient
mening
tetanu
patient
number
new
diagnos
case
leprosi
conclus
common
diseas
remain
malaria
caus
plasmodium
falciparum
sensit
chloroquin
area
earli
stage
easi
treatabl
persist
high
mortal
rate
especi
among
children
year
next
common
diseas
bacteri
infect
especi
respiratori
tract
infect
diarrhoeal
diseas
despit
excel
antibiot
sensit
neglig
resist
due
low
consumpt
group
diseas
repres
main
caus
morbid
mortal
especi
vulner
group
children
year
saturday
night
fever
r
gowda
tunbridg
mckendrick
sheffield
uk
introduct
pyrexia
unknown
origin
puo
one
challeng
problem
clinician
patient
travel
extens
around
world
possibl
legion
therefor
care
thorough
histori
examin
method
systemat
approach
investig
crucial
describ
extrem
challeng
case
highlight
pitfal
investig
diagnosi
puo
case
report
caucasian
man
present
histori
cyclic
fever
myalgia
weight
loss
night
sweat
fever
reoccur
clockwork
like
regular
week
everi
week
saturday
episod
patient
felt
extrem
unwel
bed
bound
howev
complet
resolut
occur
within
hour
inflammatori
marker
rais
esr
creactiv
protein
mgl
signific
travel
histori
around
world
work
navi
prompt
us
undertak
extens
puo
screen
wide
rang
investig
puo
import
infect
multipl
whole
bodi
imag
bone
marrow
undertaken
abnorm
gallston
gallbladd
increas
uptak
right
upper
abdomen
indium
label
white
cell
scan
postul
might
sourc
fever
patient
underw
laparoscop
cholecystectomi
unfortun
resolv
symptom
despit
sequenti
empir
therapi
chloroquin
doxycyclin
two
trial
colchicin
inflammatori
famili
disord
consid
symptom
persist
final
profound
dramat
respons
indomethacin
symptom
pyrexia
inflammatori
marker
settl
rapidli
discuss
case
demonstr
difficulti
diagnosi
manag
puo
patient
travel
numer
exot
locat
widen
differenti
diagnosi
prompt
us
pursu
unusu
tropic
infect
result
investig
howev
care
evalu
subsequ
medicalsurg
intervent
potenti
danger
patient
cholecystectomi
without
benefit
although
caus
found
empir
therapi
help
resolv
symptom
occasion
may
feasibl
option
use
case
discuss
approach
investig
puo
background
tetanu
lifethreaten
infect
rel
uncommon
develop
countri
occur
frequent
develop
countri
case
fatal
rate
earli
diagnosi
manag
may
life
save
studi
made
analysi
effect
prognost
factor
outcom
patient
tetanu
seen
hospit
method
patient
admit
clinic
diagnosi
tetanu
karadeniz
technic
univers
hospit
trabzon
turkey
retrospect
review
data
analys
determin
sociodemograph
featur
clinic
find
analysi
made
use
spss
packag
chisquar
analysi
student
ttest
use
comparison
data
result
total
patient
admit
hospit
studi
period
patient
diagnos
emerg
servic
clinic
examin
respiratori
support
provid
case
patient
surviv
die
incub
period
survivor
day
die
day
p
factor
significantli
influenc
surviv
includ
sever
spasm
ci
p
dysphagia
ci
p
provis
respiratori
support
ci
p
prognost
factor
investig
logist
regress
incub
period
ci
p
provis
respiratori
support
time
hospit
ci
p
found
independ
prognost
factor
tetanu
conclus
tetanu
still
sever
problem
develop
countri
potenti
fatal
diseas
rate
high
fatal
patient
due
short
incub
period
sever
clinic
find
necess
respiratori
support
increas
mortal
oneday
extens
incub
period
increas
chanc
life
major
tetanu
case
occur
among
person
inadequ
vaccin
unknown
vaccin
histori
acut
injuri
primari
immun
schedul
booster
immun
import
prevent
measur
greatli
reduc
incid
tetanu
determin
tetanu
antibodi
level
among
emerg
depart
patient
present
injuri
k
caglar
k
hizel
altuncek
demircan
r
karaku
ankara
tr
object
studi
undertaken
assess
tetanu
immun
statu
patient
present
emerg
depart
tertiari
care
hospit
accid
materi
total
patient
women
men
age
enrol
studi
patient
variou
injuri
patient
present
demograph
data
tetanu
immun
histori
given
patient
record
tetanu
antibodi
level
serum
sampl
subject
measur
use
doubleantigen
enzymelink
immunosorb
assay
seroimmun
tetanu
classifi
suscept
iuml
basic
protect
iuml
full
protect
iuml
result
term
protect
tetanu
found
statist
signific
differ
patient
histori
complet
primari
immun
seri
patient
among
patient
recal
primari
tetanu
vaccin
histori
antibodi
titr
iuml
contrari
seroprotect
rate
significantli
higher
p
among
subject
state
receiv
primari
immun
seri
subject
receiv
tetanu
booster
vaccin
last
year
protect
antibodi
level
overal
patient
found
suscept
tetanu
basic
protect
fulli
protect
suscept
tetanu
among
femal
found
significantli
p
lower
among
male
emerg
depart
patient
rate
suscept
subject
among
femal
show
highest
valu
age
conclus
emerg
depart
patient
injuri
possibl
risk
tetanu
taken
account
especi
receiv
recal
primari
childhood
immun
seri
women
particularli
year
age
injuri
greatest
risk
booster
vaccin
given
emerg
depart
practic
without
delay
order
avoid
leav
mani
unprotect
tetanu
immunis
statu
among
women
childbear
age
three
provinc
turkey
object
goal
studi
assess
tetanu
immun
statu
among
childbear
age
women
relat
tetanu
vaccin
dose
three
select
provinc
turkey
method
total
subject
randomli
select
health
centr
area
diyarbakir
antalya
samsun
februari
octob
statist
signific
differ
provinc
age
group
gender
resid
p
year
old
women
select
analys
tetanu
immun
among
childbear
age
women
tetanu
antibodi
titr
determin
use
inhous
elisa
particl
agglutin
test
antibodi
titr
iuml
accept
protect
level
statist
analys
done
quisquar
test
student
ttest
oneway
anova
logist
regress
analysi
use
spss
window
special
softwar
prepar
use
visual
basic
access
result
women
divid
three
age
group
among
yearsold
women
n
tetanu
antibodi
level
higher
women
children
without
children
demonstr
effect
pregnant
vaccin
age
specif
fertil
rate
turkey
typic
cumul
among
age
less
year
old
median
age
first
marriag
turkey
base
data
women
age
year
old
accept
childbear
age
analysi
protect
antibodi
level
among
subject
receiv
two
singletyp
tetanu
vaccin
dose
among
provinc
studi
antalya
highest
immun
p
percentag
protect
antibodi
level
among
women
antalya
diyarbakir
samsun
invers
associ
percentag
immun
level
age
p
conclus
although
pregnant
vaccin
seem
effect
tetanu
immun
among
women
childbear
age
enough
need
reinforc
pregnant
vaccin
intens
antenat
care
servic
encourag
pregnant
women
receiv
servic
object
turkey
whole
cell
pertussi
vaccin
administ
month
old
booster
monthold
children
coverag
regard
lifespan
antibodi
year
vaccin
efficaci
around
school
children
adolesc
adult
becom
vulner
infect
aim
studi
determin
magnitud
acuterec
infect
older
individu
threat
pertussi
infect
pose
infant
also
want
measur
antibodi
level
chilbear
age
women
estim
frequenc
passiv
acquir
protect
antibodi
newborn
method
questionnair
blood
specimen
collect
healthi
individu
three
provinc
divers
region
turkey
age
group
month
old
year
old
statist
signific
differ
number
subject
base
age
group
gender
resid
p
igg
antipt
antibodi
measur
inhous
elisa
elisa
unit
eu
ml
euml
evalu
acut
andor
recent
infect
euml
protect
level
euml
chilbear
age
women
n
protect
babi
first
dose
vaccin
month
statist
analysi
done
spss
window
chisquar
test
pearson
correl
result
antipt
titr
lowest
yearold
respect
high
titr
percentag
increas
age
maximum
yearold
euml
yearold
euml
total
subject
euml
respect
unprotect
individu
situat
opposit
highest
percentag
observ
yearold
group
respect
decreas
yearold
yearold
unprotect
subject
total
antibodi
titr
eu
ml
found
yearold
women
conclus
acuterec
infect
everi
agegroup
lower
yearold
show
high
suscept
indic
risk
seriou
pertussi
infect
besid
nearli
half
childbear
age
women
enough
antibodi
protect
newborn
improv
primari
vaccin
procedur
addit
vaccin
older
age
group
need
consid
protect
infant
immun
tetanu
effect
vaccin
turkey
object
immun
statu
tetanu
relat
vaccin
investig
among
healthi
popul
turkey
method
questionnair
blood
specimen
collect
healthi
individu
three
provinc
divers
region
turkey
studi
subject
month
old
year
old
statist
signific
differ
number
subject
base
age
group
gender
resid
p
inhous
elisa
particl
agglutin
test
chemoserotherapeut
research
institut
kumamoto
japan
perform
detect
antibodi
questionnair
subject
vaccin
histori
evalu
statist
analysi
done
use
visual
basic
access
student
ttest
result
characterist
distribut
tetanu
antibodi
titr
differ
age
group
titr
group
distribut
peak
frequenc
iuml
scatter
lower
level
less
iuml
group
older
object
studi
aim
ass
immun
statu
pertussi
among
healthi
popul
three
geograph
differ
provinc
turkey
relat
vaccin
statu
whole
cell
pertussi
vaccin
combin
diphtheria
tetanu
toxoid
dwpt
method
communitybas
seroepidemiolog
survey
implement
antalya
diyarbakir
samsun
februari
octob
total
subject
age
month
old
health
centr
select
use
stratifi
randomis
sampl
method
statist
differ
three
provinc
age
group
gender
resid
p
obtain
consent
particip
questionnair
blood
sampl
collect
antibodi
pertussi
toxin
pt
filament
haemagglutinin
fha
assay
inhous
enzymelink
immunosorb
assay
elisa
titr
elisa
unit
ml
accept
antibodi
posit
statist
analys
done
use
spss
window
special
softwar
prepar
use
visual
basic
logist
regress
chisquar
test
result
dwpt
vaccin
coverag
dose
among
children
yearold
higher
older
age
everi
provinc
p
valu
significantli
lower
diyarbakir
two
provinc
antalya
samsun
p
howev
antibodyposit
rate
antipt
antiptantifha
higher
diyarbakir
samsun
antalya
antifha
higher
antalya
samsun
p
posit
antibodi
level
antipt
antifha
lowest
yearold
three
provinc
increas
age
yearold
maintain
among
adult
among
year
old
antipt
antifha
posit
rate
higher
femal
male
p
conclus
connect
vaccin
coverag
antibodi
preval
presenc
high
titr
pt
antibodi
among
age
show
wide
preval
b
pertussi
infect
suggest
potenti
adult
play
reservoir
b
pertussi
import
achiev
high
vaccin
coverag
especi
among
infant
whose
mortal
due
pertussi
higher
age
group
addit
immun
adult
health
worker
famili
like
close
contact
infant
consid
ii
iii
iv
introduct
rubella
usual
mild
diseas
infect
first
month
pregnanc
sever
consequ
congenit
rubella
syndrom
nation
rubella
immun
programm
greec
introduc
chang
activ
polici
immun
adult
suscept
women
reproduct
age
implement
date
object
purpos
studi
determin
current
statu
rubella
immun
women
childbear
age
period
year
estim
chang
immun
statu
rubella
outbreak
greec
method
examin
total
serum
sampl
women
year
old
attend
nation
refer
center
rubella
viru
sampl
test
total
antibodi
hai
assay
rubeo
kit
biorad
igg
igm
antibodi
elisa
enzygnost
dade
berhingdslab
result
suscept
rate
rubella
found
period
period
larg
epidem
rubella
congenit
rubella
syndrom
occur
follow
smaller
one
acut
rubella
infect
serolog
confirm
person
year
respect
conclus
high
suscept
rate
rubella
observ
among
women
reproduct
age
period
result
appear
rubella
outbreak
although
sensit
declin
sharpli
smaller
outbreak
occur
result
indic
comprehens
polici
still
need
order
elimin
rubella
congenit
rubella
syndrom
greec
diagnosi
tuberculosi
suspect
endem
area
use
enzymelink
immunospot
assay
gammainterferon
object
evalu
valu
ex
vivo
enzymelink
immunospot
assay
gamma
interferon
tbelispot
rapid
diagnosi
activ
tuberculosi
clinic
suspect
endem
area
method
januari
june
patient
whose
clinic
symptom
radiograph
find
compat
tuberculosi
recruit
blood
sampl
obtain
tbelispot
assay
within
day
microbiolog
studi
perform
result
sixtyf
suspect
studi
includ
activ
tuberculosi
thirtyf
patient
underli
comorbid
condit
thirtyseven
patient
posit
cultur
tuberculosi
wherea
nontubercul
mycobacteria
isol
patient
overal
sensit
specif
tbelispot
assay
respect
posit
neg
predict
valu
respect
conclus
result
show
accuraci
tbelispot
assay
activ
tuberculosi
clinic
suspect
higher
even
environ
highli
contamin
nontubercul
mycobacteria
autoantibodi
cytokin
patient
mycobacteri
infect
system
infect
due
nontubercul
mycobacteria
ntm
bcg
describ
patient
immunodefici
particular
individu
defect
depend
ifng
pathway
select
highli
suscept
mycobacteria
salmonella
recent
case
aquir
susceptib
mycobacteri
infect
due
high
affin
autoantibodi
ifng
describ
object
goal
investig
cytokin
specif
autoimmun
patient
unusu
recurr
andor
dissemin
infect
environment
ntm
mycobacterium
tuberculosi
mtb
method
sera
sampl
includ
studi
belong
follow
group
ntm
mtb
dissemin
infect
n
pulmonari
tb
system
lupu
erythematosu
sle
pulmonari
tb
sle
vasculitispulmonari
tb
vascul
salmonelosi
recurr
infect
due
opportunist
microorgan
nonrel
autoimmun
diseas
patient
antitnfa
treatment
healthi
individu
cytokin
specif
autoantibodi
ifng
tnfa
gmcsf
screen
multipl
antigen
fix
immunoassay
mafi
sampl
patient
anti
tnf
treatment
infliximab
includ
control
system
autoantibodi
titer
posit
sampl
confirm
direct
elisa
result
detect
autoantibodi
case
case
case
ifng
case
tnfa
case
gmcsf
case
autoantibodi
cytokin
could
found
healthi
control
conclus
autoantibodi
cytokin
may
present
patient
unusu
recurr
andor
dissemin
infect
environment
ntm
mtb
potenti
diseas
modul
role
autoantibodi
discuss
refer
doffing
r
patel
kumararatn
ds
human
immunodefici
predispos
intracellular
bacteri
infect
curr
opin
rheumatol
tuberculin
skin
test
among
health
care
worker
countri
high
tuberculosi
preval
booster
convers
rate
k
hizel
f
ozer
maral
f
akta
ankara
tr
object
determin
tuberculin
skin
test
tst
survey
convers
rate
among
health
care
worker
hcw
teach
hospit
turkey
thu
assess
whether
hcw
increas
risk
tuberculosi
tb
countri
high
preval
univers
bcg
vaccin
effect
previou
bcg
vaccin
result
tst
also
investig
method
twostep
tst
administ
consent
hcw
hospit
particip
complet
standard
questionnair
regard
demograph
data
includ
age
gender
workplac
occup
previou
bcg
vaccin
histori
exposur
tuberculosi
tst
reappli
hcw
neg
reaction
twostep
test
result
particip
posit
tst
reaction
initi
test
higher
preval
posit
tst
reaction
found
among
particip
work
surgic
ward
ci
medic
ward
nurs
ci
clerk
receptionist
administr
personnel
presenc
bcg
scar
significantli
associ
posit
tst
respons
among
employe
neg
tst
reaction
underw
second
test
booster
reaction
found
convers
found
particip
convers
significantli
associ
variabl
examin
conclus
high
tb
preval
countri
hcw
increas
risk
infect
effect
previou
bcg
vaccin
result
tst
minim
posit
respons
tst
relat
natur
infect
rather
previou
vaccin
studi
support
cdc
recommend
emphas
screen
hcw
tst
benefici
evalu
tb
exposur
suitabl
high
tb
preval
countri
nontubercul
mycobacteria
ntm
group
bacteria
caus
pulmonari
system
diseas
increas
risk
ntb
infect
frequent
patient
acquir
immunodefici
syndrom
aid
hivneg
patient
suffer
immunosuppress
due
previou
pulmonari
diseas
old
age
alcohol
rapid
detect
identif
mycobacteria
new
strategi
develop
novel
method
hplc
bactec
nap
test
commerci
dna
probe
recommend
identif
ntm
speci
recent
new
molecular
test
base
pcr
techniqu
revers
hybrid
procedur
introduc
simultan
identif
differ
mycobacteri
speci
object
aim
studi
perform
dna
line
probe
assay
innolipa
mycobacteria
identif
mycobacteri
speci
obtain
sputum
sampl
collect
form
hivneg
patient
evalu
risk
factor
pulmonari
ntm
infect
method
test
ntm
strain
patient
pulmonari
tuberculosi
symptom
isol
centr
within
last
year
strain
process
subcultur
lj
medium
confirm
ntm
use
niacin
test
morpholog
assess
organ
lipa
assay
base
pcr
revers
hybrid
procedur
amplif
ribosom
rrna
spacer
region
subsequ
biotinyl
pcr
product
hybrid
specif
object
mycobacterium
tuberculosi
today
singl
greatest
caus
mortal
due
infecti
agent
routin
mycobacterium
infect
diagnos
microscop
examin
presenc
acidfast
bacilli
afb
convent
cultur
techniqu
detect
mycobacterium
cultur
take
week
month
afb
test
lack
sensit
specif
compar
cultur
sensit
use
variou
avail
naat
system
gener
lower
addit
naat
base
system
requir
much
handson
time
obtain
dnarna
suffici
qualiti
thu
requir
rapid
sensit
diagnost
system
tb
diagnost
still
larg
unmet
method
pilot
studi
perform
appli
autom
sampl
prepar
mycobacterium
dna
respiratori
sampl
util
magnet
particl
system
bug
n
bead
tm
genpoint
norway
heatinactiv
mycobacterium
cell
initi
adsorb
paramagnet
particl
magnet
separ
sampl
materi
rapid
lysi
rt
releas
dna
adsorb
onto
magnet
particl
wash
purifi
dna
transfer
microwel
realtim
pcr
analysi
refer
sampl
cultiv
convent
liquid
solid
medium
week
sampl
analys
use
bug
n
bead
follow
roch
coba
amplicor
detect
system
tuberculosi
well
result
smear
posit
respiratori
sampl
full
agreement
bug
n
bead
tm
isol
procedur
combin
pcr
detect
convent
cultiv
agreement
result
obtain
use
bug
n
bead
tm
combin
coba
amplicor
detect
cultiv
result
indic
bug
n
bead
sampl
prepar
system
sensit
compar
cultiv
obtain
smear
posit
sampl
result
bug
n
bead
tm
procedur
combin
rtpcr
coba
amplicor
could
obtain
within
work
day
wherea
sever
week
necessari
identifi
tuberculosi
posit
sampl
cultiv
furthermor
fact
pcr
coba
amplicor
procedur
use
downstream
detect
system
demonstr
differ
naat
may
use
combin
bug
n
bead
tm
challeng
system
smear
neg
sampl
nonrespiratori
sampl
includ
extens
studi
gold
nanoparticl
probebas
diagnost
system
rapid
sensit
detect
tuberculosi
reemerg
major
infecti
diseas
sever
area
world
tuberculosi
mtb
infect
continu
increas
worldwid
estim
annual
grow
rate
applic
new
method
base
nanotechnolog
simplifi
bacteri
dna
detect
improv
mtb
identif
make
diagnosi
infect
caus
pathogen
faster
less
expens
convent
method
describ
rapid
sensit
colorimetr
method
base
use
gold
nanoparticl
functionalis
thiolat
oligonucleotid
mtb
detect
directli
clinic
sampl
without
prior
dna
amplif
object
aim
work
screen
clinic
specimen
presenc
mtb
use
approv
innolipa
riftb
kit
novel
gold
nanoprobebas
method
method
use
gold
nanoprobebas
method
consist
visual
spectrophotometr
comparison
blank
contain
gold
nanoprob
alon
neg
contain
dna
sampl
previous
test
confirm
neg
mtb
posit
contain
dna
sampl
posit
mtb
solut
nacl
addit
blank
neg
sampl
turn
initi
pink
bluepurpl
colour
denot
gold
nanoprob
aggreg
case
posit
sampl
solut
maintain
origin
pink
colour
nacl
addit
presenceabs
gold
nanoprob
aggreg
corrobor
uvvis
spectra
object
tubercul
pleuriti
remain
major
health
problem
worldwid
laboratori
diagnosi
usual
involv
pleural
fluid
pf
analysi
pleural
tissu
histopatholog
plu
specimen
cultur
pcr
diagnost
yield
pf
pcr
howev
variabl
differ
studi
larg
volum
specimen
may
give
better
microbiolog
diagnosi
certain
condit
describ
pf
cultur
mtuberculosi
pcr
vagin
discharg
ctrachomati
higher
pf
volum
may
provid
better
diagnost
yield
tb
pleuriti
method
prospect
observ
studi
conduct
patient
lymphocyt
exud
pleural
effus
univers
hospit
decemb
novemb
diagnosi
tb
pleuriti
made
either
presenc
pleural
granuloma
without
acid
fast
bacilli
plu
respons
antitubercul
therapi
posit
mycobacteri
cultur
pf
andor
pleural
tissu
patient
final
diagnos
serv
control
group
pleural
fluid
divid
laboratori
four
differ
volum
ml
process
specimen
centrifug
pellet
produc
use
dna
extract
nest
pcr
use
primer
target
conserv
among
organ
tb
complex
group
perform
standard
pcr
precaut
exercis
presenc
pcr
inhibitor
test
specimen
result
patient
control
enrol
tabl
tb
group
specimen
ml
show
posit
pcr
result
sensit
respect
control
sampl
reveal
neg
result
volum
use
group
posit
pcr
also
gave
posit
result
volum
group
posit
pcr
cover
posit
result
group
plu
addit
case
process
specimen
occasion
produc
larg
sticki
pellet
potenti
affect
dna
qualiti
pcr
inhibitor
detect
three
specimen
differ
patient
ml
control
conclus
higher
volum
pleural
fluid
increas
diagnost
sensit
tubercul
pleuriti
pcr
certain
extent
toolarg
volum
howev
unsuit
probabl
due
presenc
interf
protein
substanc
appropri
pleural
fluid
volum
assess
verifi
laboratori
object
quantiferongold
tb
test
detect
interferon
gamma
product
whole
blood
incub
purifi
mycobacteri
antigen
test
abl
detect
latent
activ
tb
fulli
evalu
patient
present
suspect
activ
tb
studi
investig
use
test
introduct
larg
region
teach
hospit
uk
high
incid
tuberculosi
infect
method
quantiferongold
tb
test
introduc
routin
clinic
practis
centr
earli
patient
detail
prospect
enter
clinic
databas
studi
review
patient
demograph
indic
test
turnaround
time
result
addit
clinic
valu
test
quantiferongold
tb
test
perform
patient
attend
depart
infect
suspect
activ
tuberculosi
result
compar
convent
test
includ
tuberculin
skin
test
tst
microscopi
cultur
histolog
radiolog
result
studi
period
jansept
test
request
major
request
suspect
activ
tuberculosi
patient
attend
depart
infect
includ
hivposit
immunosuppress
patient
number
patient
receiv
tst
declin
quantiferongold
tb
test
introduc
patient
confirm
tuberculosi
infect
gener
good
agreement
clinic
find
quantiferontb
test
howev
case
dissemin
tb
immunocompet
patient
neg
test
possibl
reason
find
discuss
case
test
consid
led
chang
clinic
manag
antitb
therapi
either
commenc
discontinu
direct
result
quantiferongold
test
result
conclus
quantiferongold
tb
test
consider
valu
manag
patient
suspect
tb
led
chang
treatment
signific
number
patient
result
must
interpret
conjunct
avail
inform
interferongamma
test
like
play
increasingli
import
role
manag
patient
suspect
tb
replac
use
tuberculin
skin
test
institut
object
mtuberculosi
isol
receiv
midland
region
centr
mycobacteriolog
prospect
type
miruvntr
aim
prospect
detect
link
patient
activ
tb
diseas
support
convent
method
initi
analysi
epidemiolog
data
present
studi
method
etr
miruvntr
loci
amplifi
isol
amplicon
load
onto
dna
fragment
analysi
system
analys
mlmin
bp
basic
epidemiolog
data
gather
specimen
form
analys
comparison
miruvntr
type
result
use
bionumer
version
result
cluster
rate
ten
strateg
health
region
rang
averag
cluster
miruvntr
profil
present
region
miruvntr
cluster
profil
present
median
differ
region
median
patient
age
year
old
rang
preval
age
group
year
old
patient
isol
patient
year
old
isol
respiratori
specimen
nonrespiratori
unknown
preval
miruvntr
profil
vntr
miru
isol
detect
laboratori
health
region
across
midland
isol
rifampicin
resist
isol
isoniazid
resist
patient
infect
mdrtb
mdrtb
isol
group
cluster
miruvntr
type
repres
transmiss
rate
mdrtb
thu
suggest
mdrtb
transmit
midland
conclus
rel
high
transmiss
rate
proport
respiratori
case
rel
low
median
age
case
suggest
emerg
tb
midland
may
due
newli
acquir
infect
diseas
reactiv
js
lin
yy
yu
cy
lin
changhua
tw
object
clinic
util
outcom
molecular
diagnosi
directli
clinic
sampl
becom
popular
perform
need
monitor
period
studi
aim
assess
perform
bd
protec
et
system
protec
direct
detect
mtbc
pulmonari
nonpulmonari
sampl
tertial
care
medic
centr
method
octob
retrospect
review
laboratori
result
pulmonari
nonpulmonari
sampl
refer
direct
detect
mtbc
protec
dtb
probe
bd
use
amplifi
dna
fragment
ie
within
mtbc
gene
posit
rate
mtbc
identifi
protec
compar
one
determin
rapid
cultur
system
bd
bactec
mgit
follow
molecular
identif
use
inhous
multiplex
pcr
result
total
clinic
sampl
consist
pulmonari
nonpulmonari
specimen
recruit
studi
nonpulmonari
sampl
obtain
ascit
blood
csf
pleural
effus
gastric
juic
synovi
fluid
urin
pu
other
sampl
also
request
mtbc
cultur
simultan
posit
rate
mtbc
protec
wherea
pulmonari
nonpulmonari
sampl
respect
among
sampl
submit
protec
well
cultur
posit
rate
mtbc
protec
compar
cultur
pattern
also
shown
subgroup
analysi
protec
compar
cultur
ie
vs
pulmonari
sampl
vs
nonpulmonari
sampl
sampl
show
posit
mtbc
protec
cultur
pulmonari
nonpulmonari
subgroup
three
sampl
posit
mtbc
cultur
neg
protec
wherea
sampl
posit
mtbc
protec
neg
cultur
concord
rate
posit
neg
protec
et
system
cultur
conclus
lower
submiss
rate
mtbc
cultur
along
direct
detect
note
clinic
behaviour
although
concord
rate
mtbc
identif
direct
detect
cultur
seem
accept
high
fals
neg
rate
protec
remind
import
simultan
cultur
mtbc
direct
detect
clinic
sampl
clonal
divers
mycobacterium
tuberculosi
sputum
specimen
individu
patient
pulmonari
tuberculosi
c
shiohira
bhusal
n
yaman
okinawa
jp
object
isol
mycobacterium
tuberculosi
sputum
specimen
princip
tool
make
definit
diagnosi
tuberculosi
patient
isol
gener
consid
monoclon
natur
directli
employ
phenotyp
genotyp
character
howev
properti
individu
coloni
singl
specimen
larg
remain
unknown
present
studi
determin
clonal
divers
tuberculosi
isol
individu
patient
pulmonari
tuberculosi
use
antimycobacteri
suscept
test
restrict
fragment
length
polymorph
rflp
method
total
nine
patient
includ
studi
five
newli
diagnos
four
undergo
chemotherapi
sputum
specimen
treat
nalcnaoh
plate
middlebrook
agar
plate
incub
coloni
select
subcultur
individu
coloni
antimycobacteri
suscept
eight
agent
determin
broth
microdilut
test
dna
fingerprint
pattern
analys
use
rflp
well
spoligotyp
result
signific
differ
among
individu
coloni
singl
isol
suscept
test
three
isol
includ
one
newli
diagnos
mixtur
suscept
resist
coloni
streptomycin
isoniazid
andor
ethambutol
wherea
rflp
reveal
five
isol
includ
three
newli
diagnos
contain
heterogen
coloni
rflp
howev
found
signific
correl
rflp
pattern
antimycobacteri
suscept
studi
indic
patient
pulmonari
tuberculosi
clonal
divers
phenotyp
genotyp
character
present
divers
isol
patient
treat
antimycobacteri
agent
like
induct
drug
resist
accumul
spontan
mutat
howev
polyclon
infect
mtuberculosi
patient
previous
treat
often
case
possibl
infect
polyclon
strain
mtuberculosi
heterogen
drug
suscept
singl
episod
tuberculosi
import
consider
epidemiolog
therapeut
aspect
object
hiv
coinfect
import
risk
factor
progress
latent
tuberculosi
infect
ltbi
overt
tuberculosi
diseas
diagnosi
ltbi
tradit
reli
tuberculin
skin
test
tst
result
specif
tst
confound
previou
bcg
vaccin
result
falseposit
tst
result
sensit
reduc
patient
sever
immunosuppress
cutan
anergi
result
falseneg
tst
result
novel
interferongamma
releas
assay
igra
util
mtuberculosi
specif
antigen
provid
result
confound
bcgvaccin
goal
studi
compar
perform
two
commerci
avail
igra
patient
swiss
hiv
cohort
studi
shc
patient
novemb
march
hivposit
immigr
male
femal
origin
subsaharan
africa
prospect
studi
ltbi
regular
clinic
followup
visit
patient
shc
respect
cell
count
pt
pt
pt
median
cell
count
rang
method
two
igra
test
system
use
accord
respect
kit
instruct
quantiferontb
gold
intub
qft
cellesti
ltd
carnegi
australia
spottb
oxford
immunotec
ltd
oxford
uk
latter
peripher
blood
mononuclear
cell
separ
ml
citrateblood
vacutain
cell
prepar
tube
becton
dickinson
franklin
lake
usa
within
two
hour
phlebotomi
qft
infgamma
releas
plasma
detect
eia
provid
manufactur
spottb
infgamma
spot
form
cell
count
aid
elispot
reader
system
aid
gmbh
strassberg
germani
result
total
patient
posit
test
result
qft
spottb
respect
observ
agreement
assay
kappa
confid
limit
conclus
good
agreement
qft
spottb
suggest
assay
equival
diagnosi
ltbi
hiv
patient
object
identif
acidfast
bacilli
afb
sputum
tissu
definit
diagnosi
tuberculosi
howev
method
diagnosi
restrict
certain
limit
serolog
diagnosi
tuberculosi
use
long
time
aim
studi
determin
sensit
specif
antigen
igg
iga
igm
find
patient
tubercul
assess
applic
serolog
diagnosi
pulmonari
tuberculosi
method
elisa
test
base
mycobacteri
use
measur
specif
iga
igm
igg
antibodi
sera
case
tuberculosi
case
tubercul
hiv
posit
patient
control
healthi
volunt
control
patient
chronic
diseas
differ
type
data
igg
use
enzymelink
immunosorb
assay
elisa
chest
radiographi
tuberculosi
cultur
patholog
obtain
cutoff
valu
igg
iga
igm
chosen
accord
receiv
oper
characterist
roc
analysi
sensit
specif
posit
likelihood
ratio
determin
result
mean
level
igg
iga
igm
significantli
higher
patient
pulmonari
tuberculosi
compar
control
groupssensit
igg
test
specif
iga
test
show
sensit
specif
combin
igg
iga
test
show
sensit
specif
posit
likelihood
ratio
studi
chosen
cutoff
valu
igg
iga
igm
set
elisa
unit
conclus
studi
show
good
specif
reason
posit
likelihood
ratio
test
combin
iga
igg
new
cutoff
point
consid
diagnosi
adult
tuberculosi
combin
use
test
allow
increas
diagnosi
tuberculosi
implement
dot
set
high
preval
drugresist
tuberculosi
balabanova
fedorin
zakharova
v
nikolayevskyy
r
atun
r
coker
f
drobniewski
london
uk
samara
ru
dot
programm
implement
russian
feder
one
high
burden
countri
object
describ
dot
cohort
recruit
samara
oblast
pilot
oblast
assess
outcom
method
dot
cohort
recruit
april
till
septemb
across
civil
prison
sector
standard
technic
document
diagnostictreat
protocol
employ
receiv
cultur
underw
subsequ
epidemiolog
molecular
type
use
insert
detect
dnaadnan
intergen
region
result
patient
recruit
new
case
smearposit
total
new
case
bacteriolog
confirm
tb
drug
resist
rate
includ
multidrug
resist
substanti
significantli
higher
rate
prison
patient
versu
civil
patient
tabl
approxim
half
isol
strain
belong
beij
famili
significantli
higher
proport
isol
prison
compar
civilian
vs
ci
total
patient
success
complet
cours
tb
therapi
fail
default
rate
significantli
higher
among
smearposit
patient
compar
smearneg
rr
ci
death
rate
significantli
higher
proport
smearposit
case
die
versu
smearneg
rr
ci
conclus
lower
case
detect
rate
address
chang
nation
polici
radiolog
screen
prioritaris
bacteriolog
diagnost
monitor
measur
cure
tb
well
improv
laboratori
servic
rate
success
treatment
threshold
slightli
higher
report
dot
pilot
region
former
soviet
union
high
preval
primari
drug
resist
associ
beij
strain
prove
activ
transmiss
vital
improv
patient
adher
therapi
reduc
acquir
resist
improv
institut
infect
control
measur
prevent
transmiss
introduct
rapid
techniqu
drug
resist
identif
allow
earli
resist
detect
need
consid
multidrugresist
tuberculosi
guidelin
tailor
immigr
bregenz
f
schmid
c
ther
aarau
ch
background
guidelin
recommend
empir
therapi
et
tuberculosi
tb
four
firstlin
drug
patient
multidrugresist
mdr
tb
risk
treatment
failur
acquir
addit
resist
mdr
tb
consid
standard
regimen
fail
mdr
preval
countri
former
soviet
union
case
report
report
case
mongolian
woman
present
night
sweat
abdomin
pain
may
travel
switzerland
march
microscop
sputum
examin
cultur
pcr
neg
chest
ctscan
show
multipl
nodul
lung
mediastinum
bronchial
biopsi
show
necrotis
granuloma
et
start
rifampicin
rif
isoniazid
inh
pyrazinamid
pza
ethambutol
emb
fever
persist
patient
condit
deterior
ctscan
show
progress
diseas
multipl
abscess
vertebr
osteolyt
lesion
cultur
repeat
et
switch
linezolid
moxifloxacin
amikacin
august
resist
test
octob
show
resist
inh
rif
emb
sm
pza
cycloserin
sensit
fluorochinolon
linezolid
amikacin
pa
capreomycin
sequenti
resist
test
confirm
pza
resist
acquir
first
et
dec
simplifi
oral
regimen
start
linezolid
moxifloxacin
cours
complic
sever
peripher
axon
degener
probabl
due
linezolid
decemb
cathet
relat
p
aeruginosa
sepsi
march
replac
linezolid
amikacin
may
patient
good
gener
condit
therapi
discontinu
month
august
conclus
standard
treatment
four
five
firstlin
agent
may
fail
patient
immigr
region
high
preval
mdr
tb
may
induc
resist
et
necessari
patient
suspect
mdr
tb
local
resist
data
taken
consider
risk
treatment
failur
et
weigh
risk
associ
delay
treatment
wait
resist
result
object
growth
tuberculosi
ratelimit
mani
diagnost
procedur
includ
drug
sensit
test
dst
attempt
speed
dst
organ
includ
detect
microbi
metabol
optic
imag
microcoloni
current
molecular
method
determin
full
drug
resist
pattern
requir
guid
effect
treatment
regim
object
work
use
highli
porou
ceram
anopor
cultur
support
facilit
rapid
detect
tuberculosi
growth
appli
capabl
dst
novel
methodolog
one
exploit
high
poros
excel
cultur
imag
properti
anopor
method
steril
anopor
strip
place
upon
middlebrook
agar
plate
inocul
tuberculosi
stain
rif
inh
rif
inhr
plate
incub
incub
degre
c
cultur
kill
place
filter
paper
disk
satur
methanol
heat
treatment
follow
transfer
anopor
microscop
slide
cover
film
solidifi
agaros
contain
lm
dye
min
stain
cell
anopor
surfac
accomplish
minim
disrupt
microcoloni
surfac
microcoloni
imag
directli
use
olympu
epifluoresc
microscop
equip
fluorotar
lens
imag
captur
use
kappa
ccd
camera
bmp
file
imag
analys
use
imagej
softwar
result
coloni
tuberculosi
visibl
day
incub
anopor
strip
place
middlebrook
agar
plate
similar
size
morpholog
cultur
directli
agar
base
individu
cell
microcoloni
could
detect
syto
stain
day
cultur
increas
microcoloni
area
found
signific
p
n
mann
whitney
utest
indic
growth
occur
dst
test
isoniazid
rifampin
progress
result
shown
conclus
anopor
effect
cultur
support
tuberculosi
imag
microcoloni
situ
use
detect
growth
within
day
inocul
appli
dst
abil
kill
stain
imag
microcoloni
situ
facilit
porou
inert
rigid
natur
anopor
identif
mycobacterium
tuberculosi
subtyp
strongli
associ
multidrug
resist
within
beij
famili
v
nikolayevskyy
brown
balabanova
bazhora
asmolov
f
drobniewski
london
uk
odessa
ua
background
investig
tuberculosi
drug
resist
rate
preval
certain
genotyp
associ
mutat
confer
drug
resist
ukrain
may
contribut
significantli
develop
appropri
intervent
combat
converg
tb
hiv
epidem
object
determin
degre
isoniazid
rifampicin
multipl
drug
resist
mdr
associ
beij
famili
isol
subgroup
within
beij
famili
ii
identifi
molecular
genotyp
method
suitabl
differenti
isol
popul
highli
conserv
genotyp
domin
iii
confirm
hypothesi
prison
major
driver
drug
resist
method
noncommerci
revers
hybrid
assay
macroarray
use
detect
key
mutat
respons
develop
resist
rifampicin
isoniazid
genotyp
done
use
multilocu
vntr
type
use
panel
miru
etr
loci
beij
strain
identifi
use
spoligotyp
result
total
tuberculosi
strain
isol
patient
radiolog
bacteriolog
confirm
tb
odessa
nikolaev
region
southern
ukrain
investig
mdr
rate
significantli
higher
former
prison
inmat
compar
never
prison
vs
rr
ci
mutat
codon
rpob
gene
codon
katg
gene
domin
drug
resist
strain
overal
discriminatori
abil
vntr
genotyp
given
group
ukrainian
isol
higher
provid
spoligotyp
hgdi
versu
beij
strain
compris
two
larg
cluster
form
strain
share
miruetr
signatur
respect
isol
latter
miruetr
signatur
common
among
previous
imprison
patient
preval
mutat
confer
mdr
significantli
higher
subgroup
beij
strain
share
vntr
signatur
compar
beij
strain
vs
rr
ci
conclus
significantli
higher
preval
drugresist
beij
strain
former
prison
inmat
suggest
prison
major
driver
drugresist
tb
beij
genotyp
vntr
signatur
strongli
associ
drug
resist
may
respons
rapid
transmiss
mdr
tb
ukrain
object
analyz
evolut
clinicoepidemiolog
characterist
case
extrapulmonari
tuberculosi
microbiolog
confirm
popul
belong
sector
iii
zaragoza
hcu
lozano
blesa
valu
mean
rflp
relationship
isol
strain
differ
clinic
present
diseas
materi
method
retrospect
studi
patient
extrapulmonari
tbc
made
case
posit
cultur
tuberculosi
locat
differ
pulmonari
one
period
studi
revis
variabl
age
nation
origin
servic
type
specimen
clinic
hiv
sensibl
antituberculostat
drug
evolut
diseas
studi
rflp
carri
faculti
medicin
zaragoza
isol
strain
june
june
establish
relationship
found
cluster
differ
extrapulmonari
locat
result
isol
tuberculosi
extrapulmonari
locat
patient
biggest
number
case
year
frequent
locat
pleural
tb
lymphnod
tb
genitourinari
tb
sampl
baciloscopi
posit
strain
grew
lowesteinjensen
medium
made
mean
present
type
resist
antituberculostat
drug
resist
isoniazid
isoniazid
estreptomicini
anoth
one
isoniazidetambuhtol
patient
immigr
come
africa
resist
type
detect
patient
hiv
neg
serolog
determin
ignor
isol
strain
part
cluster
tipif
among
case
pulmonari
extrapulmonari
tuberculosi
diagnos
period
studi
one
come
pleural
biopsi
found
resist
isoniazid
conclus
extrapulmonari
locat
patient
diagnos
tuberculosi
manifest
depend
factor
associ
host
data
conclud
ident
pattern
rflp
correspond
specif
locat
diseas
tuberculosi
tipif
use
prove
valuabl
tool
epidemiolog
tbc
studi
case
extrapulmonari
tbc
appear
insid
cluster
determin
period
studi
evalu
tuberculin
skin
test
quantiferontb
gold
identif
ltbi
activ
tb
among
irregular
immigr
milan
itali
g
orlando
merli
valerio
l
cordier
bergonzi
villa
cargnel
milan
object
tuberculosi
infect
increas
worldwid
target
test
identifi
person
high
risk
tb
would
benefit
treatment
latent
tb
infect
ltbi
would
includ
recent
irregular
immigr
develop
countri
tuberculin
skin
test
tst
gener
accept
routin
evalu
differenti
tuberculosi
infect
bcg
vaccin
need
least
access
health
care
facil
reduc
diagnost
power
critic
set
report
interim
analysi
clinic
trial
tst
quantiferontb
gold
evalu
identif
tb
infect
among
irregular
immigr
method
consent
immigr
observ
opera
san
francesco
outpati
depart
health
problem
underw
tst
evalu
time
h
inject
ml
tu
ppd
blood
punctur
tst
consid
posit
indur
less
mm
recent
immigr
greater
mm
old
immigr
whole
heparin
venou
blood
sampl
analys
h
incub
quantiferontb
assay
cell
mediat
immun
respons
tuberculosisspecif
antigen
conclus
tuberculosi
diseas
incid
santiago
higher
expect
social
econom
level
decreas
sinc
programm
establish
probabl
due
exhaust
follow
case
dot
implement
high
incid
persist
younger
group
special
pulmonari
diseas
although
decreas
observ
percentag
hiv
tuberculosi
coinfect
determin
epidemiolog
characterist
tuberculosi
santiago
tuberculosi
paediatr
adult
popul
athen
greec
greec
kanavaki
karabela
skroubel
e
varon
anagnost
raftopoul
h
morait
n
spyridi
nikola
athen
gr
object
studi
retrospect
new
pediatr
adult
tb
case
diagnos
nation
refer
laboratori
tb
athen
period
materi
method
pediatr
tb
case
adult
tb
case
children
year
year
year
year
age
result
discuss
peak
new
tb
case
notic
popul
studi
great
concern
peak
pediatr
adult
tb
case
note
migrat
reach
highest
peak
greec
relat
resist
main
first
line
antituberculu
drug
tb
isol
pediatr
popul
resist
isoniazid
inh
rifampicin
rif
multidrug
resist
inhrif
howev
interest
adult
popul
resist
inh
significantli
lower
resist
rif
multidrug
resist
concern
streptomycin
sm
also
interest
pediatr
tb
isol
resist
contrast
tb
isol
adult
popul
studi
satisfi
explan
find
necessari
investig
young
patient
medic
file
attempt
associ
contact
young
patient
infect
adult
purpos
near
futur
immigr
countri
high
preval
tuberculosi
tb
may
allow
signific
contribut
increas
tb
rate
industri
world
screen
tuberculosi
enabl
new
immigr
receiv
import
medic
evalu
treatment
provid
use
surveil
data
object
aim
studi
assess
preval
tuberculin
skin
test
tst
posit
among
immigr
newli
arriv
greec
materi
method
allow
resid
permit
immigr
greec
screen
tb
screen
procedur
includ
tst
chest
xray
thorough
physic
examin
immigr
screen
tb
twomonth
period
includ
studi
demograph
data
record
subject
statist
analysi
perform
use
logist
regress
pearson
chisquar
test
categor
variabl
student
ttest
normal
distribut
mannwhitney
u
test
skew
numer
variabl
statist
signific
level
set
p
result
total
immigr
screen
male
femal
mean
age
year
mean
time
greec
year
onehundr
twentyon
immigr
origin
europ
asia
africa
tst
posit
subject
male
femal
p
signific
differ
preval
tst
posit
respect
origin
among
subject
develop
detect
skin
indur
presenc
bcg
scar
associ
greater
tst
reaction
size
mm
vs
mm
subject
bcg
scar
respect
p
conclus
preval
posit
tst
among
immigr
greec
neglig
bcg
vaccin
earli
childhood
must
substanti
alter
interpret
tst
adult
given
low
risk
acquir
tbc
arriv
greec
prevent
therapi
consid
immigr
posit
skin
test
tst
clear
chest
xray
recent
exposur
known
sourc
case
tuberculosi
adjust
risk
advers
effect
chemoprophylact
agent
epidemiolog
mycobacterium
bovi
diseas
ferrol
spain
object
examin
current
epidemiolog
mycobacterium
bovi
diseas
compar
patient
characterist
patient
tuberculosi
diseas
commun
method
prospect
studi
surveil
epidemiolog
treatment
complet
data
case
tuberculosi
tuberculosi
unit
variabl
examin
includ
sex
age
race
countri
birth
main
locat
diseas
drug
suscept
hiv
infect
statu
initi
medic
medic
provid
type
treatment
complet
cours
diseas
differ
bovi
tuberculosi
patient
characterist
treatment
complet
rate
compar
use
v
test
fisher
exact
test
median
compar
use
mannwhitney
test
differ
consid
statist
signific
level
p
result
case
cultureposit
tuberculosi
identifi
tuberculosi
identifi
bovi
incid
per
personyear
patient
infect
bovi
hivneg
adult
born
spain
none
travel
outsid
spain
link
might
allow
airborn
persontoperson
transmiss
bovi
discov
among
patient
older
vs
year
extrapulmonari
diseas
vs
p
compar
tuberculosi
patient
bovi
isol
resist
pyrazinamid
differ
resist
isoniazid
vs
rifampin
vs
compar
tuberculosi
median
treatment
durat
approxim
month
greater
bovi
tuberculosi
patient
differ
frequenc
direct
observ
treatment
vs
treatment
complet
rate
default
vs
toxic
hepat
vs
evolut
death
tb
vs
relaps
vs
signific
mean
followup
month
rang
personmonth
conclus
predomin
clinic
present
consist
progress
latent
tb
infect
persontoperson
airborn
transmiss
identifi
bovi
infect
frequent
extrapulmonari
local
durat
treatment
tend
longer
patient
infect
bovi
complet
rate
evolut
compar
patient
infect
tuberculosi
tuberculosi
reemerg
diseas
itali
correl
hiv
infect
risk
factor
compar
nativ
resid
foreign
immigr
background
tuberculosi
born
increas
morbid
mortal
rate
due
chang
epidemiolog
scenario
diffus
resist
strain
recent
profound
modif
occur
among
predispos
factor
increas
mean
patient
p
age
concurr
diseas
jatrogen
immunosuppress
alcohol
drug
use
migrat
hiv
pandem
play
key
role
process
method
among
consecut
p
hospit
due
sinc
compar
p
itali
immigr
extraeuropean
countri
relat
number
risk
factor
includ
hiv
infect
result
compar
immigr
nativ
italian
p
higher
frequenc
hivaid
p
prodomin
pleuropulmonari
involv
versu
lymphnod
andor
dissemin
among
hivinfect
p
versu
nonhivinfect
one
p
moreov
italian
greater
mean
age
p
increas
frequenc
broader
spectrum
predispos
condit
posit
histori
chronic
lung
heart
liver
kidney
diseas
diabet
mellitu
malign
collagen
vascular
diseas
p
foreign
lower
frequenc
gener
support
factor
low
incom
economicsoci
problem
cigarett
smoke
alcoholdrug
abus
p
versu
italian
decad
experi
shed
light
two
differ
pattern
local
p
predominatli
repres
elderli
frequent
concurr
disord
specif
risk
factor
frequent
hiv
infect
predomin
involv
site
pulmonari
one
immigr
repres
otherwis
healthi
younger
p
develop
preval
lung
local
conclus
clinician
awar
need
attent
order
obtain
rapid
diagnosi
treatment
reduc
transmiss
risk
progress
integr
immigr
local
popul
may
lead
increas
risk
dissemin
especi
among
local
vulner
older
popul
object
evalu
complianc
side
effect
efficaci
short
cours
chemoprophylaxi
tuberculosi
isoniazid
plu
rifampin
month
compar
cours
isoniazid
month
patient
method
prospect
compar
random
open
studi
patient
suitabl
criteria
chemoprophylaxi
accord
guidelin
centr
diseas
control
hiv
posit
patient
exclud
patient
divid
group
group
receiv
isoniazid
mg
per
day
plu
rifampin
mg
per
day
month
group
ii
receiv
isoniazid
mg
per
day
month
realis
clinic
analyt
followup
period
treatment
result
patient
includ
group
group
ii
group
compar
base
level
hepatotox
patient
group
front
group
ii
p
signif
statist
differ
seriou
hepatotox
vs
digest
toxic
vs
cutan
toxic
vs
chemoprophylaxi
retir
end
treatment
patient
group
patient
group
ii
averag
followup
patient
month
case
tuberculosi
detect
moment
conclus
short
cours
isoniazid
plu
rifampin
month
equal
effect
standard
cours
isoniazid
month
latent
tuberculosi
infect
toxic
short
cours
lower
probabl
minor
time
exposit
background
variou
atyp
mycobacteria
describ
caus
diseas
hivinfect
patient
report
first
case
dissemin
infect
mycobacterium
sherrisii
advanc
immunocompromis
patient
case
report
year
old
causasian
male
refer
hospit
may
fever
unknown
origin
gener
weak
notic
sever
month
patient
test
posit
hiv
infect
septemb
hospitalis
pulmonari
tuberculosi
februari
antiretrovir
therapi
start
nevirapin
lamivudin
stavudin
relaps
tuberculosi
suspect
treat
rifampicin
isoniazid
ethambutol
pyrazinamidon
admiss
cell
count
six
nineteen
day
later
five
sputum
sampl
one
periton
effus
sampl
two
blood
cultur
grew
posit
atyp
mycobacteria
bacteria
thought
simia
treatment
chang
clarithromycin
rifabutin
ethambutol
without
clinic
improv
neither
microbiolog
control
anoth
blood
cultur
posit
final
identif
reveal
sherrisii
two
month
drug
suscept
test
bactec
method
show
sensibl
clarithromycin
ethambutol
rifabutin
intermedi
sensibl
amikacin
resist
ciprofloxacin
eventu
ad
amikacin
moxifloxacin
rel
efficaci
gener
improv
negativ
bacteri
sampl
discuss
sherrisii
recent
describ
mycobacteria
phylogenet
relat
simia
diagnosi
confirm
gene
sequenc
rrna
dnadna
hybrid
clinic
case
report
hivinfect
african
male
pulmonari
injuri
combin
clarithromycin
rifabutin
ethambutol
moxifloxacin
amikacin
show
clinic
microbiolog
efficaci
case
combin
ineffect
despit
vitro
sensit
conclus
infect
sherrisii
consid
emerg
pathogen
hiv
infect
patient
poor
immunolog
statu
best
treatment
yet
definit
may
strictli
correl
vitro
data
presenc
mycobacteria
colon
biopsi
patient
inflammatori
bowel
diseas
object
crohn
diseas
chronic
condit
inflamm
intestin
strong
correl
presenc
mycobacterium
avium
subspeci
paratuberculosi
crohn
diseas
previous
infer
far
higher
incid
paratuberculosi
pcr
posit
shown
gut
crohn
patient
healthi
peopl
howev
clear
paratuberculosi
etiolog
impact
pathogenesi
crohn
diseas
coincid
crohn
patient
increas
predisposit
colonis
paratuberculosi
extend
question
ask
increas
presenc
mycobacteria
gener
colon
biopsi
patient
inflammatori
bowel
diseas
ibd
crohn
diseas
ulcer
coliti
compar
healthi
peopl
facilit
mycobacteri
detect
use
cultiv
enrich
media
combin
direct
detect
pcr
method
biopsi
prospect
taken
inflammatori
lesion
section
colon
patient
submit
colonoscopi
suspect
ibd
one
hundr
healthi
control
also
includ
patient
later
group
accord
ibd
statu
crohn
diseas
ulcer
coliti
condit
healthi
colon
biopsi
investig
presenc
mycobacteria
paratuberculosisspecif
pcr
analysi
cultiv
bactec
mgit
continu
cultur
system
specimen
cultiv
mycobactinenrich
bbltm
middlebrook
medium
mycobacteri
strain
isol
identifi
speciesspecif
hybrid
pcr
well
rdna
pcr
sequenc
blast
analysi
result
among
sampl
patient
includ
patient
cultur
posit
patient
pcr
posit
patient
crohn
diseas
mycobacteria
far
detect
biopsi
healthi
control
result
complet
studi
present
conclus
taken
togeth
find
studi
gener
novel
knowledg
occurr
mycobacteria
human
gut
extend
basi
defin
mycobacteria
etiolog
role
ibd
special
emphasi
crohn
diseas
preval
nontubercul
mycobacteria
belgian
adult
cystic
fibrosi
popul
develt
w
laffut
l
dupont
j
verhaegen
leuven
object
increas
surviv
cystic
fibrosi
cf
patient
colonis
infect
new
respiratori
pathogen
emerg
among
nontubercul
mycobacteria
ntm
ntm
ubiquit
microorgan
geograph
differ
preval
exist
present
studi
done
determin
preval
ntm
adult
cfpatient
attend
univers
hospit
leuven
belgium
method
month
period
februari
june
sputum
sampl
obtain
adult
cf
patient
attend
outpati
clinic
sampl
decontamin
use
nalcnaoh
method
describ
american
societi
microbiolog
mycobacteria
growth
indic
tube
mgit
becton
dickinson
usa
use
cultur
medium
incub
week
bactec
mgit
becton
dickinson
usa
case
overgrowth
microorgan
mycobacteria
second
decontamin
follow
method
describ
bang
et
al
perform
sampl
indic
clinician
empyema
necessitati
en
rare
seen
infect
soft
tissu
form
spontan
drainag
empyema
pariet
pleura
although
common
site
subcutan
tissu
chest
wall
may
includ
esophagu
breast
retroperitoneum
pericardium
groin
vertebr
column
present
patient
es
chest
wall
retroperiton
space
psoa
abscess
complic
untreat
tubercul
empyema
male
patient
admit
two
month
histori
two
grow
mass
left
posterolater
chest
wall
left
lumber
area
follow
left
chest
pain
physic
examin
reveal
fluctuat
cm
diamet
fix
pain
two
swell
diminish
pulmonari
sound
left
hemithorax
chest
xray
disclos
disclosur
left
costadiaphragmat
sinu
narrow
left
intercost
space
chest
ct
scan
reveal
subcutan
cm
diamet
locul
collect
high
densiti
fluid
left
later
chest
associ
pleural
space
multilocul
cm
diamet
fluid
collect
paraspin
musculatur
lie
psoa
muscl
retroperitoneum
thoracenthesi
reveal
empyemat
fluid
neg
nonspecif
cultur
cultur
aspir
thorac
wall
mass
also
neg
nonspecif
bacilli
laboratori
examin
normal
except
mild
leucocytosi
increas
esr
mm
hour
left
thoracotomi
perform
diagnosi
es
purul
collect
pleural
space
abscess
format
within
thorac
wall
retroperitoneum
aspir
later
patient
underw
resect
destruct
tissu
left
pleural
decort
procedur
complet
placement
drainag
tube
pleural
abdomin
wall
retroperiton
space
histopatholog
examin
resect
tissu
pleura
confirm
granulomat
inflamm
caseou
necrosi
inh
rif
emb
pza
given
patient
two
month
treatment
continu
addit
month
inh
rif
month
therapi
patient
good
health
en
wellknown
howev
extrem
rare
complic
tubercul
empyema
although
morbid
mortal
high
possibl
treat
appropri
surgic
debrid
drainag
antitubercul
treatment
without
sequela
increas
incid
mycobacterium
xenopi
zaragoza
spain
emerg
pathogen
product
improv
laboratori
method
xenopi
record
review
recov
xenopi
isol
isol
consid
patient
suffer
diseas
caus
xenopi
number
decreas
second
half
studi
period
vs
case
pulmonari
diseas
frequent
clinic
present
one
patient
clinic
xenopi
dissemin
diseas
period
eighti
percent
patient
diseas
male
mean
age
year
common
risk
factor
associ
diseas
due
xenopi
smoke
infect
human
immunodefici
viru
hiv
chronic
obstruct
pulmonari
diseas
mean
cell
count
hivinfect
patient
diagnosi
x
frequent
clinic
featur
respiratori
symptom
follow
fever
constitut
symptom
chest
radiograph
reveal
cavit
pulmonari
diseas
patient
nodular
diseas
incid
unilater
diseas
common
treatment
regimen
isoniazid
rifampicin
ethambutol
averag
durat
month
treatment
case
nonhivassoci
diseas
favour
outcom
hivassoci
pulmonari
dissemin
diseas
poor
conclus
increas
xenopi
isol
note
three
main
hospit
zaragoza
spain
due
chang
cultur
techniqu
sensit
laboratori
isol
techniqu
rather
true
increas
clinic
diseas
chronic
pulmonari
diseas
common
clinic
manifest
xenopi
nonimmunocompromis
patient
hivinfect
patient
caus
dissemin
pulmonari
diseas
mycobacterium
chelona
continu
ambulatori
periton
dialysi
associ
periton
unrecognis
entiti
gupta
p
cockwel
da
birmingham
uk
introduct
continu
ambulatori
periton
dialysi
capd
initi
treatment
patient
endstag
renal
diseas
esrd
uk
periton
major
complic
frequent
indic
discontinu
capd
mycobacteria
rare
report
periton
object
describ
unusu
case
capd
periton
due
mycobacterium
chelona
chelona
method
univers
hospit
birmingham
one
uk
lead
centr
renal
dialysi
transplant
investig
capd
periton
includ
microscopi
periton
dialysi
pd
fluid
white
blood
cell
count
cultur
inocul
blood
cultur
bottl
monitor
autom
system
bactec
becton
dickenson
microbiolog
system
case
old
man
esrd
convert
capd
may
month
develop
cloudi
pd
effluent
abdomin
pain
fever
start
intraperiton
ip
vancomycin
oral
po
levofloxacin
accord
unit
protocol
microscop
examin
pd
fluid
reveal
neutrophil
mononuclear
cell
signal
posit
day
incub
organ
could
seen
microscopi
day
incub
subcultur
plate
fine
growth
becam
visibl
microscopi
growth
show
faint
gramposit
bacillu
subsequ
found
resist
routin
test
antibiot
identif
organ
prove
difficult
routin
laboratori
method
later
identifi
mchelona
refer
laboratori
health
protect
agenc
london
antibiot
treatment
chang
po
clarithromycin
ip
amikacin
latter
subsequ
chang
po
ciprofloxacin
basi
sensit
result
clinic
laboratori
sign
periton
persist
spite
week
antibiot
capd
cathet
remov
result
gradual
resolut
symptom
cathet
tip
grew
mchelona
antibiot
continu
month
one
year
follow
patient
remain
well
free
periton
relat
complic
conclus
atyp
mycobacteria
includ
mchelona
consid
cultur
neg
capd
periton
investig
capd
periton
includ
procedur
mycobacteri
isol
remov
periton
cathet
addit
antibiot
requir
manag
periton
object
report
case
nontubercul
mycobacteri
kerat
photorefract
keratectomi
myopia
method
woman
good
health
develop
increas
conjunctiv
red
swell
mark
decreas
vision
right
eye
week
unilater
photorefract
keratectomi
myopia
initi
treatment
includ
topic
steroid
ofloxacin
ophthalm
drop
system
treatment
fluconazol
vibramycin
week
without
improv
patient
refer
hospit
diagnosi
infecti
kerat
corneal
ulcer
right
eye
made
corneal
scrape
sent
cultur
microscop
examin
therapi
vancomycin
tobramycin
initi
result
acidfast
bacteria
seen
smear
cultur
lowensteinjensen
medium
grew
mycobacterium
chelona
complex
group
iii
abscessu
identifi
use
two
differ
revers
hybrid
line
probe
assay
genotyp
mycobacteria
cm
hain
lifesci
germani
belgium
suscept
test
perform
e
test
method
solna
sweden
isol
suscept
amikacin
clarithromycin
base
microbiolog
result
topic
therapi
use
amikacin
initi
week
treatment
due
noimprov
topic
imipenem
ad
treatment
regimen
medic
discontinu
week
later
final
visual
acuiti
conclus
case
emphas
possibl
nontubercul
mycobacteri
kerat
potenti
sightthreaten
complic
photorefract
keratectomi
myopia
possibl
difficulti
treat
infect
earli
accur
diagnosi
lead
prompt
manag
infect
immedi
aggress
antibiot
therapi
leprosi
elimin
campaign
qazvin
provinc
iran
r
qassemi
barqi
qazvin
ir
introduct
leprosi
elimin
campaign
whole
innov
action
accomplish
leprosi
case
find
particularli
multi
bacillari
type
promot
health
staff
capac
increas
peopl
knowledg
particip
differ
activ
leprosi
elimin
leprosi
case
find
treatment
multi
drug
therapi
main
aim
lec
endem
countri
achiev
lec
object
purpos
studi
leprosi
new
case
find
among
hous
hold
contact
previou
patient
leprosi
also
among
nativ
endem
area
qazvin
provinc
materi
method
intervent
crosssect
studi
first
name
address
patient
leprosi
record
treat
qazvin
provinc
list
base
qazvin
health
centr
provinc
document
household
contact
patient
recogn
record
local
examin
leprosi
sign
point
view
expert
team
cutan
smear
prepar
suspect
case
smear
studi
leprosi
bacteriolog
microscop
result
studi
period
household
contact
previou
patient
leprosi
person
endem
area
examin
suspect
case
leprosi
case
confirm
new
patient
leprosi
incid
rate
type
point
view
case
multi
bacillari
case
puci
bacillari
one
new
patient
yearsold
age
group
perform
lec
qazvin
provinc
indic
action
programm
esr
andor
crp
high
patient
liver
enzym
increas
patient
concern
treatment
three
patient
treat
twenti
patient
receiv
rifampin
inh
receiv
also
ethambutol
eleven
patient
also
treat
corticosteroid
outcom
infect
favour
case
one
stop
treatment
first
month
conclus
bcg
infect
may
occur
mani
month
end
bcg
therapi
spectrum
clinic
manifest
wide
cultur
bovi
rare
posit
diagnosi
suspect
clinic
histori
histolog
tomodensitometr
find
guidelin
treatment
need
extrapulmonari
tuberculosi
immunocompet
adult
turunc
yz
demiroglu
h
uncu
colakoglu
h
arslan
ankara
tr
object
although
tuberculosi
usual
attack
lung
result
pulmonari
tuberculosi
form
organ
may
also
affect
lead
extrapulmonari
tuberculosi
ept
dissemin
tuberculosi
studi
retrospect
analys
incid
clinic
site
risk
factor
ept
patient
admit
hospit
ept
januari
januari
turkey
tuberculosi
still
frequent
seen
method
total
patient
diagnos
ept
januari
januari
enrol
retrospect
studi
result
forti
six
case
diagnos
ept
year
period
twenti
two
male
femal
mean
age
patient
year
rang
year
patient
tubercul
lymphaden
diagnosid
genitourinari
system
tubercul
pott
diseas
miliari
tuberculosi
periton
tubercul
skin
tuberculosi
bone
tuberculosi
joint
tuberculosi
symptom
usual
nonspecif
relat
site
infect
common
symptom
fever
fatigu
concurr
diseas
previou
histori
tuberculosi
histori
contact
infect
patient
determin
major
risk
factor
ept
patient
previou
histori
pulmonari
tuberculosi
chronic
renal
failur
diabet
ept
diagnos
histopatholog
method
microbiolog
method
patient
six
case
cultur
grew
bacteria
ept
diagnos
help
clinic
laboratori
imag
andor
histopatholog
studi
surgeri
requir
patient
tubercul
lymphaden
pott
diseas
tubercul
osteomyel
studi
patient
die
one
miliari
tuberculosi
patient
tubercul
mening
conclus
physician
awar
unusu
present
local
tuberculosi
consid
ept
differenti
diagnosi
patient
nonspecif
symptom
fever
fatigu
headach
night
sweat
lowback
pain
weight
loss
cigarett
smoke
associ
pulmonari
tuberculosi
adult
rasoolinejad
farazi
haj
abdul
baghi
p
hashemi
p
kheirandish
tehran
ir
object
smoke
tuberculosi
widespread
mani
year
world
two
health
problem
develop
countriessmok
tuberculosi
preval
men
women
aim
hospit
base
casecontrol
studi
determin
effect
smoke
pulmonari
tb
male
adult
method
subject
male
age
year
pulmonari
tb
control
patient
match
age
socioeconom
condit
chosen
nontb
patient
admit
hospit
june
august
order
reduc
bia
subject
select
differ
ward
patient
without
hiv
diabet
mellitu
base
inclus
exclus
criteria
data
collect
direct
interview
use
questionnair
analys
use
odd
ratio
chisquar
mantelhaenzel
condit
logist
regress
result
base
univari
analysi
cigarett
smoke
time
studi
p
age
smoke
start
p
durat
smoke
p
p
number
cigarett
smoke
per
day
p
p
significantli
associ
pulmonari
tuberculosi
multivari
condit
logist
regress
analysi
show
smoke
independ
risk
factor
increas
risk
pulmonari
tuberculosi
p
p
analysi
age
smoke
start
p
p
number
cigarett
smoke
per
day
p
p
significantli
increas
risk
pulmonari
tuberculosi
conclus
base
result
smoke
independ
risk
factor
pulmonari
tuberculosi
definit
associ
two
matter
therefor
effect
antismok
campaign
expect
posit
repercuss
tb
preval
smoke
cessat
must
consid
promot
level
health
care
provid
object
reduc
suscept
disinfect
link
reduc
suscept
antibiot
use
disinfect
may
select
mutant
reduc
suscept
disinfect
antibiot
would
concern
mutant
persist
accumul
within
food
chain
studi
abil
mutant
deriv
salmonella
typhimurium
follow
exposur
disinfect
colonis
persist
chicken
compar
isogen
parent
dayold
chick
model
mutant
aris
exposur
common
domest
chlorophenol
disinfect
triclosan
aldehydebas
farm
disinfect
superkil
studi
method
minimum
inhibitori
concentr
mic
variou
disinfect
antibiot
determin
agar
dilut
method
mutant
salmonella
typhimurium
select
plate
coloni
form
unit
cfu
media
supplement
mic
disinfect
three
mutant
exhibit
low
mgl
medium
mgl
high
mgl
level
resist
triclosan
two
exhibit
increas
toler
superkil
select
chick
infect
oral
gavag
c
cfu
per
bird
c
mix
mutant
parent
strain
competit
index
experi
infect
monitor
twice
weekli
cloacal
swab
day
postinfect
weigh
swab
vortex
salin
ml
dilut
plate
ml
onto
media
without
antibiot
differenti
strain
coloni
count
overnight
incub
infect
calcul
cfug
faecal
matter
result
mutant
show
reduc
suscept
clinic
antibiot
mutant
strain
significantli
less
abl
persist
parent
strain
persist
chicken
gut
case
even
day
postinfect
amount
approxim
total
salmonella
popul
cfug
faecal
matter
conclus
exposur
salmonella
typhimurium
disinfect
gave
rise
mutant
reduc
suscept
disinfect
andor
antibiot
compar
isogen
parent
strain
mutant
still
abl
persist
chicken
gut
end
experi
studi
rat
pulmonari
inflammatori
reaction
induc
nprotein
sarscov
effect
glucocorticoid
l
hao
j
qu
shanghai
cn
object
studi
rat
pulmonari
inflammatori
reaction
induc
nprotein
sarscov
effect
glucocorticoid
method
rat
pulmonari
inflammatori
reaction
induc
intratrach
instal
nprotein
sarscov
dose
mgkg
rat
randomli
divid
four
group
salin
control
group
nc
nprotein
group
one
h
nprotein
group
two
h
nproteindexamethason
group
mgkg
blood
bronchial
alveolar
lavag
fluid
balf
lung
tissu
collect
challeng
cytolog
histopatholog
chang
lung
tissu
observ
wetdri
ratio
wd
lung
tissu
determin
transform
growth
serum
balf
measur
elisa
low
dose
ceftazidim
inhibit
penicillinbind
protein
pbp
gramneg
bacteria
caus
filamentform
relat
high
endotoxinreleas
vitro
possibl
high
cytokin
respons
vivo
high
dose
ceftazidim
caus
bind
induc
bacteri
lysi
earlier
studi
show
continu
infus
ceftazidim
mgkg
prevent
filamentform
lead
earli
high
cytokin
respons
rapid
lysi
bacteria
hypothes
filamentform
endotoxin
retain
bacteri
cellwal
induc
lower
initi
cytokin
releas
consequ
might
risk
postpon
potenti
sever
inflammatori
respons
bacteria
kill
treatment
object
investig
bacteri
kill
cytokin
respons
exposur
bacteri
filament
betalactam
antibiot
differ
pbpaffin
method
experi
neutropen
swiss
mice
challeng
cfu
ecoli
atcc
thigh
muscl
inocul
mgkg
ceftazidim
given
either
iv
bolu
continu
infus
hour
start
ceftazidim
mice
inject
meropenem
enhanc
bacteri
kill
hour
mice
sacrif
measur
circul
tnfalfa
bacteri
count
morpholog
result
hour
continu
ceftazidim
bacteria
show
rodshap
debri
bolustr
mice
show
filament
im
higher
concentr
p
found
hour
continu
ceftazidim
subsequ
meropeneminject
tnf
rose
higher
level
continu
group
until
hour
p
hour
cytokin
concentr
lower
still
level
bolustr
mice
p
cfucount
lower
continu
treat
mice
result
aim
effect
bacteri
lysi
conclus
continu
infus
mgkg
ceftazidim
prevent
filamentform
lead
signific
higher
concentr
circul
tnfalfa
contrast
iv
bolu
addit
meropenem
cytokin
rise
even
reflect
lysi
concomitt
releas
endotoxin
initi
continu
treat
group
confirm
bacteri
count
filamentform
shown
bolu
ceftazidim
associ
less
efficaci
antibiot
induc
bacteri
lysi
might
thu
disadvantag
amoxicillin
earli
delay
treatment
serotyp
pneumococc
acut
otiti
media
previous
immunis
vs
nonimmunis
gerbil
object
resist
commonli
util
antimicrobi
blactam
macrolid
fluoroquinolon
fq
pose
challeng
respect
empir
treatment
commun
acquir
pneumonia
telithromycin
tel
ketolid
high
activ
resist
strain
approv
treatment
respiratori
tract
infect
undertook
examin
efficaci
vivo
comparison
azithromycin
object
intracellular
persist
aureu
acknowledg
year
report
deal
issu
variou
celllin
vitro
aureu
studi
concept
experiment
anim
model
vivo
purpos
studi
develop
vivo
model
enabl
us
easili
screen
diversifi
extracellular
well
intracellular
kill
differ
antibiot
method
aureu
penr
methi
use
throughout
antibiot
test
includ
dicloxacillin
cefuroxim
gentamicin
rifampicin
clindamycin
azithromycin
mic
measur
etest
infect
induc
intraperiton
inject
cfuml
mucin
femal
nmri
mice
two
h
later
mice
treat
singl
dose
antibiot
salin
control
four
h
later
mice
kill
periton
wash
ml
salin
perform
fluid
retract
total
bacteri
count
quantifi
periton
wash
cell
fraction
isol
centrifug
extracellular
bacteri
count
quantifi
supernat
remain
extracellular
bacteria
pellet
kill
resuspens
hbss
contain
lgml
lysostaphin
cell
lyse
cold
steril
water
intracellular
count
quantifi
result
shown
tabl
reduct
number
cover
number
reduct
rel
salin
treat
control
conclus
intracellular
result
surpris
betalactam
sinc
known
poor
accumul
cell
even
show
better
result
rifampicin
known
activ
extraand
intracellularli
poor
reduct
number
seen
gentamicin
intracellularli
could
associ
poor
slow
penetr
azithromycin
clindamycin
reveal
bacteriostat
behaviour
conclus
new
vivo
model
work
satisfactorili
futur
perspect
complex
pkpd
studi
perform
efficaci
telavancin
treatment
experiment
endocard
due
glycopeptideintermedi
suscept
staphylococcu
aureu
object
primari
line
innat
defenc
bacteri
pathogen
consist
resid
macrophag
resid
tissu
polymorphonuclear
neutrophil
pmn
migrat
blood
site
infect
follow
stimul
macrophag
secretori
product
produc
larg
array
bio
molecul
present
macrophag
secretori
product
msp
includ
pro
well
antiinflammatori
cytokin
influenc
ultim
outcom
infect
present
investig
plan
studi
contribut
msp
produc
respons
interact
macrophag
plank
tonic
bio
film
cell
p
aeruginosa
virul
pathogen
mous
model
ascend
urinari
tract
infect
special
relev
sinc
receptor
structur
mous
urinari
tract
found
similar
human
method
plankton
bio
film
cell
clinic
standard
strain
p
aeruginosa
expos
murin
periton
macrophag
macrophag
secretori
product
collect
macrophag
secretori
product
character
term
cytokin
level
protein
content
presenc
reactiv
nitrogen
intermedi
reactiv
oxygen
speci
organ
grown
presenc
respect
msp
pyelonephrit
potenti
assess
result
organ
grown
presenc
msp
virul
vivo
indic
signific
increas
renal
bacteri
load
tissu
patholog
malionaldehyd
product
neutrophil
recruit
result
present
studi
bring
pathogen
pose
mechan
exploit
host
defenc
mechan
surviv
lead
chronic
recurr
infect
implic
find
relat
urinari
tract
infect
uti
caus
p
aeruginosa
discuss
genet
analysi
algin
product
cystic
fibrosi
pseudomona
aeruginosa
isol
scandinavian
patient
ciofu
wassermann
u
johansen
n
scandinavian
cystic
fibrosi
studi
consortium
p
aeruginosa
adapt
lung
environ
patient
cystic
fibrosi
lead
chronic
lung
infect
one
typic
phenotyp
chang
occurr
mucoid
coloni
morpholog
indic
overproduct
algin
one
mechan
convers
mucoid
base
mutat
algut
mucabcd
cluster
encod
stress
factor
algt
regul
investig
kind
mutat
respons
algin
phenotyp
scandinavian
cf
patient
sequenc
algt
muca
mucb
mucd
gene
pair
mucoidnonmucoid
p
aeruginosa
isol
pfge
pattern
patient
chronic
infect
attend
cf
centr
copenhagen
aarhu
patient
oslo
patient
uppsala
patient
mean
amount
algin
produc
mucoid
nonmucoid
paeruginosa
isol
mgl
respect
found
mutat
muca
mucoid
nonmucoid
p
aeruginosa
isol
common
mutat
found
ct
transit
region
lead
prematur
stop
codon
follow
mutat
delet
insert
isol
h
studi
use
modifi
microtiterpl
assay
chang
microbi
adhes
solvent
mat
estim
use
biphas
method
calcul
percentag
cell
adher
hexadecan
polar
solvent
chlorophorm
acid
solvent
electron
acceptor
ethyl
acet
strongli
basic
solvent
electron
donor
result
signific
increas
adhes
major
strain
p
aeruginosa
exponenti
stationari
growth
phase
bacteri
adhes
hexadecan
cell
surfac
hydrophob
strain
differ
growth
phase
strain
result
adher
adhes
percentag
chlorophorm
ethyl
acet
higher
hexadecan
differ
statist
signific
almost
strain
two
growth
phase
two
solvent
similar
van
der
waal
lw
properti
differ
acidbas
characterist
allow
us
confirm
bipolar
charact
bacteri
strain
studi
result
suggest
increas
adhes
valu
exponenti
stationari
growth
phase
due
mainli
chang
lw
interact
conclus
increas
adhes
valu
exponenti
stationari
phase
partial
explain
increas
cell
surfac
hydrophob
valu
two
solvent
regard
measur
electron
donorbas
electron
acceptoracid
characterist
bacteria
confirm
bipolar
charact
object
antibiot
often
present
site
infect
subinhibitori
concentr
human
treat
intermitt
dosag
schedul
antibiot
suprainhibitori
concentr
alway
follow
sub
inhibitori
level
aim
studi
determin
effect
sub
minim
inhibitori
concentr
submic
ceftazidim
meropenem
adher
abil
pseudomona
aeruginosa
strain
isol
varieti
isol
site
method
total
p
aeruginosa
strain
isol
differ
clinic
specimen
urin
bronchial
secret
ear
throat
wound
swab
use
abil
strain
adher
three
differ
cell
line
buffalo
green
monkey
kidney
hela
human
fetal
fibroblast
detect
immunofluoresc
stain
bacteri
adher
cell
line
test
treatment
antibiot
comparison
made
morpholog
exposur
strain
mic
antibiot
well
number
bacteria
attach
cell
number
exposur
concentr
antibiot
result
strain
adher
well
use
cell
line
signific
differ
adher
strain
three
cell
line
use
upon
comparison
number
attach
bacteria
exposur
submic
antibiot
statist
signific
differ
determin
exposur
strain
mic
ceftazidim
exposur
strain
concentr
meropenem
use
submic
antibiot
alter
bacteri
adher
abil
also
morpholog
morpholog
chang
promin
bacteri
exposur
mic
ceftazidim
meropenem
higher
concentr
antibiot
caus
format
long
filament
irregular
swell
high
correl
observ
chang
length
bacteria
loss
adher
abil
conclus
alter
bacteri
morpholog
caus
submic
ceftazidim
meropenem
relat
subsequ
loss
bacteri
adher
abil
vitro
studi
influenc
phenyl
lactic
acid
produc
lactobacillu
probiot
strain
pathogen
featur
pseudomona
aeruginosa
strain
introduct
previou
studi
concern
probiot
activ
lactobacillu
strain
shown
possess
inhibitori
activ
toward
growth
pathogen
bacteria
biochem
analysi
organ
acid
profil
show
probiot
strain
produc
phenyl
lactic
acid
pla
signific
amount
purpos
studi
investig
influenc
pla
rate
growth
express
enzymat
virul
factor
antiobiot
resist
marker
adher
capac
cellular
inert
substrata
p
aeruginosa
strain
recent
isol
bio
filmform
infect
materi
method
seven
ps
aeruginosa
strain
isol
central
venou
cathet
piec
tracheal
bronchopulmonari
secret
cultiv
liquid
nutrient
broth
presenc
differ
concentr
pla
dissolv
methanol
water
microbi
cultur
harvest
differ
time
bacteri
growth
curv
h
investig
express
differ
enzymat
factor
haemolyt
activ
caseinas
gelatinas
amylas
lecithinas
lipas
mucinas
adhes
invas
cellular
substrat
repres
hela
cell
cravioto
adapt
method
adhes
inert
substrata
repres
central
venou
cathet
piec
antibioresist
marker
disk
diffus
method
influenc
pla
bacteri
cell
viabil
assay
viabl
cell
count
use
calibr
loop
method
agar
spectrophotometr
asses
microbi
cultur
densiti
result
pla
influenc
growth
rate
bacteri
cell
dose
depend
manner
pla
gener
affect
pattern
solubl
enzymat
factor
secret
differ
incub
time
haemolyt
activ
lipas
caseinas
one
except
ie
activ
dnase
secret
logarithm
phase
cultur
presenc
pla
control
cultur
becam
posit
stationari
growth
phase
notic
pla
induc
morpholog
chang
bacteri
cell
suggest
influenc
express
bacteri
cell
surfaceassoci
molecul
influenc
pla
adher
capac
cellular
inert
substrata
either
inhibitori
stimulatori
depend
test
strain
express
antibiot
resist
mechan
test
strain
affect
bloodstream
infect
due
pseudomona
aeruginosa
clinic
outcom
associ
pathogenesisrel
gene
endimiani
b
pini
baj
f
luzzaro
toniolo
vares
object
p
aeruginosa
pa
overcom
host
defenc
mechan
use
two
main
protein
secret
system
type
ii
system
involv
product
exotoxin
exoa
elastas
lasa
lasb
phospholipas
c
plch
plcn
b
type
iii
system
implic
product
exoenzym
exo
exot
phospholipas
exou
adenyl
cyclas
exoy
neuroaminidas
play
import
role
pa
adher
epitheli
cell
studi
plan
evalu
whether
pathogenesisrel
gene
link
clinic
featur
outcom
patient
painduc
bloodstream
infect
bsi
method
thirtyeight
pa
isol
caus
bsi
institut
studi
twenti
strain
multidrug
resist
mdr
phenotyp
real
time
pcr
appli
biosystem
foster
citi
ca
use
evalu
presenc
exo
exot
exou
exoy
lasb
plch
plcn
exoa
clinic
record
bsipati
examin
retrospect
age
length
hospit
stay
underli
diseas
mccabejackson
classif
charlson
weight
index
sever
sepsi
primari
sourc
infect
clinic
outcom
evalu
statist
analysi
perform
use
statistica
softwar
statsoft
tulsa
ok
result
pa
isol
posit
follow
gene
exot
exou
lasb
plch
plcn
exoa
remain
exo
exoy
gene
detect
isol
respect
independ
statist
analysi
show
mdr
phenotyp
associ
exo
gene
p
p
respect
rapidli
fatal
underli
diseas
associ
exo
gene
p
signific
differ
observ
regard
exoy
gene
overal
isol
posit
entir
type
iii
secret
pathway
statist
analysi
show
signific
clinic
microbiolog
differ
observ
regard
type
iii
system
conclus
compar
publish
data
result
show
genotyp
pa
strain
caus
bsi
similar
determin
pneumonia
cf
patient
notabl
two
central
pathogenet
gene
exo
frequent
associ
mdr
strain
find
suggest
pa
isol
show
mdr
trait
may
virul
suscept
strain
mr
imag
experiment
mening
vivo
correl
diseas
sever
background
breakdown
bloodbrainbarri
bbb
alter
cerebr
blood
suppli
oedema
brain
ultim
hydrocephalu
nervou
tissu
damag
factor
believ
associ
diseas
sever
pneumococc
mening
development
relat
deleteri
entiti
diseas
remain
defin
materialsmethod
mening
induc
intracistern
inject
x
cfuml
pneumonia
serotyp
n
salin
n
rat
randomis
sacrif
infect
salin
inocul
time
h
postinfect
brain
harvest
histopatholog
prior
imag
rat
subject
clinic
neurolog
score
cerebrospin
fluid
blood
sampl
obtain
mr
imag
acquir
use
sisco
imag
system
quantit
diffus
dynam
mri
post
contrast
mmolkg
gddtpa
brain
oedema
measur
adc
map
calcul
imag
acquir
bvalu
smm
bloodbrain
barrier
integr
perfus
delay
investig
dynam
mri
gadolinium
enhanc
kinet
ventricular
size
accur
measur
mean
ventriclebrain
ratio
coron
mr
imag
result
mening
confirm
pneumococc
growth
csf
increas
csf
pleocytosi
rat
mening
expectedli
differ
highli
significantli
salin
inocul
control
examin
paramet
wbc
count
clinic
score
motor
score
ventriclebrain
vb
ratio
brain
oedema
bbbintegr
cerebr
perfus
adc
twoway
anova
p
increas
ventriclebrain
ratio
found
closest
correl
clinic
diseas
motor
perform
score
spearman
rank
rho
rho
p
respect
presenc
cerebr
damag
associ
extrem
valu
examin
paramet
conclus
cours
diseas
predict
sever
termin
ill
develop
within
hour
infect
twelv
hour
infect
bbb
integr
reduc
associ
increas
indic
vasogen
brain
oedema
reduc
cerebr
perfus
sever
clinic
deterior
develop
h
onward
associ
increas
ventricular
size
decreas
adc
cytotox
oedema
cortic
compress
decreas
perfus
wherea
bbb
integr
csf
infect
pleocytosi
reach
maximum
h
transmiss
communityacquir
methicillinresist
staphylococcu
aureu
infect
household
contact
taiwan
method
denka
seiken
use
detect
enterotoxin
b
c
type
exfoli
toxin
b
product
pcr
detect
tst
eta
etb
gene
allow
confirm
toxigen
resist
antibiot
test
disk
diffus
method
oxoid
phage
type
perform
standard
method
use
intern
set
phage
phl
london
mrsa
pvl
posit
strain
character
smai
macro
restrict
analysi
resolv
pfge
sccmec
type
multiplex
pcr
assay
prophag
type
assay
preliminari
character
prophag
type
concern
pvl
product
result
presenc
lukslukf
gene
detect
aureu
strain
isol
mainli
deepseat
skin
infect
refer
nrl
staphylococci
niph
pragu
czech
microbiolog
laboratori
product
enterotoxin
ad
found
pvl
posit
strain
three
strain
also
produc
one
strain
produc
exfoli
toxin
pvl
posit
strain
resist
oxacilin
mrsa
strain
hospit
acquir
multiresist
four
mrsa
strain
character
molecular
method
correl
known
european
mrsa
type
sizeabl
part
pvl
posit
mssa
isol
resist
erythromycin
amoxicillin
clavulan
clindamycin
resist
antibiot
rare
conclus
multiresist
hospit
acquir
strain
czech
pvl
posit
isol
show
resist
oxacillin
pvl
posit
strain
phagetyp
predominantli
classifi
phage
group
ii
acknowledg
work
support
research
programm
ministri
educ
youth
sport
czech
republ
increas
incid
higher
vancomycin
minim
inhibitori
concentr
chang
pattern
antibiot
suscept
methicillinresist
staphylococcu
aureu
isol
singl
institut
studi
lu
p
holtom
lo
angel
us
background
rate
methicillinresist
staphylococcu
aureu
mrsa
infect
institut
staphylococcu
aureu
infect
thank
recent
communityacquir
mrsa
camrsa
epidem
yet
littl
known
chang
antibiot
suscept
pattern
strain
camrsa
replac
tradit
hospitalacquir
mrsa
becom
new
hospit
flora
manifest
new
pattern
antibiot
suscept
anoth
grow
concern
glycopeptid
heteroresist
incid
mrsa
higher
vancomycin
minim
inhibitori
concentr
vancmic
unknown
sought
address
two
issu
epidemiolog
studi
method
microbiolog
data
mrsa
isol
hospit
septemb
march
analys
sampl
locat
isol
antibiot
suscept
vancmic
compil
result
month
period
mrsa
isol
nasal
cultur
includ
recurr
infect
count
isol
found
resist
antibiot
addit
beta
lactam
isol
found
vancmic
isol
vancmic
greater
came
patient
emerg
depart
primari
care
clinic
isol
found
multidrug
resist
conclus
studi
demonstr
institut
mrsa
antibiot
suscept
resembl
camrsa
higher
vancomycin
mic
among
mrsa
seen
increas
frequenc
followup
studi
need
determin
clinic
signific
find
preval
differ
virul
factor
enteroaggreg
escherichia
coli
isol
caus
diarrhoea
children
ifakara
tanzania
capac
persist
colon
micro
biota
howev
almost
exclus
demonstr
bacteria
sampl
western
countri
studi
examin
phylogenet
group
distribut
relat
virul
gene
carriag
colon
persist
e
coli
obtain
pakistani
infant
method
e
coli
strain
sampl
colon
microbiota
pakistani
infant
follow
longitudin
first
six
month
life
individu
strain
identifi
multilocu
enzym
electrophoresi
strain
appear
one
occas
defin
resid
strain
isol
singl
occas
defin
transient
strain
character
respect
carriag
sever
virulenceassoci
gene
test
phylogenet
origin
use
triplex
pcr
polymeras
chain
reaction
result
overal
e
coli
strain
identifi
pakistani
infant
forti
seven
percent
belong
phylogenet
group
group
strain
belong
phylogenet
group
significantli
often
carri
gene
fima
p
compar
strain
compar
swedish
group
e
coli
strain
pakistani
strain
lack
gene
sfade
fimbria
neub
antigen
papg
class
iii
significantli
less
often
carri
gene
papc
p
hyla
p
contrast
previou
find
swedish
e
coli
strain
group
strain
pakistani
infant
like
persist
intestin
micro
biota
strain
phylogenet
group
conclus
result
suggest
e
coli
group
strain
pakistani
infant
differ
substanti
western
group
strain
lower
carriag
rate
variou
virul
factor
gene
may
explain
inferior
capac
persist
micro
biota
suggest
accumul
virul
gene
strain
occur
subdivis
e
coli
strain
four
phylogenet
group
pathogen
island
escherichia
coli
yersinia
highpathogen
island
significantli
associ
persist
e
coli
intestin
swedish
infant
ae
stblom
adlerberth
ae
wold
fl
nowrouzian
se
object
virul
associ
gene
often
locat
particular
region
bacteri
chromosom
term
pathogen
island
uropathogen
escherichia
coli
strain
often
carri
pathogen
island
pathogen
island
pai
first
identifi
uropathogen
e
coli
strain
highpathogen
island
hpi
origin
found
yersinia
speci
examin
whether
pathogen
island
may
contribut
persist
e
coli
normal
nich
colon
microflora
method
e
coli
obtain
swedish
infant
follow
regular
sampl
faecal
flora
first
year
life
analyz
e
coli
isol
identifi
strain
level
random
amplifi
polymorph
dna
rapd
total
strain
classifi
strain
resid
persist
wk
microflora
could
classifi
transient
persist
wk
micro
flora
strain
assess
carriag
pai
hpi
use
singl
pcr
duplex
pcr
assay
respect
result
fifti
six
percent
e
coli
strain
harbour
hpi
pai
respect
resid
strain
significantli
often
transient
strain
possess
pai
vs
p
hpi
vs
p
result
indic
hpi
pai
enhanc
colon
capac
e
coli
strain
intestin
virul
associ
trait
character
resid
e
coli
strain
may
contribut
persist
intestin
micro
flora
well
increas
pathogen
capabl
urinari
tract
relationship
phylogenet
group
escherichia
coli
isol
clinic
characterist
patient
bacteraemia
f
jaureguy
e
carbonnel
bonacorsi
e
bingen
b
picard
x
nassif
lortholari
bobigni
pari
fr
object
aim
studi
assess
relationship
phylogenet
group
escherichia
coli
strain
isol
bacteraemia
clinic
characterist
sepsi
method
prospect
studi
conduct
decemb
decemb
patient
includ
children
e
coli
bacteremia
necker
avicenn
univers
hospit
pari
franc
clinic
data
includ
primari
sourc
bacteremia
underli
diseas
includ
immunodefici
hospit
versu
commun
acquir
origin
outcom
bacteriolog
data
includ
determin
phylogenet
group
perform
triplex
pcr
chua
yjaa
dna
fragment
antibiot
suscept
amoxicillin
amx
ofloxacin
ofx
trimethoprimsulfamethoxazol
stx
result
among
case
patient
older
year
immunocompromis
sever
sepsi
score
accord
bone
criteria
stage
stage
stage
e
coli
blood
infect
nosocomi
origin
frequent
sourc
bacteremia
urinari
tract
follow
digest
tract
strain
distribut
phylogenet
group
sixti
three
percent
isol
resist
amx
stx
ofx
factori
analysi
correspond
conduct
data
allow
distinct
group
strain
strain
belong
phylogenet
group
frequent
associ
follow
characterist
suscept
test
antibiot
commun
acquir
infect
urinari
tract
origin
immunocompet
host
favour
outcom
strain
belong
phylogenet
group
frequent
associ
resist
test
antibiot
hospit
acquir
infect
non
urinari
tract
origin
immunocompromis
host
stage
higher
mortal
conclus
result
distinguish
urosepsi
due
group
suscept
strain
infect
immunocompet
patient
favour
outcom
ii
bacteraemia
other
sourc
due
group
resist
strain
infect
older
immunocompromis
patient
sever
outcom
burden
clostridium
difficil
associ
diseas
nh
hospit
trust
england
summari
statement
result
first
year
mandatori
c
difficil
report
compar
result
trend
observ
nation
voluntari
report
system
period
method
surveil
clostridium
difficil
associ
diseas
cdad
includ
mandatori
healthcareassoci
infect
surveil
system
nh
acut
trust
england
sinc
januari
data
collect
quarterli
acut
trust
england
treat
patient
age
year
find
first
year
mandatori
surveil
compar
result
nation
voluntari
system
report
use
estim
current
burden
cdad
assess
nation
trend
purpos
mandatori
surveil
scheme
microbiolog
laboratori
requir
test
diarrhoeal
specimen
evid
cdad
patient
year
old
diagnos
cdad
preced
four
week
diarrhoeal
stool
defin
take
shape
contain
nondiarrho
stool
test
cdad
laboratori
test
specimen
c
difficil
toxin
use
either
immunoassay
detect
toxin
toxin
b
neutralis
cell
cytotox
assay
method
use
subject
appropri
qualiti
assur
mandatori
surveil
scheme
distinguish
hospit
communityacquir
case
even
case
consid
communityacquir
report
trust
detect
result
period
januarydecemb
hpa
receiv
report
cdad
acut
nh
trust
two
trust
submit
data
one
trust
submit
data
three
quarter
four
trust
case
report
contrast
nation
voluntari
report
system
indic
case
patient
age
year
rel
ascertain
nine
region
given
attach
figur
indic
ascertain
voluntari
surveil
cdad
find
appli
year
analysi
trend
conclus
total
number
cdad
report
age
group
voluntari
scheme
appli
ascertain
factor
seen
select
age
group
mandatori
suggest
total
burden
case
age
group
case
vitro
investig
proinflammatori
properti
helicobact
pylori
strain
involv
lowgrad
gastric
mucosa
associ
lymphoid
tissu
lymphoma
p
lehour
g
lasn
galloi
menard
ruskon
fourmestraux
jc
delchier
f
megraud
bordeaux
pari
creteil
fr
object
previou
studi
studi
main
h
pylori
virul
factor
strain
isol
patient
low
grade
gastric
mucosa
associ
lymphoid
tissu
malt
lymphoma
show
none
associ
strain
lehour
et
al
infec
immun
postul
malt
pathogenesi
link
proinflammatori
h
pylori
strain
nevertheless
assumpt
strain
possess
unknown
proinflammatori
factor
lack
confirm
investig
abil
h
pylori
malt
strain
two
h
pylori
sequenc
strain
induc
secret
human
gastric
adenocarcinoma
epitheli
ag
cell
line
method
h
pylori
strain
harvest
day
plate
cultur
resuspend
brucella
broth
broth
adjust
optic
densiti
nm
correspond
approxim
x
cfuml
bacteri
suspens
inocul
well
triplic
ag
cell
cultur
confluenc
fb
medium
h
co
cultur
supernat
recov
order
quantifi
immedi
freez
proinflammatori
cytokin
quantikin
human
immunoassay
r
system
result
level
obtain
refer
strain
line
valu
publish
literatur
vitro
model
product
depend
function
cag
secret
system
studi
caga
posit
caga
neg
malt
strain
high
product
observ
caga
posit
strain
pgml
neg
caga
strain
induc
low
rate
pg
ml
indic
proinflammatori
potenti
import
proinflammatori
factor
conclus
although
involv
h
pylori
strain
malt
lymphoma
well
establish
gastric
inflamm
especi
caga
neg
strain
repres
seem
pathomechan
cancer
current
test
malt
lymphoma
strain
also
analys
result
accord
presenc
main
h
pylori
virul
factor
put
virul
gene
identifi
laboratori
object
neuron
injuri
pneumococc
mening
consequ
direct
toxic
proinflammatori
activ
bacteri
compon
antibiot
standard
therapi
consist
highli
effect
bacteriolyt
betalactam
antibiot
howev
betalactam
antibiot
act
bacteri
lyse
result
increas
releas
bacteri
product
method
primari
cultur
mous
microgli
cell
primari
mous
cortex
neuron
expos
cultur
supernat
streptococcu
pneumonia
grown
tryptic
soy
broth
without
addit
antibiot
treatment
nonbacteriolyt
antibiot
clindamycin
rifampin
ceftriaxon
result
primari
mous
microgli
cell
activ
cultur
supernat
streptococcu
pneumonia
direct
toxic
effect
pneumococc
cultur
supernat
primari
neuron
detect
treatment
pneumococc
cultur
clindamycin
rifampin
comparison
ceftriaxon
significantli
reduc
proinflammatori
action
cultur
supernat
microgli
cell
effect
also
present
sequenti
therapi
nonbacteriolyt
bacteriolyt
antibiot
trigger
sir
patient
acut
pancreat
compar
sir
patient
sepsi
method
peripher
blood
monocyt
isol
patient
densiti
gradient
centrifug
whole
blood
incub
rpmi
remov
nonadher
cell
twelv
patient
sepsi
patient
acut
pancreat
symptom
present
within
hour
admiss
diagnosi
ml
blood
sampl
half
assay
isol
monocyt
ml
centrifug
serum
estim
tumour
necrosi
alpha
tnfa
half
monocyt
incub
presenc
patient
serum
supernat
collect
half
lyze
estim
lysat
enzymat
chromogen
assay
tnfa
estim
serum
cell
supernat
enzym
immunoassay
result
median
se
tnfa
serum
septic
patient
patient
acut
pancreat
pgml
respect
respect
valu
septic
patient
acut
pancreat
pgml
p
respect
valu
intracellular
activ
cell
p
tnfa
monocyt
supernat
differ
patient
acut
pancreat
sepsi
result
remain
unalt
presenc
patient
serum
monocyt
supernat
patient
sepsi
consider
increas
addit
patient
serum
compar
patient
pancreat
see
figur
conclus
data
shown
monocyt
activ
differ
acut
pancreat
sepsi
differ
kinet
releas
might
specul
exist
probabl
antiinflammatori
mechan
activ
acut
pancreat
sepsi
recombin
escherichia
coli
model
studi
potenti
pathogen
agent
burkholderia
pseudomalleiphospholipas
c
b
sadowska
wieckowskaszakiel
w
rudnicka
korbsris
b
rozalska
lodz
pl
bangkok
th
object
burkholderia
pseudomallei
etiolog
agent
melioidosi
endem
diseas
whose
acut
form
manifest
pulmonari
septicem
infect
abscess
format
pathogen
factor
gramneg
bacilli
known
well
enough
howev
worth
note
produc
mani
enzym
includ
phospholipas
c
plc
hypothesis
plc
import
b
pseudomallei
interact
host
immun
cell
method
parent
e
coli
strain
plc
recombin
mutant
e
coli
produc
phospholipas
c
b
pseudomallei
plc
use
studi
mous
periton
macrophag
infect
fitclabel
normal
bacteria
determin
adher
cell
fluorimetr
assay
ingest
intracellular
kill
coloni
form
unitsassay
supernat
collect
estim
product
tnfalpha
infect
phagocyt
use
duoset
elisa
randd
result
adher
e
coli
macrophag
stronger
e
coli
mutant
also
correspond
better
ingest
intracellular
kill
plcstrain
use
phagocyt
interestingli
phagocyt
activ
cell
infect
mix
popul
e
coli
plc
plc
strain
diminish
compar
activ
homogen
popul
bacteria
two
hour
incub
macrophag
e
coli
strain
led
product
tnfalpha
level
detect
limit
howev
stimulatori
effect
parent
mutant
strain
well
homoand
heterogen
cultur
similar
conclus
product
phospholipas
c
seem
disturb
phagocyt
secretori
activ
macrophag
thu
data
suggest
enzym
play
import
role
surviv
b
pseudomallei
insid
profession
phagocyt
investig
even
suggest
phospholipas
c
b
pseudomallei
play
similar
role
pathogenesi
melioidosi
phospholipas
listeria
monocytogen
take
place
escap
bacteria
phagolisosom
object
fusobacterium
necrophorum
fn
presum
part
normal
human
throat
flora
fusobacterium
necrophorum
subsp
funduliform
caus
tonsil
peritonsillar
abscess
lemierr
syndrom
studi
preval
fn
healthi
control
patient
acut
chronic
tonsil
novel
realtim
pcr
assay
analys
associ
group
c
streptococci
fn
tonsil
patient
method
throat
swab
healthi
control
age
median
year
swab
tonsil
patient
age
median
year
examin
quantit
fn
novel
fn
subspeci
specif
realtim
pcr
assay
swab
group
simultan
inocul
aerob
columbia
blood
agar
detect
haemolyt
streptococci
anaerob
order
find
fn
result
pcr
detect
control
fn
subsp
funduliform
throat
quantiti
rang
form
approx
cfuswab
mean
cfuswab
fn
found
none
posit
cultur
neither
fn
hemolyt
streptococci
agar
plate
fifti
percent
swab
tonsil
patient
reveal
fn
subsp
funduliform
pcr
quantiti
rage
cfuswab
mean
cfuswab
posit
pcr
sampl
cfuswab
posit
fn
cultur
number
posit
sampl
amount
cfuswab
significantli
greater
swab
tonsil
patient
p
patient
group
c
streptococci
significantli
higher
cfuswab
valu
without
group
c
streptococci
cfuswab
mean
cfuswab
result
summar
tabl
conclus
fn
subsp
funduliform
part
normal
throat
flora
small
quantiti
healthi
control
higher
quantiti
patient
acut
chronic
tonsil
young
peopl
indic
fn
may
caus
tonsil
addit
studi
indic
concomit
group
c
streptococci
may
aggrav
tonsil
object
invas
salmonella
report
induc
apoptosi
macrophag
part
infect
process
may
allow
avoid
detect
innat
immun
system
howev
induct
apoptosi
remain
look
differ
host
environ
experienc
pathogen
success
pathogen
overcom
host
environment
stress
coordin
express
variou
gene
eventu
protein
sinc
surfac
microb
like
come
contact
host
initi
attempt
made
identifi
salmonella
outer
membran
protein
omp
may
get
express
one
environment
condit
simul
vivo
one
assess
apoptot
potenti
method
typhi
grown
irondeplet
oxid
stress
well
anaerob
condit
omp
profil
compar
phenotyp
similar
among
stressesinduc
protein
assess
basi
similar
molecular
weight
cross
reactiv
hplc
apoptosi
assess
nucleosom
dna
nuclear
stain
acridin
orangeethidium
bromid
costain
well
flow
cytometri
done
estim
cytokin
tnfa
reactiv
nitrogen
intermedi
lipid
per
oxid
level
antioxid
superoxid
dismutas
catalys
done
result
kda
omp
found
express
enhanc
intens
select
stress
condit
comparison
normal
condit
protein
express
anaerob
oxid
stress
react
antibodi
rais
ironregul
omp
indic
share
least
epitop
singl
peak
observ
subject
pool
kda
protein
sampl
hplc
confirm
puriti
phenotyp
similar
protein
reactiv
pool
kda
protein
widal
posit
sera
typhoid
patient
reveal
vivo
express
stressinduc
kda
omp
caus
apoptot
cell
death
macrophag
significantli
enhanc
express
cytokin
tnfa
detect
macrophag
interact
stress
omp
signific
increas
level
oxid
decreas
antioxid
also
observ
conclus
find
studi
may
relev
better
understand
pathophysiolog
diseas
hostpathogen
interact
futur
develop
diagnost
well
prevent
strategi
gramposit
gramneg
bacteria
induc
differ
cytokin
human
peripher
blood
mononuclear
cell
irrespect
taxonom
related
johansson
bigsten
c
hessl
wold
goteborg
se
object
upon
bacteri
stimul
tissu
macrophag
produc
varieti
cytokin
orchestr
immun
respons
necessari
clear
infect
earlier
studi
shown
gramposit
bacteria
induc
higher
level
ifngamma
tnf
human
peripher
blood
mononuclear
cell
pbmc
gramneg
bacteria
wherea
gramneg
induc
much
gramposit
aim
studi
examin
dichotomi
true
gramposit
gramneg
bacteria
irrespect
posit
taxonom
system
relat
cytokin
product
phagocytosi
method
pbmc
healthi
blood
donor
incub
speci
uvinactiv
gramposit
gramneg
bacteria
well
spread
taxonom
system
tnf
measur
supernat
h
ifngamma
elisa
phagocytosi
studi
cytospin
prepar
min
incub
result
irrespect
posit
phylogenet
tree
gramposit
bacteria
induc
ifngamma
tnf
gramneg
gramneg
bacteria
potent
stimul
gramposit
induc
equal
amount
gramposit
gramneg
bacteria
product
ifngamma
tnf
strongli
correl
differ
gramposit
gramneg
bacteria
degre
phagocytosi
correl
cytokin
product
bacteria
phagocytos
conclus
result
confirm
gramposit
gramneg
bacteria
trigger
differ
cytokin
pattern
human
monocyt
irrespect
genet
related
differ
composit
bacteri
wall
like
account
differ
invas
providencia
alcalifacien
cell
maszewska
torzewska
rozalski
lodz
pl
object
providencia
alcalifacien
gramneg
bacterium
famili
enterobacteriacea
thought
caus
diarrhoea
travel
children
cell
invas
fulfil
duke
criteria
igg
class
antiphas
titr
detect
patient
treat
doxycyclin
recov
two
patient
significantli
older
immunocompromis
other
die
eventu
conclus
q
fever
rare
notifi
diseas
northern
greec
data
indic
howev
q
fever
consid
public
health
problem
sever
clinic
manifest
gramneg
commens
gut
bacteria
escherichia
coli
bacteroid
sp
suspect
contribut
profoundli
inflammatori
bowel
diseas
crohn
diseas
ulcer
coliti
recent
shown
bacteri
group
accumul
high
level
inflam
ileum
trigger
sever
immunopatholog
acut
panil
suscept
mice
infect
peror
cyst
toxoplasma
gondii
thu
model
excel
suit
studi
hostbacterialrelationship
small
intestin
inflamm
unravel
mechan
bacteria
aggrav
ileal
inflamm
investig
sever
small
intestin
inflamm
mice
lack
tolllik
receptor
tlr
constitut
import
compon
bacteriarel
innat
immun
system
escherichia
coli
bacteroid
sp
accumul
compar
level
ileiti
concentr
differ
significantli
inflam
ilea
wild
type
mice
mice
lack
howev
sever
ileiti
clearli
diminish
mice
lack
indic
reduc
histolog
score
letal
highli
specif
bacteri
lipopolysaccharid
lp
find
provid
evid
commens
gut
bacteria
aggrav
immunopatholog
intestin
inflamm
via
sens
bacteri
lp
might
play
key
role
inflammatori
process
condit
mucou
stomach
membran
region
bloodgroov
shigellosi
chemich
snitsar
sumi
ua
object
studi
mucou
stomach
membran
region
bloodgroov
msmrb
cours
late
reconvalesc
shigellosi
sh
investig
chang
depend
therapi
sharp
period
method
cours
late
reconvalesc
person
examin
suffer
middlesever
sh
receiv
standard
treatment
group
enterosorb
one
antibacteri
ii
group
two
antibacteri
iii
group
msmrb
defin
cliren
hydrogen
cardiac
portion
cp
averag
third
bodi
b
pylor
portion
pp
stomach
result
full
normal
msmrb
portion
stomach
defin
group
patient
cp
b
pp
mlmin
gr
group
patient
got
posit
dynam
msmrb
cours
treatment
cp
b
pp
mlmin
gr
lowest
poorest
paramet
msmrb
term
prognosi
receiv
iii
group
examin
cp
b
pp
mlmin
gr
patient
bloodgroov
age
norm
portion
stomach
mlmin
gr
accordingli
differ
data
receiv
cours
hospitalis
msmrb
group
also
consider
data
examin
group
patient
receiv
enterosorb
direct
strong
correl
degre
msmrb
recoveri
reveal
therapi
perform
sharp
period
enterosorbt
antibacteri
therapi
conclus
cours
late
reconvalesc
shigellosi
normal
msmrb
portion
stomach
occur
examin
whose
treatment
enterosorb
use
enterosorb
antibacteri
medica
usag
two
antibacteri
medica
sharp
period
treatment
influenc
msmrb
neg
vitro
model
analys
effect
mycobacteria
infect
hiv
replic
boluda
r
delgado
md
folgueira
madrid
es
object
macrophag
import
cellular
target
hiv
mycobacteri
infect
vitro
hiv
infect
human
differenti
macrophag
difficult
usual
requir
addit
colonystimul
factor
mask
role
mycobacterium
spp
confect
viral
replic
studi
develop
infect
model
use
recombin
retrovirus
analys
role
mycobacterium
spp
infect
effect
divers
cytokin
hiv
replic
human
macrophag
method
retrovir
vector
base
lucgfp
repseudotyp
vesicular
stomat
viru
glycoprotein
vsvg
use
infect
macrophag
differenti
peripher
blood
monocyt
mdm
cultur
day
medium
contain
human
serum
plate
contain
x
cellswel
infect
recombin
retroviru
moi
day
cell
incub
tuberculosi
strain
rv
clinic
isol
present
differ
suscept
pattern
avium
fortuitum
ratio
sever
cytokin
tnfa
ifng
sonic
tuberculosi
avium
fortuitum
atcc
strain
also
test
h
stimul
mycobacteri
infect
effect
cytokin
mycobacterium
spp
hiv
replic
quantifi
measur
luciferas
activ
gfp
express
experi
made
cell
least
three
differ
donor
statist
analysi
perform
use
oneway
anova
test
result
percentag
macrophag
infect
use
recombin
retroviru
higher
confect
mycobacterium
strain
test
induc
increas
hiv
replic
fold
present
statist
signific
p
macrophag
coinfect
tuberculosi
strain
proinflamatori
cytokin
tnfa
ifng
show
signific
effect
hiv
replic
cell
stimul
mycobacterium
sonic
augment
hiv
replic
lower
level
coinfect
viabl
bacilli
conclus
hiv
infect
model
describ
studi
allow
get
high
grade
hiv
infect
human
macrophag
studi
effect
cytokin
product
driven
mycobacteria
mycobacterium
spp
coinfect
